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Abstract
Hypoxia is defined as a deficiency in the amount of oxygen reaching the
tissues, and is a common problem in critically ill patients. It is not currently possible
to predict how well an individual will adapt to hypoxic conditions, and patients
presenting with hypoxia are often treated with supplemental oxygen. However, this
blanket-treatment approach is not suitable in all cases and a more personalised
approach is required.
My thesis project builds on information acquired during the Caudwell Xtreme
Everest (CXE 2007) expedition, where over 200 volunteers trekked to Everest Base
Camp. CXE uses studies on healthy volunteers exposed to extreme environments
to aid in the understanding of the complicated issues concerned with critical illness,
and aims to use these findings to improve the treatment of critically ill patients,
without putting them directly at risk.
My thesis project has combined physiological information acquired during
CXE with biochemical information measured in plasma samples taken during CXE.
Performance at altitude has been used as a proxy for hypoxia adaptation, with
individuals who show a small loss of performance at altitude compared to London
assumed to be adapting better compared to individuals who show a larger loss.
Analysis of the physiological and biochemical data for a core group of 24
individuals has culminated in the application of multiple linear regression to produce
a number of models capable of predicting the key changes in physiological response
as a function of a number of biochemical metabolites. These models have been used
to identify a set of biochemical metabolites to measure in a further 190 individuals,
to allow validation and training of the models on a larger sample size. These models
can then be adapted for use in a critical illness environment, to allow the prediction
of how well an individual will adapt to hypoxic conditions.
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Chapter 1
Introduction
1.1 Project motivation
Intensive care units (ICUs) treat patients with life-threatening conditions. Patients
admitted to ICUs require constant monitoring and treatment from specialised equip-
ment to keep the body functioning. Critical care is increasingly becoming a part
of people’s lives, with one in four people expected to receive treatment in an ICU
during their lifetime. Over 120 000 patients were admitted to ICUs in the UK in
2006 alone [CASE, 2012].
Many critically ill patients su↵er from oxygen starvation of one kind or an-
other, known as hypoxia, which can be caused by a lack of oxygen delivery to the
cells, or by an inability to utilise the oxygen delivered to the cells, due to conditions
such as mitochondrial dysfunction. It is not currently possible to predict when an
individual will have di culty adapting to these conditions. An inability to adapt to
a lack of oxygen can become increasingly serious in a very short period of time, and
is even more dangerous when combined with other factors associated with critical
illness. Currently, the main treatment for cellular hypoxia is to increase oxygen
delivery via an oxygen mask. However, in some cases an overload of oxygen to the
system can have no e↵ect, or even cause harm, such as retinopathy of prematurity
in newborn babies, which causes severe scarring and blindness due to both oxygen
toxicity and hypoxia. It is therefore vital that doctors are able to track how well an
individual is coping with hypoxic exposure, and to be able to foresee any di culties
they may have in adapting to these lower oxygen levels.
A more personalised approach to treating critically ill patients would be
preferable to the current blanket-treatment approach, but is complicated by the
lack of understanding of the process of cellular hypoxia adaptation, and by the
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lack of data from critically ill patients. Invasive studies on critically ill patients are
di cult to perform due to the highly unstable and serious nature of their condition.
Any studies carry a high risk of making the patient’s condition worse, and may be
of no benefit to that individual in the short or longer-term.
Studies using cultured cells are of little use here, as the response varies sig-
nificantly between cell and tissue types. The exposure to multiple stress pathways
means that critically ill patients are not exposed to hypoxia in isolation, and many
stress response pathways overlap and interact with one another, to produce a com-
plex systems response, which we may not be able to replicate in an animal model
system. Similarly, chamber studies expose individuals to hypoxia in isolation, and
miss out on looking at interactive systems responses associated with critical illness.
Caudwell Xtreme Everest (CXE) is a research project coordinated by Uni-
versity College London (UCL) Centre for Altitude, Space and Extreme Environment
Medicine (CASE). CXE uses studies on healthy volunteers exposed to extreme en-
vironments to aid in the understanding of the complicated issues concerned with
critical illness, and aims to use these findings to improve the treatment of critically
ill patients, without putting them directly at risk. During CXE 2007, individuals
climbed to Everest Base Camp, with exercise performance tests and blood sampling
administered during the ascent. Exercise performance (as measured via cardiopul-
monary exercise testing) was used as a proxy for hypoxia adaptation, with individ-
uals showing similar performance levels to those seen at London assumed to be the
better adapters [CASE, 2012].
This thesis project builds on the work carried out during CXE 2007, by com-
bining information from exercise performance tests carried out during the expedition
with biochemical data derived from blood samples collected during the ascent. Sev-
eral stages of statistical analysis have been carried out to increase the understanding
of why some individuals adapt to hypoxia better than others. The information has
been analysed together, with the aim of producing a model capable of predicting
how well an individual will perform, and therefore adapt to the extreme environment
at high altitude. It is hoped that these models can be adapted for use in a critical
care environment, helping to track how well an individual is adapting to hypoxia,
and being able to take necessary interventional treatment to aid individuals who are
having di culty in adapting to hypoxic exposure.
2
1.2 Background of the problem
1.2.1 Hypoxia
In humans, oxygen is required for respiration and energy generation within cells,
and is vital for the life of most multicellular organisms on Earth. Hypoxia gener-
ally describes several conditions caused by the starvation of oxygen, and can occur
naturally, for example during periods of strenuous exercise or during ascent to high
altitude, where oxygen availability is reduced.
Most humans can ascend to around 2500m without experiencing any prob-
lems with hypoxic stress [McArdle et al., 2007]. However, when ascending further,
individuals may begin to su↵er from acute mountain sickness (AMS), and display
symptoms similar to those of a mild case of flu or a hangover, which usually abate
after a few days of acclimatisation [McArdle et al., 2007]. AMS can progress to more
severe conditions such as high altitude cerebral edema (HACE), and high altitude
pulmonary edema (HAPE). HACE is usually preceded by progressive AMS symp-
toms, and is a condition where the brain tissue swells due to leakage of fluid from the
capillaries, and can cause death due to brain herniation [Ba¨rtsch and Saltin, 2008].
HAPE is a condition where fluid collects in the lung, impairing gas exchange, and
can lead to fatal respiratory failure. Both of these conditions are life-threatening,
and individuals su↵ering from HACE or HAPE would need to be immediately moved
to a lower altitude to recover.
Exposure to even a moderate altitude can cause significant problems for
some individuals. The problem of adapting to altitude is of great interest due to
millions of people travelling to high altitudes each year for business and holidays
worldwide. During such travels, individuals rarely take su cient time to acclimatise
to the reduced oxygen availability and other challenges at altitude, resulting in a
high susceptibility to illness [Bezruchka, 1992].
High altitude research has been carried out for well over 100 years, and as
such, the general response to hypoxic exposure is well documented [Ba¨rtsch and
Saltin, 2008]. However, it is still not understood why some individuals seem prone
to AMS when ascending to altitude and others are not. The ability to predict how
well an individual will respond to hypoxic exposure could be invaluable in allowing
the better preparation for exposure to higher altitude, and limiting the cases of
HACE and HAPE that occur at altitude [Richalet et al., 2012; Maggiorini, 2001].
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1.2.2 Hypoxia and critical illness
Hypoxia is a common problem in critically ill patients, and can contribute to, or be
a result of the illness itself [Grocott et al., 2007]. Individuals vary in how well they
can adapt to hypoxic conditions, and there is currently no way to predict how well
an individual will cope when exposed to a hypoxic environment, in the same way
that it is not possible to predict when an individual will become ill at altitude. The
ability to track how well an individual is coping with increased hypoxic exposure
could be very useful in a critical illness environment, where patients’ conditions can
deteriorate quickly, and swift responses to any lack of adaptation could mean the
di↵erence between a patient surviving or not.
1.2.3 General response to hypoxia
Acclimatisation is the process of an organism adapting to a gradual change in its
environment, such as temperature, UV or hypoxic exposure, which enables it to
continue to function in the altered environment. Full acclimatisation to high altitude
usually requires at least a few weeks, and the time needed varies significantly between
individuals, with some being unable to adapt to certain extreme altitudes at all.
Acute exposure to high altitude results in an increase in respiration (hyper-
ventilation) and an increase in blood flow, to compensate for the lower oxygen levels
available. The increase in blood flow seen at altitude is due to an increase in both
blood pressure and heart rate, but not stroke volume (the volume of blood pumped
from one ventricle of the heart with each beat) [McArdle et al., 2007]. Any change
in ventilation leads to an alteration in the acid-base balance of the blood, and is
strictly controlled.
Carbon dioxide is produced as a by-product of respiration within cells and
di↵uses into the blood, where it is transported to the lung and exhaled. Carbon diox-
ide enters the red blood cells and reacts with water to form carbonic acid (H2CO3).
This reaction is catalysed by the enzyme carbonic anhydrase, which is found in
virtually every cell, and in particularly high concentrations within red blood cells.
Carbonic acid dissociates into bicarbonate (HCO 3 ) and hydrogen ions (H+), as
shown in equation 1.1. This reaction also occurs outside red blood cells, however, at
a much slower pace. Any hydrogen ions formed combine with haemoglobin within
the red blood cell, limiting the reduction in pH within the red blood cell and acting
as a natural bu↵er. Bicarbonate ions di↵use out of the red blood cells into the
plasma, whilst being replaced by chloride (Cl ) ions, known as the chloride shift.
At the lung, these reactions reverse; bicarbonate ions move into red blood cells and
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combine with hydrogen ions to form carbonic acid. This acid is then broken down
into carbon dioxide and water, and the carbon dioxide formed di↵uses out of the
red blood cells and into the alveoli, where it can be expelled via the lungs.
CO2 +H2O ⌦ H2CO3 ⌦ H+ +HCO 3 (1.1)
Blood pH is tightly regulated to between 7.35-7.45, and hyperventilation
removes carbon dioxide from the blood, shifting the chemical equilibrium shown in
equation 1.1 towards the left to replace the CO2 removed. This in turn raises the
pH of the blood, known as respiratory alkalosis, which limits the extent to which
ventilation can be increased in response to hypoxic exposure.
Continued exposure to altitude results in further acclimatisation processes
occurring within the body. These adaptations to prolonged altitude exposure take
longer to occur than initial exposure responses, and improve the body’s tolerance
to long-term altitude exposure. Long-term acclimatisation includes an increased
excretion of bicarbonate, which removes excess base from the body and allows ven-
tilation to remain elevated without causing alkalosis. Synthesis of haemoglobin and
erythrocytes is increased due to increased production of the erythrocyte production-
stimulating hormone erythropoietin (EPO). This increases the blood’s oxygen car-
rying capacity, and is the most important long-term adaptation to altitude expo-
sure [McArdle et al., 2007]. Bicarbonate, haemoglobin and EPO levels have been
measured in individuals to track this acclimatisation during CXE 2007. A summary
of the adaptive responses to hypoxic exposure is shown in Table 1.1.
Studies on native highlanders living on di↵erent continents have given in-
sights into long-term evolutionary adaptation to high altitude. Interestingly, adap-
tation to hypoxia di↵ers between populations. Andean highlanders from South
America are characterised by high numbers of red blood cells and haemoglobin con-
centrations, whereas Tibetan highlanders show haemoglobin levels that are similar
to comparable US sea level individuals [Beall et al., 1998]. Tibetans are therefore
thought to have adapted other mechanisms for long-term adaptation to altitude,
such as higher forearm blood flow and circulating nitric oxide products [Erzurum
et al., 2007]. Further study of generational adaptation such as that seen in Tibetan
highlanders may aid in our understanding of acclimatisation to chronic hypoxia.
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Figure 1.1: The ascent profile for participants of the Caudwell Xtreme Everest Ex-
pedition, 2007. The blue line indicates the general ascent profile for all individuals.
Individuals denoted lab sta↵ remained at Everest Base Camp at 5300m until the
end of the expedition, and did not ascend further. The red line indicates where
the 14 individuals of the climber group descended back down to Pheriche, and also
ascended further than Base Camp, with 8 individuals summiting at 8848m. The
labelled boxes indicate where and when testing took place during the ascent, and
show the days over which sampling took place; London (75m), Kathmandu (1300m),
Namche (3500m), Pheriche (4250m) and Everest Base Camp (5300m).
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1.3 Caudwell Xtreme Everest 2007
Caudwell Xtreme Everest (CXE) 2007 was the largest ever field-study of human
adaptation to hypoxia, and saw over 200 volunteers climb to Everest base camp
(5300m). Various measurements such as cardiopulmonary exercise testing, blood
sampling and muscle biopsies were taken at five di↵erent laboratories on the way
up. A second core group of 24 doctors and scientists also took part in the ascent,
consisting of 10 lab sta↵ individuals, who stayed at Base Camp with the volunteer
group, and 14 climber individuals, who ascended further and attempted to summit,
with 8 succeeding [Grocott et al., 2007]. The ascent profile from the expedition
is shown in Figure 1.1, which shows the basic ascent profile for all participants in
blue, and where the climber group ascended further than base camp, in red. The
laboratories where testing took place during the ascent are also marked; London
(75m), Kathmandu (1300m), Namche (3500m), Pheriche (4250m) and Everest Base
Camp (5300m).
The ascent exposed the team to multiple stresses, including reduced oxy-
gen levels and increased exposure to cold and UV light. Critically ill patients are
similarly exposed to multiple stresses, such as trauma, tissue hypoxia and infec-
tion [Grocott, 2008; Grocott et al., 2007]. As the responses to these di↵erent stresses
would occur simultaneously, isolating one single aspect (such as hypoxia adaptation)
is very di cult. Adaptive stress-response pathways also overlap and communicate
with one another, to produce a complicated systems response. CXE 2007 aimed to
increase the understanding of a very complex adaptation process, with the aim of
using the results to aid the treatment of critically ill patients.
During the expedition only a small number of individuals su↵ered with alti-
tude sickness. However, three became seriously ill and had to be taken to a lower
altitude to recover. An additional individual also became ill, but later recovered.
It was hoped that these four individuals would show some di↵erences to other core
team members in their response to altitude in one or more of the measurements. It
was hoped that these di↵erences may help identify why some individuals adapt to
hypoxia better than others, to help in the understanding of di↵erences in individual’s
adaptability to low oxygen levels.
The value of the data from CXE 2007 is that it shows how metabolites
from many di↵erent biochemical pathways change with increasing altitude, includ-
ing those associated with hypoxia adaptation, inflammation, metabolism and home-
ostasis. No other study has looked at such a vast array of biochemical metabolites
at altitude, or has had the ability to combine this data with so many physiological
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measurements. Therefore, this project o↵ers a unique opportunity to gain insight
into what is happening in the body as altitude increases, in multiple biochemical
and physiological pathways at the same time.
1.3.1 Exercise performance testing
During CXE 2007, Cardiopulmonary Exercise Testing (CPX/CPET) was performed
on each individual at di↵erent locations during the ascent. CPX testing measures
an individual’s ability to do exercise or work as a measure of their aerobic fitness, by
assessing pulmonary and cardiac function as a measure of the whole-body response
to performing exercise. CPX testing was used as part of the CXE study to assess
each individual’s ability to do work compared to sea level, and analyse how this
changed as they ascended.
Performance was expected to decrease as the expedition progressed, due
to decreasing oxygen availability as the climbers ascended. Oxygen is required
by cells for respiration, the process by which complex organic substances such as
carbohydrates, lipids and proteins are broken down in the presence of oxygen to
produce adenosine triphosphate (ATP) [McArdle et al., 2007]. ATP is the energy
currency of the cell and used to perform many of the cell’s energy-requiring processes
(such as work), and is therefore vital to the survival of the cell [Voet and Voet, 2004].
In the presence of su cient oxygen, glucose is broken down via aerobic respi-
ration, where 38 ATP molecules are generated from one glucose molecule, as shown
in equation 1.2. However, if insu cient oxygen is available then anaerobic respira-
tion is stimulated, which generates only 2 ATP per glucose molecule and 2 lactate
molecules, as shown in equation 1.3.
C6H12O6 + 38ADP + 38Pi + 6O2 ! 6CO2 + 44H2O + 38ATP (1.2)
C6H12O6 + 2ADP + 2Pi ! 2C3H6O3 + 2H+ + 2H2O + 2ATP (1.3)
Aerobic breakdown of glucose is obviously preferred due to the much higher
yield of ATP obtained, and supplies the majority of ATP up to the anaerobic thresh-
old, where anaerobic breakdown of glucose occurs to supplement the aerobic break-
down of glucose as the work rate increases. As the climbers ascended during CXE
2007, oxygen availability decreased. CPX testing was used to assess how well each
individual was adapting to the decreased oxygen levels available, with exercise per-
formance being used as a model for hypoxia adaptation. Individuals who show a
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large decrease in the ability to do work at high altitude were considered to be adapt-
ing poorly, as they are not able to do as much work compared to sea level with less
oxygen available. Individuals who performed in a similar manner or showed a small
decrease in their ability to do work compared to sea level were considered to be
adapting well, as they were able to do a similar amount of physical work with less
oxygen available, and therefore must be adapting to use the lower levels of oxygen
available more productively.
1.3.2 Other methods of studying human adaptation to hypoxia
Hypobaric chamber studies have been used by some groups as a highly-controlled
simulation of the ascent to Everest base camp and beyond [Wagner, 2010]. A hypo-
baric chamber experiment would not have been possible on the scale of CXE 2007,
as the expedition took place over 78 days and involved a very large group of indi-
viduals. Chamber studies are very expensive to run, whereas climbing participants
usually contribute financially to the expedition. In addition, hypobaric chambers
only expose individuals to hypoxic stress and occasional exercise testing, and do not
encompass systemic responses to multiple stresses encountered during an expedition
such as CXE 2007. Both types of study are useful, depending on the questions being
asked, and in this case an expedition was more suitable due to the large number of
participants and the application of the results to critically ill patients.
1.3.3 Biomarkers
Biomarkers are characteristics that can be measured to give information on the
normal state of an organism, to track the progress of an illness, the body’s response
to an illness or to monitor the response to a treatment. Plasma biomarkers in
particular are of great interest, due to the ease in which blood samples can be
obtained in the clinical environment. Biomarkers are already used as markers of
ischemia, heart failure and inflammation in the field of cardiac medicine. However, it
is only recently that single biomarkers have started to be combined into multimarker
strategies [Maisel et al., 2006].
Figure 1.1 shows the ascent profile for CXE 2007, and identifies the five
laboratories where exercise performance testing and blood sampling were performed.
The blood samples were spun down in each laboratory, and the plasma frozen and
stored for later analysis. These plasma samples were used at The University of
Warwick to measure multiple biochemical metabolites, including metabolites known
to play a role in hypoxia adaptation, markers of inflammation and metabolism-
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Dataset Parameter
type
Number of
variables
Collected Analysed Number of
individuals
Number of
measurements
Core Physiological 65 CXE 2007 CXE 2007 24 7
Biochemical 59 CXE 2007 University
of Warwick
24 7
Trekker Physiological 62 CXE 2007 CXE 2007 190 5
Biochemical - CXE 2007 Yet to be
analysed
190 5
Diary Physiological 16 CXE 2007 CXE 2007 24 78
Table 1.2: A summary of the di↵erent datasets collected during CXE 2007. Plasma
samples were measured at The University of Warwick.
related metabolites.
Biochemical and physiological information have been analysed together in
this thesis, to see if changes in physiological measurements (used as an indicator of
hypoxia adaptation) can be predicted by changes in biochemical measurements at
lower altitudes. This would therefore enable the prediction of how well an individual
will adapt to a higher altitude by taking a blood sample at a lower altitude.
1.3.4 Data available
Three di↵erent datasets have been used during this thesis project, which contain
measurements for the 24 core team members obtained during di↵erent stages of the
expedition. An overview of the di↵erent datasets is shown in Table 1.2.
The core team data is the main dataset that has been used during this thesis
project, and contains information about the 24 core team members only. The core
dataset contains physiological information collected during CXE 2007, as well as
biochemical information measured by myself and other members of the Feelisch
laboratory at The University of Warwick in plasma samples collected during CXE
2007. This dataset has been used to understand the overall changes occurring in
each of the 24 core team individuals during the expedition, and all modelling e↵orts
have been based on this dataset.
The diary data is an additional dataset collected for the 24 core team mem-
bers, consisting of daily measurements taken during the expedition, and shows the
day-to-day variation of each measurement. It contains only a small number of phys-
iological measurements such as heart rate and respiratory rate before and after a
simple 2-minute step exercise test, designed to look at how the body was adapting
to changes in altitude. This dataset has been used to look at the reliability and
day-to-day variability of some of the physiological measurements, i.e. if the same
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Response pathway Parameters involved
Oxygen regulation HIF-1↵ targets
Redox regulation Nitric oxide and reactive oxygen species metabolites
Inflammation / stress Cytokines, acute phase proteins
Metabolism / organ function Hormones
Table 1.3: A summary of the di↵erent biochemical pathways assessed during this
thesis project, giving an idea of di↵erent response pathways measured, and which
biochemical metabolites were used as anologues for the di↵erent pathways.
measurement is taken on two subsequent days, how similar are they?
The trekker data contains information about the 190 volunteers (individuals
from the general population, not core team members) who took part in the expe-
dition, and stayed at Everest Base Camp. This dataset only contains physiological
information about the exercise performance tests carried out during the ascent.
Plasma samples are available for these individuals, and are being kept in storage at
-80oC until use. The trekker plasma samples can be measured for various biochem-
ical metabolites identified during data analysis, to validate the models formed from
the core team dataset.
1.4 Biochemical adaptation to hypoxia
During CXE 2007, plasma samples were collected at five di↵erent laboratories dur-
ing the ascent, as detailed in Figure 1.1. These plasma samples were measured by
myself and other members of the Feelisch laboratory at The University of Warwick,
to investigate how the biochemical makeup of the plasma changed during the ascent.
Metabolites measured include readouts of hormonal activity, acid-base balance, in-
flammation, regulatory pathways and redox regulation. A summary of the biochem-
ical pathways measured is shown in Table 1.3. Many of the metabolites measured
are known targets of HIF-1↵, the master gene regulator for hypoxia adaptation.
Other metabolites were measured to gain insight into how related metabolites may
be changing. This section gives an overview of which biochemical metabolites were
measured and the reasoning behind these selections.
1.4.1 Oxygen regulation
Oxygen levels are constantly monitored by redox-sensitive and oxygen-responsive
transcription factors and cytokines within the body [Haddad, 2002]. Any change in
the amount of oxygen available leads to a pre-defined response mediated primarily
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by hypoxia inducible factor (HIF)-1↵, the master gene regulator for hypoxia adap-
tation, which has over 300 confirmed downstream targets [Haddad, 2002; Wenger,
2002]. In the presence of oxygen, the HIF-1↵ protein undergoes continuous protea-
somal degradation. During hypoxia the protein is stabilised and binds to hypoxia-
responsive element (HRE) sites on DNA to cause activation of hypoxia-inducible
targets. Examples of targets include erythropoietin [Semenza and Wang, 1992],
transferrin, energy metabolism genes, cell proliferation genes and vascular develop-
ment genes, for example vascular endothelial growth factor (VEGF) and inducible
nitric oxide synthase (iNOS). This allows the cell to switch from using oxygen to
produce energy during aerobic respiration, to anaerobic respiration when oxygen is
scarce. HIF-1↵ is also known to be regulated by several other molecules, including
nitric oxide (NO) and reactive oxygen species (ROS) [Wenger, 2002]. Several HIF-
1↵ targets have been measured in this study, to monitor HIF-1↵ activity and track
the progress of cellular hypoxia adaptation. These include NO metabolites, VEGF,
erythropoetin and other related metabolites.
1.4.1.1 Nitric oxide
Nitric oxide (NO) is produced enzymatically by mammalian cells and has been
found to have roles in hypoxia adaptation, as well as in the gastrointestinal tract,
immune system, central nervous system, respiratory system, cardiovascular system
and cell proliferation [Erzurum et al., 2007; Moncada et al., 1991]. NO is produced
from L-arginine via 3 isoforms of Nitric Oxide Synthase (NOS) and via reduction of
endogenous inorganic nitrite, as shown in Figure 1.2. Neuronal NOS (nNOS) and
endothelial NOS (eNOS) are both constitutively expressed, whereas inducible NOS
(iNOS) is only expressed upon exposure to specific stimuli, such as pro-inflammatory
cytokines and HIF-1↵ binding during hypoxia [Melillo et al., 1995]. Both eNOS and
nNOS play roles in hypoxia adaptation and the immune response, primarily by
increased blood flow [Erzurum et al., 2007; Delannoy et al., 2010]. This is achieved
by causing vascular smooth muscle to relax; NO di↵uses into smooth muscle cells
and activates soluble guanylate cyclase (sGC), which leads to the production of
the secondary messenger molecule cyclic guanosine monophosphate (cGMP). cGMP
then acts on smooth muscle cells, causing them to relax. eNOS knockout mice show
high blood pressure, indicating that NO also plays a role in general blood pressure
regulation [Huang, 1999; Stauss et al., 1999].
NO is oxidised in a step-wise manner to nitrite (NO 2 ) and nitrate (NO
 
3 ),
and in blood NO is almost completely converted to nitrite and nitrate [Yoshida
et al., 1983]. The main source of nitrate is from the diet, with green leafy vegetables
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Figure 1.2: A brief summary of part of the NO pathway in plasma. Nitrite and
nitrate are oxidation products of NO, but may also act as an alternative NO source.
NO binds to soluble guanylate cyclase (sGC), increasing the production of cGMP
from GTP. cGMP then acts on vascular tissue to cause smooth muscle relaxation.
Membrane-bound particulate GC (pGC) produces cGMP following stimulation by
either atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) or C-type
natriuretic peptide (CNP), independently of NO. They are measured in this study
to determine whether any change seen in cGMP is due to a change in NO, ANP,
BNP or CNP.
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being a particularly rich source. Nitrite and nitrate have also been shown to be
reduced back to NO in vivo, and may also provide an alternative source of NO in
the human cell [Lundberg and Weitzberg, 2005; Lundberg et al., 2008], as shown in
Figure 1.2.
In plasma, the half-life of NO is in the region of milliseconds [Hakim et al.,
1996]. Therefore, the amount of NO in plasma cannot currently be measured di-
rectly. Alternatively, the quantification of NO metabolites can give information
about NO production, availability and metabolism, such as those shown in Fig-
ure 1.2. Therefore, the measurement of metabolites such as nitrite, nitrate and
cGMP can give information on pathways downstream from HIF-1↵, and therefore
give information about how the body is responding to lower oxygen availability.
Several cytokines were also measured as they are known to interact with NO
and its products to facilitate inflammation, fight infection and regulate metabolism.
For example, NO is known to be generated by phagocytes as part of the human
immune response via iNOS, which can be activated by interferon-gamma (IFN- ) or
tumour necrosis factor (TNF). The activity of iNOS is inhibited by other cytokines
such as interleukin (IL)-4 and IL-10 [Moncada et al., 1991].
1.4.2 Redox regulation
The so-called oxygen paradox is that oxygen is inherently dangerous to cells, how-
ever, aerobic organisms require oxygen to generate ATP and cannot survive without
it. Each oxygen atom has two unpaired electrons in its outer shell, making it a free
radical. The reduction of oxygen to generate ATP by mitochondria is essential to the
cell, however, the univalent reduction of oxygen generates highly reactive interme-
diate species, the formation of which are promoted due to the reductive atmosphere
of the cell. Reduction of this kind can generate hydrogen peroxide (H2O2) and the
hydroxyl radical (•OH), which are known as reactive oxygen species (ROS), and can
cause large amount of damage to the cell. This is also a major problem in critically
ill patients, who have di culty in responding to increased levels of oxidative stress.
During hypoxia, there is thought to be an accumulation of reducing equiva-
lents in the mitochondrial transport chain, due to a reduction in oxygen availability
to act as an electron acceptor, which may in turn lead to an increase in the pro-
duction of ROS [Kehrer and Lund, 1994; Chandel et al., 1998]. If the cell is unable
to remove the excess ROS, it is said to be in a state of oxidative stress. ROS are
known to have an e↵ect on the stability and signalling of HIF-1↵ [Bru¨ne and Zhou,
2007], and have been shown to interact with NO to form secondary reactive nitric
oxide species and reduce the bioavailability of free NO [Bru¨ne and Zhou, 2007; Feel-
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Figure 1.3: Reactive Oxygen Species (ROS) summary, showing oxygen becoming
a free radical. This free radical can then react with nitric oxide (NO) to form
reactive nitrogen oxygen species (RNOS) such as ONOO , which can stimulate
oxidative stress within the cell. Superoxide dismutase (SOD) catalyses the dis-
mutation/disproportionation of superoxide free radical oxygen (O 2 ) into hydrogen
peroxide (H2O2) and oxygen, acting as an important antioxidant. H2O2 is then
converted into water via the action of catalase and glutathione-dependent peroxi-
dase (GPx), which leads to the formation of oxidised glutathione (GSSG). GSSG is
then readily converted back to the reduced form (GSH) by the action of glutathione
reductase (GR).
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isch, 2007], as shown in Figure 1.3. Therefore, measurement of ROS would provide
information on how the body is responding to a lower availability of oxygen.
To combat the formation of ROS within the cell, cells produce antioxidants
such as glutathione, which react with ROS and remove them from the cell safely,
as shown in Figure 1.3. It is not currently possible to measure the amount of ROS
directly. Therefore, the levels of products formed during the interaction of ROS
with biological targets such as hydroxynonenal (HNE) and isoprostanes, as well as
antioxidant levels are measured in this study as indicators of oxidative stress.
1.4.3 Inflammation
Acute-phase proteins are a class of proteins that show changes in expression in
response to inflammation, known as the acute-phase response. Inflammatory re-
sponses were expected to occur during CXE 2007 due to the high levels of stress
the team were subjected to. During injury, inflammatory cells such as macrophages
and neutrophils secrete a number of cytokines into the bloodstream, to mediate the
inflammatory response. Inflammation typically accompanies disease, and is present
in many cases of critical illness. Cytokines such as IL-1, IL-6, IL-8 and TNF-↵
were measured during this study to monitor the level of inflammatory response seen
during the expedition. Measurement of these proteins was also of interest due to
the cross-talk that occurs with NO-related metabolites during inflammatory and
immune responses, as previously mentioned in Section 1.4.1.1.
1.4.4 Metabolism and organ function
Cytokines and hormones are small protein molecules that act as signalling molecules
between cells. A large number of signalling molecules were measured to monitor
any cross-talk between cells occurring during the expedition. The measurement
of hormones such as insulin and glucagon provides information on changes in cell
metabolism during CXE 2007. Molecules such as glucose and lactate provide infor-
mation on the energy production and use of cells. Organ function was monitored
by the measurement of molecules such as creatinine, which provides information on
kidney function.
1.5 Purpose of the study
The main aim of my thesis project was to develop a series of statistical models ca-
pable of predicting how an individual will respond to hypoxic stress, from measured
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changes in certain biochemical metabolites. The models were constructed using a
population response, with the aim of applying the final models to individual cases.
There is substantial data available, including 65 physiological measurements and 59
biochemical metabolites, providing a good possibility of finding novel relationships
for modelling.
1.6 Assumptions
The general assumptions for this thesis project are that:
1. Data collected from CXE 2007 can be used to design predictive models;
2. The physiological data can be used as a reliable indicator of how well an
individual is adapting to hypoxic exposure (i.e. that exercise performance at
altitude can be used as a proxy for hypoxia adaptation);
3. The biochemical data can be used to predict a physiological response;
4. The information we extract from this data can be useful for the application
to critically ill patients;
5. The information we extract from this data can be used to inform the Xtreme
Everest 2 (XE2) follow-up study in 2013.
1.7 Research questions
In order to test the hypotheses for this thesis project, the following questions were
posed:
1. Is there a di↵erence between how the lab group and climber groups respond
to altitude?
2. Are there di↵erences in the physiological responses seen between individuals?
3. Are there di↵erences in the biochemical responses seen between individuals?
4. Which physiological measurements appear to be the most suitable for measur-
ing how well an individual is adapting to altitude/hypoxia?
5. Is there a pattern of biochemical metabolites that can be used to predict how
well an individual will adapt to hypoxia?
18
6. Can this data be used to create a model capable of predicting how well a
critically ill patient will respond to hypoxic stress?
7. Can the predictive models formed be used to inform the planned XE2 follow-up
study?
8. Can any of these predictions be validated during the planned XE2 follow-up
study?
1.8 Scope of the study
Systems Biology is an integrative inter-disciplinary approach to answering biological
questions. During this thesis project, biological experimentation has been integrated
with statistical analysis to extract as much information from the data as possible.
A Systems Biology approach is cyclic, as shown in Figure 1.4, where data is used
to inform a model, and the resulting model informs further data collection. It was
not possible to complete the cycle of data and modelling during this thesis project,
however, the results from this project can be used to inform further data collection
and analysis by other members of the Feelisch laboratory and the CXE team.
1.9 Outline of thesis
This thesis project will look at:
• The materials and methods used during this thesis project;
• The results for the biochemical measurements carried out by myself;
• The analysis of the 16 physiological measurements collected on each day of
the expedition, denoted the diary data;
• Exploratory statistical analysis of the physiological and biochemical informa-
tion available in the main dataset, denoted the core data;
• Exploratory modelling analysis, looking at relationships between physiological
and biochemical metabolites;
• A targeted modelling analysis, looking at the prediction of a change in a small
number of biologically relevant physiological measurements with a combination
of biochemical metabolites;
• A discussion of the results and applications of the models formed.
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Figure 1.4: Systems Biology - an iterative cycle of data collection (experiment), data
analysis, model construction, model analysis/refinement combined with biological
insight to validate or propose a hypothesis, which can be used to inform further
experiments.
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1.10 Thesis contribution
Throughout the course of this thesis project, I have contributed to data acquisi-
tion and undertaken all of the statistical analysis. I have become familiar with
the di culties associated with collecting these data, and gained insight into causes
of systematic and random errors. During data acquisition, I contributed to the
measurement of biochemical metabolites in plasma samples taken from the 24 core
team members during CXE 2007. I measured four oxidative stress metabolites via
assay-kits, 14 diabetes and metabolism-related metabolites using xMAP technology,
and plasma osmolality. I also helped with sea-level testing for the follow-up study
Xtreme Alps, where I gained first-hand experience in the issues regarding CPEX
testing and blood sampling.
I have performed exploratory data analysis to gain a better understanding
of the main patterns seen in the dataset, and inter-individual di↵erences seen for
physiological measurements and biochemical metabolites. I have undertaken vari-
able selection, and performed several versions of linear and multiple linear regression
analysis on the dataset, to produce a series of models, capable of predicting a phys-
iological measurement at a certain altitude, or a change in a specific physiological
metabolite between two altitudes. These models can now be used to inform further
analysis of the trekker plasma samples, and be used to inform the CXE follow-up
study in 2013.
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Chapter 2
Materials and Methods
This section details the biochemical experiments and statistical analyses that were
carried out at The University of Warwick as part of my thesis project. All detailed
experiments were carried out on plasma samples collected during CXE 2007, which
were kept stored at -80oC until use.
In addition to the data collection detailed in this section, further experiments
were carried out on aliquots of the same plasma samples by members of the Feelisch
laboratory at The University of Warwick. Physiological data were also collected
during CXE 2007, and these data have been combined into one master dataset,
denoted the core dataset. Physiological data are also available for a further 190
trekker individuals. A third dataset, denoted the diary data is an additional dataset
collected for the 24 core team members, consisting of a small number of daily physi-
ological measurements collected throughout the expedition. Collectively, these data
were used in the statistical analysis carried out as part of my thesis project.
2.1 Xtreme Alps
In 2010, a CXE follow-up study was carried out, denoted Xtreme Alps. During this
study, I contributed to the collection of sea-level physiological data and assisted with
blood sample collection. Here, I gained first-hand experience in how the VO2max
exercise performance tests were carried out, and any problems associated with these
tests. One such problem is haemolysis, where red blood cells are ruptured during
blood collection, and their contents are released into the plasma. Occurrences of
such events were recorded to help account for any anomalous measurements when
analysing the plasma samples at a later date.
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2.2 Biochemical analyses
This section details the biochemical experiments carried out as part of my thesis
project. It includes information about specific methods used, as well as some back-
ground information on the metabolites being assessed.
2.2.1 Measurement of 8-iso-Prostaglandin F2↵
Total 8-iso-Prostaglandin F2↵ (8-isoPGF2↵) levels were quantified in the 24 core
team member’s plasma samples by using a direct 8-isoPGF2↵ Enzyme Competitive
Immunoassay Kit from Assay Designs (catalogue number 901-091), according to the
supplier’s recommendations. 100µl plasma samples were hydrolysed by incubation
with 25µl of 10 N NaOH at 45oC for 2 hours. The reaction mixture was cooled on
ice for 5 minutes and neutralised with 25µl of 12 N HCl, then centrifuged in a mi-
crocentrifuge for 5 minutes. The clear neutralised supernatant was then transferred
to a new microcentrifuge tube, and 50µl of sample was used for the 8-isoPGF2↵
assay.
The samples were incubated with the 8-isoPGF2↵ antibody for 18 hours at
4oC in a 96-well plate. After incubation, the contents of the wells were emptied
and washed with wash bu↵er. Wash bu↵er was removed from the wells and the
colour was developed by incubation with 200µl of p-nitrophenyl phosphate for 45
minutes at room temperature. The reaction was stopped by the addition of 50µl of
stop solution, and the plate was read at 405nm in a Molecular Devices SpectraMax
M5 Microplate reader. A standard curve was generated by measuring the opti-
cal density of 160-100 000pg/ml of 8-isoPGF2↵ standards that had been processed
simultaneously to the samples, on the same 96-well plate.
2.2.2 Glutathione determination
2.2.2.1 Tietze glutathione recycling assay
There are several di↵erent methods for the measurement of glutathione, with the
gold standard being the Tietze recycling assay. A plate-reader adaptation of the
Tietze recycling assay protocol had previously been used in the Feelisch lab for the
determination of reduced and oxidised glutathione in fresh rat tissue and plasma.
This protocol was modified over several months, to enable measurement of both
reduced and oxidised glutathione in frozen human plasma samples.
However, after several months of work it was still not possible to obtain
consistent standard curves at low glutathione concentrations, or reliably measure
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glutathione levels in human plasma samples that had been frozen. The final sensi-
tivity for the assay was down to 0.06µM for oxidised glutathione, and 0.47µM for
reduced glutathione, and was only measurable in standards, shown in Table 2.1.
The di↵erent steps taken during the refinement of the protocol are detailed
in section 3.1.2.1. The final refined assay protocol is detailed below.
2.2.2.2 Glutathione assay protocol
Reagents:
• 1x bu↵er (0.1M) and 5x bu↵er (0.5M);
– NaPO4 (Sigma-Aldrich: S9638);
– 0.5M EDTA (Gibco/Invitrogen: 15575-038);
• NADPH (Sigma: N7505);
• 10% Metaphosphoric Acid (MPA) (Sigma-Aldrich: 239275);
• 2-Vinyl Pyridine (2-VP) (Aldrich: 132292);
• Glutathione Reductase (GR);
– Sigma (Item No. G3664-500): Glutathione reductase from Baker’s yeast;
– Roche (Ref. No. 10105678061): Glutathione reductase from yeast;
• 5,5-Dithiobis-2-nitrobenzoic acid (DTNB) (Sigma: D8130).
Standards:
GSSG (Oxidised Glutathione): 3mM stock was made by adding 0.04595g GSSG
and bu↵er to make 25ml. Two sets of tubes were labelled (23 total), and serial dilu-
tions were carried out as shown in Table 2.1. 100µl of each standard was added to a
new tube. 100µl of cold 10% MPA was added to each tube. 20µl of 2-VP was then
added to derivatise the sample, and was incubated at room temperature for 1 hour
in a flow-hood. 180µl of 5X bu↵er was added to neutralise the MPA, and the pH was
checked to make sure it was around 7. The samples were then stored on ice until use.
GSH (Reduced Glutathione): 3mM stock was made by adding 0.02305g GSH
and bu↵er to make 25ml. Two sets of tubes were labelled (17 in total) and dilutions
were carried out as shown in Table 2.1. 100µl of each reduced standard was added
to a new tube. 100µl of cold 10% MPA was added to each tube. 200µl of 5X bu↵er
was then added to neutralise the MPA, and the pH was checked to make sure it was
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Standard con-
centration (µM)
Dilution
factor
Volume of previous
solution (µL)
Volume of
bu↵er (µL)
GSSG
- 300 1:10 100 (3mM) 900
1 30 1:10 100 (300µM) 900
2 15 1:2 500 (30µM) 500
3 7.50 1.2 500 (15µM) 500
4 3.75 1.2 500 (7.50µM) 500
5 1.88 1:2 500 (3.75µM) 500
6 0.94 1:2 500 (1.88µM) 500
7 0.47 1:2 500 (0.94µM) 500
8 0.23 1:2 500 (0.47µM) 500
9 0.12 1:2 500 (0.23µM) 500
10 0.06 1:2 500 (0.12µM) 500
11 0 - - 1000
GSH
- 300 1:10 100 (3mM) 900
1 30 1:10 100 (300µM) 900
2 15 1:2 500 (30µM) 500
3 7.50 1.2 500 (15µM) 500
4 3.75 1.2 500 (7.50µM) 500
5 1.88 1:2 500 (3.75µM) 500
6 0.94 1:2 500 (1.88µM) 500
7 0.47 1:2 500 (0.94µM) 500
8 0 - - 1000
Table 2.1: Standard dilutions for reduced glutathione (GSH) and oxidised glu-
tathione (GSSG) for the Tietze glutathione recycling assay.
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around 7. The samples were then stored on ice until use.
Preparation of plasma samples: Three sets of eppendorf tubes were labelled for
each sample to be analysed; labelled MPA, oxidised (O) and reduced (R). 100µl of
10 % MPA was added to the MPA tubes, 7.5µl of 2-VP was added to the O tubes
and the R tubes were left empty. 100µl of plasma sample was added to the MPA
tubes and vortexed. The MPA precipitates any protein within the sample, so that
it did not interfere with glutathione measurement. The tubes were then centrifuged
at 10 000g for 10 minutes at 4oC. 75µl of the MPA extract (supernatant) was added
as quickly as possible to each of the O and R tubes (to prevent further reduction of
the sample). The O tubes were left to sit on ice for 1 hour. 67.5µl of 5X bu↵er was
added to the O tubes to neutralise the MPA. 75µl of 5X bu↵er was added to the R
tubes, and they were placed on ice until use.
Assay: 50µl of blank (1X bu↵er), standards or samples were added to the wells of
a 96-well microplate. 86µl bu↵er, 7µl of 10mM DTNB and 21µl of 5mM NADPH
was then added to each well. The plate was mixed well, and incubated at 37oC for
10 minutes within the microplate reader. 36µl of 15U/ml GR was added to each
well, and the change in absorbance was recorded at 412nm over 5 minutes.
Calculations: Standard curves were calculated from the OD readings for the stan-
dard samples prepared, detailed in Table 2.1. The reaction rates for the samples
were calculated by subtracting the appropriate 0.0 rate from each sample. The stan-
dard curves were then used to determine the concentrations for total and oxidised
glutathione. Reduced glutathione was calculated by subtracting twice the oxidised
glutathione concentration from the total glutathione value.
2.2.2.3 Glutathione fluorescence assay
Due to the poor reliability of the glutathione assay, reduced glutathione (GSH),
oxidised glutathione (GSSG) and total glutathione were quantified in the 24 core
team’s plasma samples by using a BioVision protocol Glutathione Assay Kit (cat-
alogue number K264-100), according to the supplier’s recommendations. 60µl of
plasma sample was thawed, and added to a microcentrifuge tube containing 20µl of
ice cold perchloric acid (PCA). The sample was vortexed and kept on ice for 5 min-
utes. The sample was spun in a microcentrifuge at 13 000g at 4oC, and 40µl of the
supernatant was collected and transferred to a new tube. 20µl of ice cold potassium
hydroxide (KOH) was added to the sample to neutralise the samples (the pH was
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tested to be 5-10). The samples were incubated on ice for 5 minutes, and then spun
in a microcentrifuge at 13 000g at 4oC for 2 minutes. 10µl of the neutralised sample
was transferred to a 96 well plate in triplicate, to measure GSH, total glutathione
and GSSG separately. These samples were then prepared further as follows:
• To detect GSH: 80µl of assay bu↵er was added to each well.
• To detect total glutathione: 70µl of assay bu↵er was added to each well.
10µl of reducing agent mix was added to each well, mixed thoroughly and
incubated at room temperature for 10 minutes to convert all GSSG present to
GSH.
• To detect GSSG: 70µl of assay bu↵er was added to each well. 10µl of GSH
quencher was added to each well, mixed well and incubated for 10 minutes at
room temperature to quench all GSH present. 10µl of reducing agent mix was
then added to each well to destroy the excess GSH quencher and convert the
GSSG present to GSH.
10µl of o-phthalaldehyde (OPA) probe was added to each well, mixed thor-
oughly and incubated at room temperature for 40 minutes. Samples were then
measured for fluorescence at 340/420nm in a Molecular Devices SpectraMax M5
Microplate reader. A standard curve was generated by measuring the fluorescence
of 0.19 - 25µM GSH and total glutathione standards that had been processed si-
multaneously to the samples, on the same 96-well plate.
2.2.3 Determination of osmolality
An Advanced Model 3300 Micro-Osmometer was used to measure the osmolality of
the 24 core team member’s plasma samples. 20µl plasma samples were loaded into
the Micro-Osmometer with the use of Advanced Ease-Eject Samplers. Each 20µl
sample was aspirated into a new sample tube, and inserted into the instrument’s
vertical holder. The holder was pressed down, and the testing began automatically,
with results being displayed after 60 seconds.
2.2.4 BioPlex analysis
A Bio-Rad BioPlex 200 system was used in conjunction with a BioPlex Pro Human
Diabetes 12 + 2-Plex Panel Complete Kit (catalogue number 171-A4S01M), accord-
ing to the supplier’s recommendations, to measure 14 cytokines in human plasma
samples (detailed in Table 2.2). Samples were prepared separately for the 12-plex
27
Metabolite Description
Adipsin Also known as Factor D, found in high levels in adipose (fat) tissue, plays
a role in humoral suppression of infectious agents. The level of adipsin
is elevated in obese individuals.
Adiponectin Involved in regulating glucose levels (decreases gluconeogenesis and in-
creases glucose uptake) as well as the breakdown of fatty acids. Exclu-
sively secreted from adipose tissue, highly abundant in plasma.
C-Peptide Produced in a long chain attached to insulin. When cleaved apart,
C-peptide plays a role in intracellular signalling pathways, has anti-
inflammatory e↵ects as well as aiding in the repair of smooth muscle
cells. It is used to distinguish between type I and type II diabetes.
GIP Glucose-dependent insulintropic peptide is a member of the secretin fam-
ily of hormones, believed to induce insulin secretion. It is induced by
hyperosmolarity of glucose in the duodenum.
Ghrelin Shown to activate the endothelial form of nitric oxide synthase. Pro-
duced by adipose tissue to induce satiation when present at high levels,
it has been associated with obesity, insulin resistance and high blood
pressure [Xu et al., 2008].
Glucagon Secreted by the pancreas, it raises blood glucose levels when they fall
low by causing the liver to break down stored glycogen into glucose.
GLP-1 Glucagon-like peptide-1, increases secretion of insulin, decreases
glucagon secretion, increases satiety in the brain, thus decreasing food
intake and promotes insulin sensitivity of cells.
IL-6 Acts as both a pro and anti-inflammatory cytokine, secreted by T-cells
and macrophages to stimulate the immune response after trauma. Also
released from muscle cells, and is elevated in response to muscle contrac-
tion. It has inhibitory e↵ects on TNF-↵, IL-1, IL-1ra and IL-10.
Insulin Secreted by the pancreas in response to high blood glucose levels. It
stimulates cells to take up glucose from the blood and promotes the
storage of glycogen. It inhibits the release of glucagon.
Leptin Plays a key role in energy uptake and energy expenditure, inducing ap-
petite and metabolism. It promotes angiogenesis by increasing VEGF
levels.
PAI-1 Plasminogen activator inhibitor-1, present in increased levels during obe-
sity and metabolic syndrome.
Resistin Secreted by immune and epithelial cells, thought to play a role in in-
flammation by increasing levels of IL-1, 6, 12 and TNF-↵. Thought to
have links to both obesity and insulin resistance.
TNF-↵ Pro-inflammatory cytokine, involved in the regulation of immune cells, it
can induce fever, induce apoptosis, sepsis (via IL-1 and IL-6 production),
induce inflammation and inhibit viral replication and tumorigenesis.
Visfatin Promotes vascular smooth muscle cell maturation, activates insulin re-
ceptors and has insulin-mimic e↵ects, such as lowering blood glucose
levels and increasing insulin sensitivity.
Table 2.2: A list of metabolites related to diabetes, inflammation and metabolism,
measured with a BioPlex machine.
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and 2-plex assays. 25µl plasma samples were diluted by adding 75µl of human-
specific BioPlex sample diluent. The samples were stored on ice until use, and 50µl
of sample was used for the BioPlex assays.
A 96-well filter plate was pre-wet with 100µl of BioPlex assay bu↵er. The
bu↵er was then removed by vacuum filtration, and the bottom of the filter plate
was dried using a lint-free paper towel. The multiplex bead working solution was
vortexed for 15-20 seconds at a medium speed, and 50µl was added to each well. The
bu↵er was then removed by vacuum filtration, and the plate was washed twice with
100µl of BioPlex wash bu↵er, removing the bu↵er by vacuum filtration after each
wash. 50µl of diluted sample or standard was added to each well, and the plate was
covered with sealing tape. The plate was placed on a microplate shaker and covered
with aluminium foil. The shaker speed was slowly increased to 1100rpm for 30
seconds, then reduced to 300rpm, and the plate was incubated at room temperature
for 30 minutes.
After incubation, the sealing tape was removed and the bu↵er was removed
by vacuum filtration. The sample was washed 3 times with 100µl of BioPlex wash
bu↵er. The BioPlex detection antibody working solution was vortexed gently, and
25µl was added to each well. The plate was covered with a new piece of sealing tape
and placed onto a microplate shaker, and covered with aluminium foil. The shaker
speed was slowly increased to 1100rpm for 30 seconds, then reduced to 300rpm, and
the plate was incubated at room temperature for 30 minutes.
After incubation, the sealing tape was taken o↵ and the bu↵er was removed
by vacuum filtration. The sample was washed 3 times with 100µl of BioPlex wash
bu↵er. The 1 x streptavidin-PE was vortexed vigorously and 50µl was added to
each well. The plate was covered with a new piece of sealing tape and placed onto
a microplate shaker, and covered with aluminium foil. The shaker speed was slowly
increased to 1100rpm for 30 seconds, then reduced to 300rpm, and the plate was
incubated at room temperature for 10 minutes.
After incubation, the sealing tape was removed and the bu↵er was removed
by vacuum filtration. The sample was washed 3 times with 100µl of BioPlex wash
bu↵er. 125µl BioPlex assay bu↵er was added to each well to re-suspend the beads,
and the plate was then covered in sealing tape. The plate was placed on a microplate
shaker at 1100rpm for 30 seconds immediately before reading plate on the BioPlex
system. The sealing tape was removed before reading.
The plate was placed in a Bio-Rad BioPlex 200 system, and read using the in-
built software. Concentrations (pg/ml) of di↵erent cytokines in the plasma samples
were determined by using the standard curves generated in the multiplex assays.
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Each standard curve was generated using eight data points, and a nonlinear least
squares minimisation algorithm was used for the curve fitting by the five-parameter
logistic equation and to determine the high and low limits of detection.
2.2.5 Cardiopulmonary Exercise Testing (CPX/CPET)
Cardiopulmonary Exercise Testing (CPX/CPET) is a set of measurements that look
at an individual’s exercise performance in terms of their cardiac and pulmonary
function. The CPX test is usually performed during exercise on a static bicycle,
during which the subject is attached to an ECG and respirometry machine, and
has a breathing mask fitted, as shown in Figure 2.1. The mask is attached to a
computer that constantly monitors oxygen consumption and carbon dioxide pro-
duction throughout the testing. The subject begins to pedal against a continually
increasing resistance setting on the bike, whilst ECG readings and oxygen and car-
bon dioxide gas samplings are continually taken. These readings are then used to
calculate an individual’s lactate threshold (LaT, the threshold at which anaerobic
respiration begins to supplement aerobic respiration), and determine their cardiopul-
monary function. The lactate threshold is determined by measuring lactate levels
in the blood during exercise, and is the point during exercise of increasing intensity
where the lactate levels in the blood rapidly begin to accumulate above normal rest-
ing levels. This indicates that the clearance of lactate can no longer keep up with
lactate production, and is used to determine when anaerobic respiration begins to
supplement energy production by aerobic respiration.
CPX measures the ventilation rate, the e↵ectiveness of ventilation, oxygen
use and clearance of carbon dioxide to give a clear picture of an individual’s car-
diopulmonary function. CPX testing was carried out during CXE 2007, to measure
each individual’s exercise performance during the expedition. A full list of the mea-
surements acquired is shown in Table 2.4.
2.3 Data available
There are three main datasets available, as detailed in Table 1.2, denoted the core
dataset, trekker dataset, and the diary dataset. The core dataset consists of physi-
ological information collected during CXE 2007, and biochemical metabolites mea-
sured in plasma samples taken during CXE 2007, and measured by both myself
and other members of the Feelisch laboratory at The University of Warwick dur-
ing the course of my thesis project. This dataset contains information for 24 core
team individuals only, including 65 physiological measurements and 59 biochemical
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Figure 2.1: Cardiopulmonary exercise testing for Caudwell Xtreme Everest 2007,
taken from the CASE website.
31
metabolites, at 7 di↵erent time-points, as detailed in Tables 2.3 and 2.4. These
measurements collectively form the basis for all analysis undertaken in Chapters 5,
6 and 7.
The trekker dataset consists of 62 physiological measurements taken during
CXE 2007, at 5 di↵erent time points. Plasma samples are available for this group
of individuals, but have not yet been measured. The diary dataset consists of 16
di↵erent daily measurements for the full 78 days of the expedition, and is available
for the 24 core team individuals only. The full list of these diary measurements is
shown in Table 4.1, and assessed in Chapter 4.
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Number Biochemical pathway Analyte shorthand name Units
1 NO Nitrite µM
2 NO Nitrate µM
3 NO Total NOx µM
4 NO RSNO nM
5 NO RNNO nM
6 NO Total RxNO nM
7 NO cGMP pmol/ml
8 NO proANP nmol/L
9 NO BNP fmol/ml
10 NO CNP pmol/L
11 ROS proCO mmol/mg
12 ROS 8-isoPGF ng/ml
13 ROS HNE mg/ml
14 ROS GSH µM
15 ROS GSSG µM
16 ROS GSH:GSSG ratio
17 ROS GSH/GSSG redox
18 Cytokines IL-↵ pg/ml
19 Cytokines IL-  pg/ml
20 Cytokines IL-1ra pg/ml
21 Cytokines IL-4 pg/ml
22 Cytokines IL-6 pg/ml
23 Cytokines IL-8 pg/ml
24 Cytokines IL-10 pg/ml
25 Cytokines IL-12(p40) pg/ml
26 Cytokines IL-13 pg/ml
27 Cytokines IL-18 pg/ml
28 Cytokines MIF pg/ml
29 Cytokines Eotaxin pg/ml
30 Cytokines TNF-↵ pg/ml
31 Cytokines IFN-  pg/ml
32 Cytokines VEGF pg/ml
33 Cytokines CRP ng/ml
34 Hormones Epinephrine ng/ml
Continued on next page
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2.3 – continued from previous page
Number Biochemical pathway Analyte shorthand name Units
35 Hormones Norepinephrine ng/ml
36 Hormones T3 pg/ml
37 Hormones T4 pg/ml
38 Hormones C-Peptide pg/ml
39 Hormones GIP pg/ml
40 Hormones Ghrelin pg/ml
41 Hormones Glucagon pg/ml
42 Hormones GLP-1 pg/ml
43 Hormones Insulin pg/ml
44 Hormones Leptin pg/ml
45 Hormones PAI-1 pg/ml
46 Hormones Resistin pg/ml
47 Hormones Visfatin pg/ml
48 Hormones Adiponectin pg/ml
49 Hormones Adipsin pg/ml
50 Hormones EPO mlU/ml
51 Hormones ET-1 pg/ml
52 Metabolic/Renal Markers Glucose mM
53 Metabolic/Renal Markers Cystatin-C ng/ml
54 Metabolic/Renal Markers Creatinine mg/dl
55 Metabolic/Renal Markers Lactate mM
56 Metabolic/Renal Markers Osmolality mOsmo/kg
57 Other Protein content mg/ml
58 Other Bicarbonate mmol/L
59 Other HSP-70 pg/ml
Table 2.3: Full list of biochemical metabolites measured in plasma samples taken
from 24 core-team individuals, at 5 di↵erent laboratories (7 di↵erent time-points)
during CXE 2007.
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Parameter Additional information
Gender
Weight Kg
Barometric pressure kilopascals (kPa)
Inspired O2 partial
pressure
The partial pressure (Pi) O2 would have if it alone occupied
a volume (kPa)
Ambient tempera-
ture
Degrees Celsius
Economy Measure of oxygen e ciency expressed as rate of oxygen
consumption per workload (mls O2 per Watt)
Maximum voluntary
ventilation
Maximal breathing capacity The greatest volume of gas that
can be breathed per minute by voluntary e↵ort - L/min
Forced expiratory
volume in 1 second
Volume exhaled during the first second of a forced expiratory
manoeuvre, started from the level of total lung capacity -
L/min
Exercise ramp
wattage
The workload increase /min during the CPX measured in
Watts
Haemoglobin Iron-containing oxygen transport protein in red blood cells
(g/dl)
Blood O2 content The volume of oxygen carried within the blood - mls O2/L
Haematocrit The volume % of red blood cells in the blood
SBP at rest Systolic Blood Pressure (mm Hg)
DBP at rest Diastolic Blood Pressure (mm Hg)
SBP after exercise (mm Hg)
DBP after exercise (mm Hg)
The following measurements were taken at rest, at lactate threshold and at VO2max
O2 consumption The volume of oxygen being consumed by the body per
minute - mls O2/kg/min
O2 consumption / kg mls O2/kg/min (normalised per kg body weight /min)
Respiratory ex-
change ratio
Ratio of CO2 production to O2 consumption. Used in
VO2max test to see when individual has reached maximal
energy consumption.
Heart rate Number of heart beats per minute (beats/min)
Continued on next page
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2.4 – continued from previous page
Parameter Additional information
Minute ventilation Volume of gas inhaled/exhaled from the lungs in one minute
(L/min)
CO2 production The di↵erence between the volume of CO2 exhaled from the
lungs and the volume inhaled into the lungs (L/min)
Respiratory equiva-
lent for O2
The ratio of the volume of inspired air and the amount of
oxygen consumed by the tissues
Respiratory equiva-
lent for CO2
The ratio of inspired air to the amount of carbon dioxide
produced
O2 pulse Surrogate of stroke volume during exercise. Normalises O2
consumption for heart rate, calculated from O2 consumption
and HR (ml O2/beat)
Respiratory rate Number of breaths per minute (breaths/min)
Tidal volume The normal volume of air displaced between normal inspira-
tion and expiration when extra e↵ort is not applied (L/min)
Partial pressure end
tidal O2
The partial pressure of oxygen at the end of exhalation (mm
Hg)
End tidal partial
pressure CO2
The level of CO2 released at the end of expiration (mm Hg)
O2 saturation Haemoglobin (Hb) saturation measured in samples obtained
from arterial puncture (%)
The following measurements were available at lactate threshold and VO2max
Work rate The amount of energy expended during physical exercise
(Watts)
Oxygen cost The volume of oxygen used by the body during LaT or at
VO2max. It is directly related to the energy demands of the
particular activity, and a↵ected the nature of the substrate
respired. Calculated by: work rate / O2 consumption (/kg)
(Watts/mlsO2/kg/min)
Table 2.4: Full list of physiological measurements measured for 24 individuals during
CPX testing, at 5 di↵erent laboratories during CXE 2007.
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2.4 Missing data
Exposure to an extreme environment, such as the conditions experienced during
CXE 2007, leads to the stimulation of multiple adaptive response pathways. These
pathways communicate and interact with one another, to produce a complex systems
response to stress. Such responses mean that missing data values are likely within a
dataset that is trying to capture the complexities of such a response. These may be
due to certain samples or a specific technique not being available for measurement
(due to illness or a temporary machine failure), human error during experiments or
measurements being either above or below quantifiable limits.
An incomplete dataset can become a problem when it comes to further anal-
ysis. Some analyses will not work with missing values, and as biological experiments
usually contain a relatively small number of samples, leaving one sample out of the
whole analysis due to one missing datapoint could bias the analyses, or leave out
vital information, leading to erroneous conclusions.
2.4.1 Treatment of incomplete datasets
If a dataset is missing values, there are two options available, depending on why val-
ues are missing. If a measured sample gives a value above or below the quantifiable
limit of the equipment, then there is still some potentially useful information that
can be gained from this datapoint. If the sample is below the detection limit of the
equipment, it is very unlikely that the sample is simply empty of the material you
are testing it for (samples are rarely completely empty of a particular metabolite).
The simplest solution to this problem would be to impute a value half-way between
zero and the lowest limit of the equipment being used. This way, some information
can be gained from the sample that may be useful to the analysis.
If samples are missing, it is more di cult to accurately impute their values.
Individual values can be estimated by assessing how that individual responds in
comparison to all other individuals, and impute the missing value based on that
individual’s average ranking within the group. For example, if the individual ranks
highly in the group for a particular metabolite, then an assumption could be made
that the individual ranks similarly for all time points, and an appropriate value
could be calculated from similarly-responding individuals. However, this may not be
appropriate in some cases, and relies heavily on the assumption that the individual
responds in a similar way compared to other individuals in the group.
There are several missing data points in both the biochemical and physiolog-
ical datasets used within this project. Due to the extreme conditions of CXE 2007,
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Biochemical metabolite Detection limit of technique used Value imputed Units
IL-13 0.63 0.315 pg/ml
Eotaxin 1.69 0.845 pg/ml
CRP 60.00 30.000 ng/ml
Adrenaline 0.12 0.060 fmol/ml
Noradrenaline 0.08 0.040 fmol/ml
Adipsin 422.00 211.000 pg/ml
EPO 0.40 0.200 mlU/ml
Table 2.5: List of imputed values for biochemical metabolites measured in plasma
samples taken during CXE 2007. All values were below the detectable limit of the
technique used, and were imputed as half-way between the lower detection limit of
the technique used and zero.
some individuals became ill during the expedition, and did not have samples taken at
particular time points. A small number of individuals su↵ered severely from hypoxia
and had to be evacuated from the mountain at higher altitudes. The biochemical
measurements contained more missing values than the physiological data, mainly
due to out of range measurements, as there is a higher level of error associated with
measuring metabolites that are present in very low concentrations. Measurements
taken at higher altitudes also contain more missing data points than measurements
taken at lower altitudes. It is important to know why a particular data point is
missing, as it can have an e↵ect on the assessment of the data, especially if it is due
to an individual being ill. Some metabolites are also missing for entire altitudes.
Due to this, several di↵erent versions of the dataset have been created, each useful
for answering di↵erent questions about the dataset. The biochemical metabolites
that had values imputed are shown in Table 2.5.
2.4.2 How missing values were treated in each dataset
For the core dataset, physiological measurements missing only a small number of
values were imputed, to restrict the amount of bias these values may have on further
analysis. This was done in a systematic way, by highlighting the individual on a box
and whisker plot showing the behaviour of the variable over all altitudes. This was
done to compare how the individual responded at known time points compared to the
rest of the group. The individual was then ranked within the group, depending on
their response. If this rank was similar across altitudes, a mean rank was calculated.
The missing variable was then imputed based on this rank - for example if the mean
rank was 2, the values for individuals ranked 1 and 2 were added and the sum
divided by two to calculate a value in-between them. If the rank varied too much
38
within the group, a value could not be imputed this way. This method assumes
that an individual’s behaviour remains relative to the way the rest of the group is
behaving, and that this relationship is the same across altitudes.
The diary dataset was collected on each day of the expedition, and has many
missing data values. No information has been imputed for this dataset, as too many
data values are missing, and any imputation would risk biasing any analysis carried
out on this dataset as it would be mainly based on estimated data points.
2.4.3 Core team datasets
Biochemical metabolites and physiological measurements that are missing some data
points are still potentially valuable for analysis. The metabolites had several missing
values, ranging from one complete altitude missing (24 missing data values) for all of
the glutathione metabolites, to six altitudes missing data for IL-10 (approximately
144 missing data values). These metabolites can provide information on how the
group are responding, but cannot be used in model building.
Due to these limitations, two separate datasets for the core team were formed.
The first dataset contained only complete information (i.e. no missing data points
for any variable included in the dataset), whereas the second dataset contained all
measurements that included enough information to be useful (i.e. they contained
at least a full altitude worth of data). The complete dataset was primarily used
for modelling analysis, as well as any analysis that could not be performed on data
with missing values. The incomplete dataset was primarily used for exploratory
data analysis, looking at general patterns of expression within the group.
There were 10 individuals missing for all physiological measurements at Ever-
est Base Camp Weeks 6 and 8. Two individuals were also missing plasma samples
for Everest Base Camp weeks 6 and 8 as they became very ill during the expedi-
tion, and had to be moved down to a lower altitude to recover. The main focus of
this project was to assess the changes that occur with increasing hypoxic exposure,
therefore, only measurements from London - Everest Base Camp Week 1 were used
for modelling. This was because Everest Base Camp weeks 6 and 8 showed altitude-
independent changes, and were missing too much information to be used reliably
for modelling purposes. A full list of the biochemical metabolites and physiological
measurements available for the core dataset are shown in Tables 2.3 and 2.4.
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2.4.4 Variables omitted from the analysis
Some of the biochemical metabolites and physiological measurements were missing
too many values to be imputed with any accuracy, and did not appear to give any
information about any changes that occurred with increasing altitude. For example,
IL-1↵ only had three samples out of 168 that were within the detectable limits of
the BioPlex assay, used to measure multiple biochemical metabolites in the plasma
samples. These biochemical metabolites have been removed from all analyses, and
are as follows:
• Interleukin-1↵
• Interleukin-4
• Interferon- 
2.5 Statistical analysis
This section details the statistical techniques carried out on all of the data available
from CXE 2007. All work was performed on a MacBook Pro, 3.06 GHz Intel Core
2 Duo, 4 GB, Mac OS X Lion 10.7.5. All data analysis was performed by myself
using the commercial software package matlab 7.12 (The MathWorks Inc., Natick,
MA, 2012).
Initial statistical techniques were used to understand how di↵erent measure-
ments were changing as altitude increased, as well as looking for patterns and sum-
marising any important observations. This information was used to define a list of
metabolites that were most suitable to be used as part of modelling e↵orts. This
section details the di↵erent types of statistical analyses used in later chapters, as
well as the mathematics behind each test.
One of my personal aims for my thesis project was to gain an understanding
of the statistical methods and empirical modelling techniques that can be applied
to biological data. Therefore, this section describes the statistical methods used in
detail.
2.5.1 Box and whisker plots
Box and whisker plots are a simple yet convenient way of summarising one or more
groups of data in a graphical form, and allowing the visual analysis of the symmetry
of data around each median and the variability within the dataset [McGill, 1978].
Here the data are summarised as a ‘box’ with the lower edge of the box showing
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the lower 25th percentile and the upper edge of the box showing the upper 75th
percentile. The median is shown as a red line bisecting the box, and the interquartile
range is the di↵erence between the 25th and 75th percentiles. The ‘whiskers’ of the
plot show the smallest and largest values not considered to be an outlier, with
an outlier defined as being more than 1.5 times the interquartile range above the
75th percentile, or below the 25th percentile [McGill et al., 1978], and were plotted
individually as a red cross (‘+’).
Box and whisker plots show the di↵erences and similarities between samples
of data without making any assumptions of the underlying statistical distributions,
and are therefore non-parametric. Box and whisker plots include more useful in-
formation than a barchart or histogram, and can act as a visual summary of the
data, and include the median value, not the mean, as the median is less influenced
by extreme values, and useful for skewed distributions. The variability in the data
is shown by the interquartile range, which is a more stable summary than the total
range, as, like the median, it is less prone to skewing due to extreme values.
The boxplot function was implemented in matlab to produce box and whisker
plots for all of the di↵erent datasets. Data for the core team members was plotted
in several places, both together, and split into lab sta↵ and climber groups, to
allow comparisons between the two di↵erent groups. Box and whisker plots of the
diary data allowed the visual analysis of the day-to-day variability of the di↵erent
physiological measurements available. The box and whisker plots presented for
the core dataset show log-transformed data, as there were some metabolites that
contained high outlying values that skewed the plots and made them di cult to
interpret. All box and whisker plots for the core dataset were presented after being
log-transformed, to maintain consistency across the figures. Box and whisker plots
for the diary dataset were presented as raw data, as log-transformation was not
necessary, and the raw data was more informative for this particular dataset.
2.5.2 Subplots
Here, a subplot divides a figure into equal segments, with each segment showing one
individual’s response, rather than giving an average of all responses. The subplot
function was implemented in matlab to produce subplot graphs of all 24 individual
responses for a particular physiological measurement or biochemical metabolite as
altitude increases, to analyse the inter-individual variability seen for that particular
measurement.
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2.5.3 F -test for assessment of equal variances
The F -test assesses whether the variances of two samples are equal, so that the
null hypothesis H0 = the samples come from populations with the same variance, is
compared to the alternative hypothesis H1 = the samples come from populations with
di↵erent variances. This test is highly sensitive to non-normality, and any departures
from normality can render the results of the F -test invalid. This is especially true
for heavy-tailed or light-tailed distributions, where the probability of getting high
values is larger or smaller than is expected for a normal distribution. For heavy-
tailed distributions, the associated p-value is smaller than the actual significance
value, resulting in false-positives. The opposite is true for light-tailed distributions,
with the associated p-value being much larger than the actual significance level,
resulting in the F -test being less likely to detect true di↵erences. However, it is
di cult to assess the assumption of normality, unless the sample sizes are very
large. When the test assumptions are met, the F -test is the most powerful test
available, however, in the case of non-normality, a non-parametric test may be more
suitable. For the F -test the sample variances are calculated as follows:
S2x =
1
n  1
nX
i=1
(xi   x¯)2, (2.1)
S2y =
1
m  1
mX
i=1
(yi   y¯)2, (2.2)
where x¯ and y¯ are the sample means, n is the number of individuals for sample x,
and m is the number of individuals for sample y. The test statistic is then as follows:
F =
S2x
S2y
, (2.3)
and has an F -distribution with n-1 andm-1 degrees of freedom if the null hypothesis
is true.
The vartest2 function was implemented in matlab for both the diary and
core datasets. This was done in part to inform the subsequent analysis of variance
and t-tests to be performed on the data, and to assess whether the variances of
groups changed between altitudes. A two-tailed F -test was performed to assess
whether the two sample variances were significantly di↵erent from one another. It
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was not of interest at this stage to assess which sample had the higher variance, just
that a di↵erence in the variance existed so that an appropriate form of the t-test
could be used. There are alternative ways to test multiple variances at the same
time, which may be more appropriate than performing multiple pair-wise analyses,
however, these tests have lower power compared to the F -test.
2.5.4 Two-sample Student t-test
The Student t-test assesses whether the means of two random, normally distributed
populations are equal [Student, 1908], so that H0 = the samples have the same mean,
is compared to the alternative hypothesis H1 = the samples have di↵erent means.
The standard form of the t-test assumes that the variances of the two populations
are equal, and that they are both drawn from populations assumed to be normally
distributed. The t statistic to test whether two means are di↵erent was calculated
as follows:
t =
x¯  y¯
SDxy
q
2
n
(2.4)
where, if the sample sizes and variances are equal:
SDxy =
r
1
2
(S2x + S
2
y), (2.5)
where S2x and S
2
y are the sample variances (as shown in equations 2.1 and 2.2),
SDxy is the pooled standard deviation, and x¯ and y¯ are the sample means. The
denominator of the t statistic is the standard error of the di↵erence between the two
means.
If the F -test resulted in a rejection of the null hypothesis (i.e. the sam-
ple variances are not equal), then Welch’s t-test was used. The t statistic is now
calculated as:
t =
x¯  y¯
sdxy
, (2.6)
where
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sdxy =
s
s2x
n
+
s2y
m
. (2.7)
Here s2 is the unbiased estimator of the variance of the two samples, and sdxy is not
a pooled variance. For significance testing, an approximate Student’s t-distribution
was used, with the number of degrees of freedom given by Satterthwaite’s approxi-
mation [Satterthwaite, 1946]:
d.f. =
 
s2x
n
+
s2y
m
!2
✓
s2x
n
◆2
(n 1) +
 
s2y
m
!2
m 1
. (2.8)
The ttest2 function was implemented in matlab, to compare the group mean
for the lab sta↵ against the group mean for the climbers on each day of the expedition
for both the core and diary datasets, at the 5% significance level. The function was
used to assess whether the lab sta↵ and climber groups responded di↵erently to one
another during the expedition, in a statistically significant manner. However, as the
two group sizes were very small, there may not have been enough power in this test
to reject the null hypothesis.
2.5.5 Paired Student t-test
The paired Student t-test is a variation of the t-test, which assesses whether the
mean di↵erence between two responses for the same individual is zero. For example,
taking a measurement in a patient before and after treatment, to see if the treatment
has had a significant e↵ect on the variable measured. The test statistic is as follows:
t =
x¯  µ
sp
n
, (2.9)
where x¯ is the sample mean, µ = 0 (or m) is the hypothesised population mean, s is
the sample standard deviation and n is the sample size. Under the null hypothesis
the test statistic will follow Student’s t-distribution with n-1 degrees of freedom.
The ttest function was implemented inmatlab after an initial positive analysis
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of variance (described in Section 2.5.6) between group means over all altitudes, to
identify exactly which groups were significantly di↵erent from one another. This
function was used for both the diary dataset and the core dataset.
2.5.6 Analysis of variance
The analysis of variance (ANOVA) is a generic statistical technique that assesses how
the mean value of a variable is a↵ected by the classification of the data according
to di↵erent sources of variation. The one-way ANOVA is a generalisation of the
two-sample t-test, appropriate for any number of groups, and is equivalent to the
two-sample t-test when assessing two groups.
If the p=0.05 (5%) level of significance is consistently accepted, then a wrong
conclusion will be drawn on average once in every 20 tests performed, known as Type
I error (rejecting the H0 when it should be accepted, i.e. a false positive). If we then
perform multiple t-tests across a range of di↵erent treatments, than the probability
of drawing at least one false conclusion is greatly increased. This probability could
be reduced by lowering the significance level to p=0.01 (1%), however, this increases
the risk of making a Type II error (failing to reject the H0, i.e. a false negative).
Analysis of variance (ANOVA) overcomes these problems by comparing any number
of sample means within a single test.
The null hypothesis for ANOVA is: H0 = the samples are drawn from nor-
mally distributed populations with equal means and variances, compared to the al-
ternative hypothesis: H1 = the samples are drawn from populations with di↵erent
means.
The test statistic can be calculated as follows:
F =
TreatMS
ResMS
, (2.10)
where:
TreatMS =
n
Pm
j=1(x¯j   x¯)2
m  1 , (2.11)
ResMS =
Pm
j=1
Pn
i=1(xji   x¯j)2
m(n  1) , (2.12)
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Source of
variation
Degrees of
freedom
Sum of squares Mean square Variance
ratio
Treatment (m-1) n
P
(x¯j   x¯)2 TreatSS / (m-1) TreatMS /
ResMS
Residual m(n-1)
PP
(xji   x¯j)2 ResSS / (m(n-1))
Total n m - 1
PP
(xji   x¯)2
Table 2.6: One-way analysis of variance table, where TreatSS refers to the treatment
sum of squares, TreatMS refers to the treatment mean square, ResSS refers to the
residual sum of squares and ResMS refers to the residual mean square. To complete
the test, the variance ratio was compared with tabulated critical values of the F -
distribution to test the null hypothesis for the ANOVA.
The treatment mean square (TreatMS) is calculated by dividing the treat-
ment sum of squares (the sum of squared deviations of the treatment (sample) means
multiplied by the number of observation per sample) by its degrees of freedom (m-
1). The residual mean square (ResMS) is calculated by dividing the residual sum
of squares (the sum of squared deviations of the individual observations about their
respective sample means) by its degrees of freedom (m(n-1)).
The treatment sum of squares and residual sum of squares add up to the total
sum of squares, which is the sum of the squared deviations of the individual obser-
vations about the overall mean. These values allow the construction of an ANOVA
table, which summarises all of the di↵erent components of variance, assuming equal
replication, such as that shown in Table 2.6. To complete the test, the variance
ratio was compared with tabulated critical values of the F -distribution to test the
null hypothesis for the ANOVA.
2.5.6.1 Assumptions in ANOVA
• The residuals (observations minus the treatment mean) should be approxi-
mately normally distributed;
• The residuals should have a common variance, which is not related to the
treatment or magnitude of the mean response;
• The observations are independent.
A two-way ANOVA is a generalisation of the paired t-test, which allows the
assessment of more than two treatments. This test looks at the grouping of exper-
imental units into blocks, with the same number of experimental units per block.
We can use ANOVA to calculate the treatment sum of squares, the block sum of
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Source of
variation
Degrees of
freedom
Sum of squares Mean square Variance
ratio
Blocks (b-1) t
P
(x¯i   x¯)2 BlkSS / (b-1) BlkMS /
ResMS
Treatment (t-1) b
P
(x¯j   x¯)2 TreatSS / (t-1) TreatMS /
ResMS
Residual (b-1)(t-1) by subtraction ResSS / ((b-1)(t-1))
Total b t - 1
PP
(xji   x¯)2
Table 2.7: Two-way analysis of variance table without interactions, where BlkSS
refers to the block sum of squares, BlkMS refers to the block mean square, TreatSS
refers to the treatment sum of squares, TreatMS refers to the treatment mean square,
ResSS refers to the residual sum of squares and ResMS refers to the residual mean
square. To complete the test, the variance ratio was compared with tabulated
critical values of the F -distribution to test the null hypothesis H0 = there is no
di↵erence between blocks or treatments.
squares (the sum of squared deviations of the block means about the overall mean)
and the total sum of squares. The residual sum of squares is usually calculated by
subtraction as follows:
Residual SS = Total SS - (Block SS + Treatment SS)
The mean squares (variance) can be calculated by dividing the sum of squares by
their respective degrees of freedom, and are used to test for di↵erences between
treatments of blocks in the same way as the one-way ANOVA, such as that shown
in Table 2.7. To complete the test, the variance ratio was compared with tabulated
critical values of the F -distribution to test the null hypothesis H0 = there is no
di↵erence between blocks or treatments.
The anovan function was implemented in matlab for both the diary and core
datasets, to assess the main e↵ects of altitude and individual on each of the mea-
sured biochemical metabolites and physiological measurements. As there are no
repeated measures available for the core dataset, we cannot assess the interactions
between individual and altitude in a formal way, therefore a two-way ANOVA with-
out interactions was performed. If the null hypothesis was rejected, then t-tests
were performed between adjacent altitudes, to assess exactly which altitudes were
significantly di↵erent from one another.
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2.5.7 Correlations
Linear correlation looks at quantifying the linear association between pairs of vari-
ables. The correlation is described as positive if ‘large’ values of both variables tend
to occur together. The correlation is described as negative if ‘large’ values of one
variable tend to occur with ‘small’ value of the other variable. If the correlated
observations lie close to a straight line the correlation is said to be high, and if the
points are more widely scattered about that line the correlation is said to be low.
The Pearson product-moment correlation coe cient (also known as Pear-
son’s r) is a measure of the strength of the linear association seen between the two
variables [Pearson, 1920]. The correlation coe cient is defined as:
r =
Pn
i=1(xi   x¯)(yi   y¯)p
[
Pn
i=1(xi   x¯)2][
Pn
i=1(yi   y¯)2]
, (2.13)
where n is the number of observations of variables x and y, and x¯ and y¯ are the
means of x and y, respectively.
The scatter and corrcoef functions were implemented in matlab to create
scatter plots and calculate the correlation coe cient r and the p-value for each pair
of variables. The p-value is the probability of getting a correlation as large as the
observed value by random chance, when the true correlation is zero. If the p-value
was less than 0.05, then the correlation between x and y was significantly di↵erent
from zero. To aid interpretation, weak correlations are defined here as having a
correlation coe cient between either -0.4 to -0.59 or 0.4 to 0.59, medium strength
correlations have a correlation coe cient between either -0.6 and -0.79 or 0.79 and
0.6, and strong correlations have a correlation coe cient between either -0.8 to -1.0
or 0.8 to 1.0. The r value and p-value were used to test the null hypothesis H0 =
there is no association between the observations of variables x and y, against the
alternative hypothesis H1 = there is an association between variables x and y. A
p-value less than 0.05, coupled with a high r value resulted in a rejection of the null
hypothesis.
Correlations were calculated within di↵erent datasets for several reasons.
Correlations were produced for the diary data to identify any redundancy in the
dataset, and assess any interesting associations between variables. Correlations were
produced during explanatory data analysis to identify potential associations between
di↵erent variables. Correlations between biochemical metabolites were produced for
variable selection for modelling, to test for any redundancy within the biochemical
metabolites. If any were identified, then potentially only one of these variables
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would be used in modelling e↵orts. Finally, correlations of residuals produced from
modelling and explanatory variables used in the model allowed the assessment of
whether there was any underlying structure to the residuals, and whether or not the
di↵erent explanatory variables were appropriate to be included in the model.
2.5.8 Smoothing
Smoothing was used to remove some of the noise inherent within a biological system,
to allow the visual comparison of di↵erent individual responses over time. Smoothing
helps to pick out patterns that may be di cult to see in noisy datasets, and can be
used to cope with day-to-day variability.
The smooth algorithm was implemented in matlab on the diary data only,
for each individual for each measurement. This was done to look at the overall
response for each individual over the entire expedition, whilst removing some of the
noise associated with the measurement. Each individual’s response was smoothed
using a 3-day running mean algorithm. The algorithm calculates the unweighted
mean of the previous, current and next data points, and creates a new data point.
The algorithm calculates successive values, and for each calculation a new value is
added into the sum and an old value drops out, smoothing each value in turn.
2.5.9 Simple Linear Regression
Simple linear regression fits a linear relationship between one dependent variable
and one independent variable. The linear regression model was fitted using the least
squares fit approach, which minimises the sum of squared vertical deviations of the
observed points around the fitted line, as shown in Figure 2.2.
2.5.9.1 ANOVA in regression
In order to assess whether the fitted regression line represents a true relationship (i.e.
is the underlying slope di↵erent from zero?) the analysis of variance (ANOVA) for
the fitted regression line was calculated. In order to construct the ANOVA, the sum
of squares explained by the regression, and residual sum of squares were determined.
These were then converted to variances (MS) by dividing by the respective degrees
of freedom. To complete the test, the regression variance was divided by the residual
variance to obtain an F -value, which was compared with tabulated critical values
of the F -distribution.
The residual sum of squares (denoted ResSS ) is the sum of the squared
di↵erences between each observed point and the fitted line. This can be calculated
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Figure 2.2: An example of a least squares fit, where a linear line is fitted through
points by minimising the squared di↵erence between the line and the observed data
point (i.e. minimising the squared lengths of the red dashed lines).
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by the following:
ResSS =
nX
i=1
(yi   (a+ bxi))2, (2.14)
summed over all of i, where a and b are the intercept and the slope of the fitted
line, respectively. Parameters a and b are shown by:
b =
nX
i=1
(xi   x¯)(yi   y¯)
nX
i=1
(xi   x¯)2
, (2.15)
a =
nX
i=1
yi   b
nX
i=1
xi
n
= y¯   bx¯ (2.16)
where x¯ and y¯ are the sample means, n is the number of observations of y. The
numerator in equation 2.15 is the corrected sum of products of x and y (denoted
Sxy), and the denominator is the corrected sum of squares of x, denoted Sxx. These
can be written as:
Sxy =
nX
i=1
(xiyi)  nx¯y¯, (2.17)
Sxx =
nX
i=1
(x2i )  nx¯2. (2.18)
The regression sum of squares (denoted RegSS ) is calculated as follows:
RegSS =
(Sxy)2
Sxx
. (2.19)
The regression and residual variances are calculated as follows:
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RegMS =
RegSS
Regdf
, (2.20)
ResMS =
ResSS
Resdf
, (2.21)
where the degrees of freedom for the regression (denoted Regdf ), is one as a straight
line model is being used. Therefore, the RegSS = RegMS for this case. The test
statistic is calculated as follows:
F =
RegMS
ResMS
. (2.22)
Additional summary statistics were calculated to assess the fit of the regression line
to the data, as follows:
2.5.9.2 Lack of fit mean square (LOFMS)
The sum of squared deviations between the observed mean at each altitude and
the fitted line, divided by the lack of fit degrees of freedom (summed across all
observations), denoted as:
LOFMS =
Pn
i=1(yˆi   y¯i)2
LOFdf
, (2.23)
where LOFdf is the lack of fit degrees of freedom (which, in this case, is two less
than the number of altitudes).
2.5.9.3 Pure error mean squares (ErrorMS)
The sum of squared deviations of individual observations about the mean for each
altitude, summed over all altitudes, divided by the degrees of freedom, denoted:
ErrorSS =
nX
i=1
(yi   yˆi)2, (2.24)
52
ErrorMS =
ErrorSSPn
i=1NA   1
(2.25)
where NA is the means square degrees of freedom, which in this case is one less than
the number of observations at altitude A.
2.5.9.4 R2 value
The coe cient of determination, or R2 value is a measure of how much of the
variability in a data set is described by a fitted model. For example, a linear regres-
sion model with an R2 value of 0.8 is describing 80% of the variability seen in the
dataset. The R2 value is calculated by dividing the error mean square by the total
mean square and subtracting this ratio from one, as follows:
TotalMS =
Pn
i=1(yi   y¯)2
Totaldf
, (2.26)
where Totaldf is the total degrees of freedom (sample size - 1).
R2 = 1  ErrorMS
TotalMS
. (2.27)
The closer the final value is to one (i.e. the smaller the ErrorMS is), the better the
model fits the data.
2.5.9.5 Assumptions for simple linear regression
• There is a linear relationship between the dependent and independent variable;
• The sample is representative of the population as a whole;
• The sample is normally distributed;
• The error is a random variable, where the mean is zero, and is conditional on
the explanatory variables;
• The errors are uncorrelated;
• The variance of the error is constant across observations.
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2.5.10 Simple linear regression uses
Simple linear regression analysis was used at several points during my thesis project.
Initially, it was used on the diary data to assess whether each physiological mea-
surement changed in a linear way with altitude. Simple linear regression analysis
was used in exploratory data analysis to see if any metabolites showed an over-
all linear change during the expedition. Simple linear regression was also used as
an initial modelling technique, to see if any of the dependent variables could be
described as a linear function of any of the explanatory variables, as described in
Section 6.2. Finally, simple linear regression was also used in the final stages of
model refinement to assess the linear dependence between explanatory variable co-
e cient values used in a model formed by multiple linear regression, and some form
of hypoxia measure. This information was used to produce a generalised model over
several altitude changes, instead of having one model per altitude di↵erence (for
example the di↵erence between all altitudes and London, not just Kathmandu and
London).
The following summary statistics are available for the analysis of the diary
data only, due to multiple measures being available at each altitude, and summarise
the information available from the regression and ANOVA.
2.5.10.1 Goodness of fit
The goodness of fit (GOF) statistic was compared to an F -distribution to assess
whether the regression line was significantly di↵erent from zero. The GOF statistic
was calculated using the RegMS (calculated in equation 2.20) and the LOFMS
(calculated in equation 2.23) as follows:
GOF =
RegMS
LOFMS
(2.28)
2.5.10.2 Lack of fit
The lack of fit (LOF) statistic was compared to an F -distribution to formally test the
goodness of fit of the regression line to the data. The LOF statistic was calculated
by dividing the LOFMS (calculated in equation 2.23) by the ErrorMS (calculated
in equation 2.25) as follows:
LOF =
LOFMS
ErrorMS
(2.29)
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If the lack of fit is large compared to the error term, then the means deviate
more from the fitted line than is to be expected, and indicates a poor fit to the line.
If the lack of fit is small compared to the error term, then this indicates that the
mean is close to the fitted line, however, there is scatter within points around the
mean.
2.5.10.3 Coe cient of Variation (CV )
The coe cient of variation is the square root of the error mean square (the scatter
of points around the mean value calculated for repeat y observations at a single
value for x ), divided by the mean, expressed as:
CV =
errorSD
y¯
, (2.30)
where errorSD is the error standard deviation (square root of the ErrorMS, calcu-
lated in equation 2.25), and y¯ is the variable mean. The CV is a relative measure of
the variability associated within a variable, and can be compared between variables.
The CV was calculated for the diary data, to assess whether particular physiological
measurements showed high or low variability day-to-day at the same altitude, and
to assess the reliability of measurements taken on a particular day.
2.5.11 Multiple Linear Regression
Simple linear regression assesses whether the dependent variable y can be described
by one explanatory variable. Multiple linear regression is an extension of simple
linear regression, where the dependent variable is potentially described by a linear
combination of several explanatory variables. Explanatory variables can be com-
bined, so that the response of one explanatory variable may depend on another.
These combination terms are calculated by multiplying together two or more ex-
planatory variables, as follows:
1. Simple linear regression; y = a+ bx
2. Multiple linear regression; y = a+ bx1 + cx2 + dx1x2,
where x1 and x2 are two separate explanatory variables, and x1x2 is the combina-
tion term. As the number of potential explanatory variables increases, it becomes
more di cult to fit them all and assess the best model fit. In this case, the best
model would be the one that best summarises the observed data available. Stepwise
55
regression techniques enable the selection of the best model for the observed data,
whilst minimising the amount of time required to assess the fit of each model.
The stepwisefit algorithm was implemented in matlab for the two di↵erent
stages of modelling undertaken during my thesis. In the exploratory modelling,
MLR was used to describe one physiological variable from a selection of potential
explanatory variables, over all altitudes. The second targeted form of modelling
looked at using MLR to describe the percentage change seen in oxygen consump-
tion or work rate with either absolute values at a low altitude of a selection of
biochemical metabolites, or the percentage di↵erence in biochemical metabolites at
low altitudes. MLR was used to form initial models and refine models for the ex-
ploratory modelling, and form initial models that were refined separately for the
targeted modelling.
The stepwisefit algorithm uses a systematic method for adding and removing
terms from a multilinear model, based on their statistical significance in a regres-
sion. The method is a combination of forward selection and backward elimination
techniques, beginning with an initial model, which is compared to the explanatory
power of incrementally larger and smaller models. At each step of the algorithm,
the p-value of an F -statistic is calculated and used to compare two models, one in-
cluding a potential term and one without it. If the term is not currently contained
in the model, the null hypothesis is that the extra term would have a coe cient of
zero if it were added to the model. If there is su cient evidence from the F -statistic
and p-values produced, then the null hypothesis is rejected and the term is added
to the model. Alternatively, if a term is currently in the model, the null hypothesis
is again that the coe cient value is zero. If the null hypothesis is not rejected, then
the term is removed from the model. This is discussed in more detail below.
The response y to predictor x is a system of linear equations:
y = bx, (2.31)
where b is a matrix of coe cient estimates.
Fitting the initial model: The vector of coe cient estimators b is computed via
a least-squares method using QR decomposition. It is possible to express x, an m-
by-n matrix, as the product of Q, an m-by-m orthogonal matrix, and R, an m-by-n
upper triangular matrix. I.e.
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x = QR. (2.32)
Define a matrix QB:
QB = Q
T y. (2.33)
Multiple both sides of equation 2.31 by QT :
QT y = QT bx. (2.34)
Substitute in for x :
QT y = QT bQR. (2.35)
As Q is orthogonal:
QQT = I, (2.36)
where I is the identity matrix. This removes the necessity to calculate an inverse
matrix to solve the set of linear equations and speeds up the calculation. Hence it
is possible to express:
QT y = bR, (2.37)
and b can be found from:
b = QB/R. (2.38)
Calculating the p-values: Following the initial model fit, explanatory variables
are tested to determine whether or not they are included in the final model. As
previously mentioned, the null hypothesis is that the variable would have a coe cient
of zero if it were included in the model, and the user specifies the entry and exit
tolerances in the form of p-values. These are calculated as follows:
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1. Determine the standard error (SE):
SE = ErrorMS
p
R/I
2
. (2.39)
2. Calculate the critical t-value:
tcrit = b/SE. (2.40)
3. Look up the p-value using the matlab function tcdf, which returns a probability
for given values of t and degrees of freedom v using the equation shown below
for the t-cumulative distribution function:
p = 2
Z  |tcrit|
 1
  (v+12 )
  (v2 )
1p
v⇡
1
(1 + t
2
v )
v+1
2
dt, (2.41)
where   is the gamma distribution.
The method for stepwise regression is then as follows:
1. Define all explanatory variables and combination terms;
2. Fit the initial model;
3. If any terms that are not already in the model have a p-value < 0.05 (i.e. it is
unlikely that the term would have a coe cient of zero if added to the model),
then add the term with the smallest p-value, and repeat the process. Else, go
to step 4;
4. If any terms in the model have a p-value > 0.1 (i.e. it is unlikely that the term
will not have a coe cient of zero), remove the one with the largest p-value
and go to step 3. Else, end.
This method may build di↵erent models depending on the initial model
formed, and the order in which terms are added and removed from the model.
The algorithm terminates when no single step will improve the model. However,
there is no guarantee that a di↵erent initial model or a di↵erent sequence of steps to
add and remove terms will not produce a better fit. Therefore, stepwise fit models
are locally optimal, but not globally optimal. For this analysis, the initial model
began with no terms in the model, and added terms into the model based on the
associated p-value.
58
2.5.11.1 Assumptions in multiple linear regression
• The dependent variable response is linearly dependent on one or more explana-
tory variables;
• The sample is representative of the population as a whole;
• The sample is normally distributed;
• The error is a random variable, where the mean is zero, and is conditional on
the explanatory variables;
• The errors are uncorrelated;
• The variance of the error is constant across observations.
2.5.12 Adjusted R2 value
The adjusted R2 value modifies the R2 value to take into account the number of
explanatory variables used within a model, with penalties for larger numbers of
explanatory variables. This is especially relevant when looking at multiple linear
regression. The adjusted R2 value will always be less than or equal to the R2 value,
and is defined as:
R¯2 = 1  ErrorSS
TotalSS
.
Totaldf
Errordf
= 1  ErrorMS
TotalMS
, (2.42)
where Totaldf is the total degrees of freedom (sample size - 1), and Errordf is the
degrees of freedom for the error [(sample size - number of explanatory variables in
the model) - 1].
The adjusted R2 value was calculated between observed data values and
predicted data values for all models formed by multiple linear regression. This
provided a measure for how much of the variability in the observed data was being
explained by the model, adjusted for the number of explanatory variables in the
model. These measures allowed the non-formal comparison of di↵erent models, to
see whether or not model refinement improved the final fit seen between observed
and predicted data. In most cases models could not be formally compared, as they
were mostly based on slightly di↵erent datasets. For example, if a model were refined
by removing one datapoint, the new model would be based on a slightly di↵erent
dataset, and could no longer be formally compared to the original model.
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Chapter 3
Biochemical Experimental
Results
This section details the results from the biochemical experiments I carried out at
The University of Warwick as part of my thesis project. It contains information
on the di↵erent experimental techniques as well as some of the key results obtained
by each technique. The purpose of this work was to collect a large set of biological
data for later modelling e↵orts, and to familiarise myself with di↵erent experimental
techniques, so that I could understand any problems that arose as a result of data
collection. The following techniques were all carried out by myself, unless stated
otherwise.
3.1 Oxidative stress
There is currently no agreement in the literature as to which measure of oxidative
stress is the most valuable or significant. Therefore, three independent metabo-
lites associated with oxidative stress were measured during this study, to gain a
clear picture about how the individuals were responding during the course of the
expedition. These were 8-iso-Prostaglandin F2↵ (8-isoPGF2↵), 4-hydroxy-2-nonenal
(HNE) [Zarkovic, 2003] and glutathione levels. 8-isoPGF2↵ and glutathione were
measured as part of my thesis project, and their measurement is detailed below.
This information was combined with the results for HNE, generated by another
member of the Feelisch group, to gain an overview of how the level of oxidative
stress changed in the individuals during the expedition.
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3.1.1 8-iso-Prostaglandin F2↵
Isoprostanes are a class of prostanoids (a group of lipid compounds derived enzy-
matically from fatty acids) that are generated as a result of the attack of arachidonic
acid by free radicals during oxidative stress. 8-isoPGF2↵ is a secondary peroxida-
tion end product, and 8-isoPGF2↵ levels have been shown to be a good indicator of
oxidative stress in humans, compared to other markers [Morrow et al., 1992].
3.1.1.1 Immunoassay
A direct 8-iso-Prostaglandin F2↵ Enzyme Competitive Immunoassay Kit (Assay De-
signs catalogue number 901-091) was used to measure 8-isoPGF2↵ levels in each of
the 24 core team member’s plasma samples, as detailed in Section 2.2.1. The kit uses
a polyclonal antibody to bind, in a competitive manner, to the 8-isoPGF2↵ avail-
able in the sample, or with an exogenous 8-isoPGF2↵ with an alkaline phosphatase
molecule covalently attached.
After a simultaneous incubation, the excess reagents were washed away,
including any excess phosphatase. A p-nitrophenylphosphate substrate was then
added, which is a chromogenic substrate that can be cleaved by a phosphatase to
produce p-nitrophenol, which is yellow in colour, as shown in equation 3.1. Af-
ter incubation, the substrate was washed away, and the amount of yellow product
formed was measured in a microplate reader at 405nm. The amount of yellow
colour produced is inversely proportional to the concentration of free 8-isoPGF2↵
in the sample. This is because the stronger the yellow colour generated, the less
8-isoPGF2↵ was present in the sample to compete with the 8-isoPGF2↵ coupled to
the phosphatase.
p  nitrophenylphosphate Phosphatase       ! p  nitrophenol(yellow) (3.1)
3.1.1.2 Results
Figure 3.1 shows the results for the 8-isoPGF immunoassay. Figure 3.1a shows all
24 core team individuals plotted over 7 time points. Figures 3.1b and 3.1c show the
results for the 10 lab sta↵ and 14 climber individuals, respectively. 8-isoPGF2↵ show
a slight increase for all individuals between London and Namche, with the climbers
having a slightly wider range of values than the lab sta↵. There is an increase in
8-isoPGF2↵ levels between Namche and Pheriche for all individuals. There is then
a decrease in 8-isoPGF2↵ levels between Pheriche and Everest Base Camp week 1
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Figure 3.1: Box and whisker plots showing how 8-isoPGF2↵ levels change in 24
core team individuals during CXE 2007, showing log transformed values for (a) all
individuals, (b) for 10 lab sta↵ individuals and (c) for 14 climber individuals. Both
lab sta↵ and climber groups show similar responses up to Everest Base Camp Week
1, with di↵erences between how the lab sta↵ and climber groups respond between
Everest Base Camp weeks 6-8.
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for all groups, with the lab sta↵ showing a larger decrease, shown in Figure 3.1b.
The lab sta↵ show an increase in 8-isoPGF2↵ levels between Everest Base Camp
weeks 1-6, whereas the climbers show a decrease. This may be due to the di↵erence
in ascent profile between the two groups here, shown in Figure 1.1, where climbers
ascended higher than lab sta↵ individuals. However, the climber levels would be
expected to increase here, and not decrease. This may be due to the climber group
having more experience at altitude than the lab sta↵ group, and showing better
anti-oxidant responses at high altitudes compared to the lab sta↵ group.
3.1.2 Glutathione determination
Reduced glutathione (GSH) is a tripeptide ( -glutamylcysteinylglycine) that con-
tains a free thiol (SH) group. GSH acts as an antioxidant, providing reducing equiv-
alents for the glutathione peroxidase catalysed reaction with harmful substances,
such as hydrogen peroxide to water, as shown in Figure 1.3. This reaction forms a
disulphide bond between two GSH molecules, forming oxidised glutathione (GSSG),
whilst simultaneously oxidising  -nicotinamide adenine dinucleotide phosphate ( -
NADPH) to NADP+. Any GSSG formed is readily converted back into GSH by the
enzyme glutathione reductase, which is also induced during oxidative stress [Haddad
and Harb, 2005; Rossi et al., 2002].
In healthy cells more than 95% of the total glutathione in the cell is in the
form of GSH and less than 5% is GSSG. If the cell is exposed to oxidative stress,
GSSG will accumulate and the ratio of GSH to GSSG will decrease. Therefore, the
quantification of GSH and GSSG can be used as an indicator of oxidative stress in
cells and tissues [Rahman et al., 2006].
3.1.2.1 The Tietze glutathione recycling assay
The Tietze assay is based on the glutathione recycling system by 5,5’-dithiobis-(2-
nitrobenzoic acid) (DTNB, also known as Ellman’s reagent) and glutathione reduc-
tase [Tietze, 1968; Rossi et al., 2002]. DTNB reacts with GSH to produce GSSG
and the chromophoric compound 2-nitro-5-thiobenzoic acid (TNB), which is yellow.
The GSSG formed is reduced back to GSH by glutathione reductase with the help of
the cofactor NADPH, as shown in Figure 3.2. Any new GSH formed is free to react
with DTNB to form more TNB. Therefore, the total glutathione concentration of a
sample can be determined by measuring the absorbance of the mixture at 412 nm,
which indicates how much TNB has been produced. This recycling system signifi-
cantly increases the sensitivity of glutathione detection compared to non-recycling
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methods [Tietze, 1968].
2-vinylpyridine (2-VP) is an alkylating agent that reacts with the thiol (SH)
group on GSH. 2-VP can be added to the mixture to derivatise any GSH present,
removing it from the reaction and allowing the quantification of GSSG present
within the sample [Gri th, 1980]. The amount of GSH can then be calculated from
subtracting twice the oxidised glutathione concentration from the total glutathione
concentration.
A working glutathione assay protocol had previously been used in the Feelisch
lab for the determination of reduced and oxidised glutathione in fresh rat tissue and
plasma. My aim was to modify the protocol to allow the determination of both
reduced and oxidised glutathione levels in frozen human plasma samples, taken from
the CXE core team. The glutathione levels in human plasma are lower than those
found in rat plasma, therefore the sensitivity of the protocol had to be increased. It
was also not known how storing the samples at -80oC may a↵ect the levels detected.
Over a period of several months, the protocol was modified to improve relia-
bility and sensitivity. The original protocol was improved to allow the detection of
significantly lower quantities of glutathione than were possible in the first attempts.
The changes incorporated included:
• Lowering the dilutions made to the samples;
• Using a di↵erent supplier for the main enzyme. Initially an enzyme from
Sigma was used, and this was then replaced with an enzyme from Roche. The
specific activity of the two enzymes was comparable;
• Including a missed neutralisation step;
• Changing the dilution of the enzyme;
• Using fresh reagents every day;
• Increasing the temperature and length of the incubation period;
• Spiking the samples with a known concentration of oxidised and reduced glu-
tathione.
Despite all of these iterations, it was still not possible to obtain consistent
standard curves at low glutathione concentrations, or reliably measure glutathione
levels in human plasma samples that had been kept frozen for an extended period
of time. The refined version of this lab assay is detailed in Section 2.2.2.1.
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Figure 3.2: DTNB reaction with reduced glutathione (GSH) to form yellow TNB.
The rate of the formation of yellow product is directly proportional to the amount
of GSH present in the sample.
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3.1.2.2 Glutathione fluorescence assay
Due to the poor reliability of the Tietze recycling assay, in the end a commer-
cial Glutathione Assay Kit (BioVision, catalogue number K264-100) was used to
quantify both reduced and total glutathione levels within the plasma samples, as
described in Section 2.2.2.3. Oxidised glutathione levels were then calculated from
these measurements. Several other commercial glutathione kits were considered,
however, they all specifically stated that ”GSSG in normal resting plasma is at or
below the lowest level of detection for the assay.”
The BioVision assay uses a molecule called o-phthalaldehyde (OPA), which
reacts selectively with reduced thiols such as GSH to generate fluorescence, allowing
the quantification of GSH within the sample. The addition of a reducing agent
converts all of the GSSG present into GSH, and the addition of OPA allows the
specific quantification of the total glutathione in the sample.
GSSG can either be calculated by subtracting GSH from total glutathione
levels, or be measured specifically by adding a quencher to remove the GSH present,
and then adding a reducing agent to destroy the quencher and convert the GSSG
present to GSH for quantification by OPA.
3.1.2.3 Results
The results for the measurement of the di↵erent glutathione components are shown
in Figure 3.3. The lack of results for London is due to all of the London measure-
ments being out of range, even for this technique. Given that levels were measurable
for all other altitudes, this result came as a surprise, and may have been the result
of an issue with the plate or user error. It was not possible to re-run this partic-
ular plate due to the limited supply of plasma samples available. London levels of
GSH and the GSH:GSSG ratio would be expected to be higher than those seen for
Kathmandu. London GSSG levels would be expected to be lower than those seen
for Kathmandu, and total glutathione would be expected to be similar to that seen
for Kathmandu.
GSH levels show a slight decrease between Kathmandu and Namche, and
GSSG levels show an increase, shown in Figures 3.3a and 3.3b, respectively. As the
individuals are exposed to hypoxia, GSH present in the plasma would react with
ROS producing GSSG, therefore GSH levels are expected to decrease, and GSSG
levels are expected to increase [Chang et al., 1989]. The resulting GSH : GSSG
ratio shows a decrease between Kathmandu and Namche, shown in Figure 3.3d,
indicating an initial increase in oxidative stress.
66
GSH and total GSH/GSSG levels then show a steady increase up to Everest
Base Camp, coupled with a decrease in GSSG levels at these altitudes. This is most
likely due to an overall increase in glutathione production, which is inducible during
oxidative stress. In addition, glutathione reductase is increased [Haddad and Harb,
2005; Rossi et al., 2002], and would convert the excess GSSG back to GSH, resulting
in the increase in the GSH:GSSG ratio seen in Figure 3.3d.
A further increase in oxidative stress is seen between Everest Base Camp
weeks 1-6, shown by a decrease in GSH and the GSH:GSSG ratio, and an increase
in GSSG. This shows an altitude-independent change, and shows the response to
prolonged exposure to extreme altitude. This may also show the limit at which the
individuals can regulate oxidative stress levels.
3.1.3 Oxidative stress summary
Overall, there was a general increase in oxidative stress seen during CXE 2007.
This was shown by an overall increase in 8-isoPGF2↵ levels shown in Figure 3.1a,
an overall increase in HNE shown in Figure 3.4a and a decrease in the ratio of
reduced to oxidised glutathione, shown in Figure 3.3d. However, this increase is
not constant across all altitudes, and the metabolite levels peak at di↵erent alti-
tudes. These di↵erences may be due to variations in the chemical reactivity and
biochemical pathways that lead to the formation of these di↵erent products. A gen-
eral increase in oxidative stress was expected during the expedition; as individuals
were exposed to higher levels of hypoxia, ROS levels would increase, producing more
ROS-products such as 8-isoPGF2↵ and HNE, and antioxidants such as GSH would
be consumed [Morrow and Roberts, 1999, 2002]. None of the measures of oxidative
stress showed a significant di↵erence between lab sta↵ and climber groups, shown by
an acceptance of the null hypothesis for a t-test performed between the two groups,
at a 5% significance level. However, this may be due to the sample sizes being too
small to have the su cient power to reject the null hypothesis at the 5% level (10
lab sta↵ individuals and 14 climber individuals), and some group di↵erences are
apparent for 8-isoPGF2↵ levels in Figure 3.1.
3.2 Osmolality
Osmolality is a measure of the number of osmoles of solute per kilogram of solvent
(osmol/kg). The number of osmoles is the number of moles of a chemical compound
that contribute to a solution’s osmotic pressure, which is the pressure which must
be applied to a solution to prevent the inward flow of water across a semi-permeable
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Figure 3.3: Box and whisker plots showing how log-transformed glutathione levels
change in 24 core team individuals during CXE 2007. (a) shows reduced glutathione
(GSH), (b) shows oxidised glutathione (GSSG), (c) shows total glutathione and (d)
shows the GSH : GSSG ratio of the plasma.
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Figure 3.4: Box and whisker plots showing how log-transformed values from hy-
droxynonenal (HNE) levels changed in 24 core team individuals during CXE 2007.
(a) shows all individuals, with a general increase during the expedition. (b) and
(c) show no real di↵erence in the response seen for the sub-groups lab sta↵ (b) or
climbers (c).
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Figure 3.5: A box and whisker plot showing the change in log-transformed plasma
osmolality of 24 core team members during CXE 2007. This measure was done as a
control, to see whether changes in other metabolites measured in the plasma were
real changes or due to a change in plasma density, due to fluid shifts or increased
diuresis (urine output). There was no significant change in plasma osmolality during
CXE 2007, assessed by the acceptance of the null hypothesis for the ANOVA at the
5% confidence level, as described in Section 2.5.6.
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membrane. An Advanced Model 3300 Micro-Osmometer was used to measure the
osmolality of the 24 core team member’s plasma samples, detailed in Section 2.2.3.
Plasma osmolality was determined by using freezing point depression (FPD) os-
mometry. Adding another solute to an initial solution lowers the freezing point
of the mixture. For example, seawater remains liquid at temperatures below 0oC
(the freezing point of pure water at atmospheric pressure) due to its salt content.
Osmometry measures the total molar concentration of dissolved solids in any solu-
tion, as the freezing point of a solution is depressed in direct relation to the solute
concentration.
3.2.1 Results
During acute exposure to high altitude, urine output generally increases (known
as diuresis) to concentrate the plasma, and increase the blood’s oxygen carrying
capacity. The body’s fluid also shifts from the intravascular space to the interstitial
and intracellular spaces, to decrease the blood plasma within hours of exposure to
hypoxia [McArdle et al., 2007]. Therefore, a general increase in plasma osmolality
was expected during the expedition. Figure 3.5 shows the osmolality levels for
the core team’s plasma samples during CXE 2007. The figure shows no change
in plasma osmolality during the expedition, confirmed by a rejection of the null
hypothesis for the ANOVA at the 5% confidence level. As CXE 2007 was a strictly-
controlled expedition, all participants were kept well-hydrated during the entire
expedition [CASE, 2012]. This would have compensated for any increased urine
output, and explain why plasma osmolality stayed constant throughout CXE 2007.
3.3 BioPlex analysis
The Bio-Rad BioPlex system is based on Luminex xMAP technology, which al-
lows the multiplexing of up to 100 di↵erent multiple ELISA-type assays to be per-
formed within a single sample. Each assay is performed on the surface of a 5.6µm
polystyrene bead. The beads are filled with di↵erent ratios of green and red fluores-
cent dye, resulting in a possible array of 100 distinct colours. Each set of beads can
be combined with a di↵erent capture molecule or antibody, which can then be mixed
with di↵erent samples in a microplate to detect the presence of specific antigens.
Detection follows a sandwich immunoassay method, where the beads are
incubated with sample, and a fluorescently-labelled reporter tag is added to bind
specifically to the sample of interest. The beads are drawn into the BioPlex machine
and passed through the machine in a single file, where two lasers excite the beads
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Figure 3.6: Log-transformed box and whisker plots showing 7 diabetes-related bio-
chemical metabolites measured in 24 individuals during CXE 2007. All of the
metabolites apart from ghrelin (shown in (c)) show di↵erences between altitudes,
shown by a rejection of the null for the ANOVA at the 5% level (as described in
Section 2.5.6, and shown in Table 3.1).
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Figure 3.7: Log-transformed box and whisker plots showing 7 diabetes-related bio-
chemical metabolites measured in 24 individuals during CXE 2007. Only C-peptide,
glucagon, GLP-1 and insulin show changes between altitudes, indicated by a rejec-
tion of the null for the ANOVA at the 5% level (as described in Section 2.5.6, and
shown in Table 3.1). However, all of these metabolites show altitude-independent
di↵erences between Everest Base Camp weeks 1-8, which were shown to be signifi-
cant by a rejection of the null for the ANOVA at the 5% level.
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Figure 3.8: Box and whisker plot showing log-transformed glucose levels in 24 indi-
viduals during CXE 2007. Glucose levels show a significant change between London
- Everest Base Camp week 1, shown by a rejection of the null hypothesis for an
ANOVA at the 5% level (shown in Table 3.1). However, there is no significant
change between Everest Base Camp weeks 1-8, as shown by an acceptance of the
null for an ANOVA at the 5% level.
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individually. The classification laser excites the dyes in each bead, identifying the
bead’s spectral address. The second laser excites the reporter molecule bound to the
antigen of interest, allowing the quantification of the captured analyte. The signals
are read simultaneously for each bead in a high-throughput manner, to allow the
fast quantification of several molecules of interest in one sample.
3.3.1 Results
The BioPlex system was used to measure a total of 14 di↵erent metabolites linked
to diabetes, obesity and metabolism, as described in Table 2.2. These metabolites
were measured in each of the core team member’s plasma samples, as detailed in
Section 2.2.4, and the results are shown in Figures 3.6 and 3.7. Two separate
2-way ANOVAs (as described in Section 2.5.6, looking for the e↵ect of altitude
and individual, without interaction) were carried out here; one for results between
London and Everest Base Camp (EBC) week 1, and the other for EBC weeks 1, 6
and 8. The first set of analyses tested for altitude-dependent changes, as there was
a change in altitude between each of the samples. The second set of analyses tested
for altitude-independent changes, as the samples were all taken at the same altitude
(Everest Base Camp, 5300m).
Figure 3.6 shows responses for adipsin, adiponectin, ghrelin, leptin, PAI-1,
resistin and TNF-↵. Ghrelin does not show a change between altitudes, or between
the three time-points at Base Camp, with significance levels for the ANOVA of 0.17
and 0.54 for London to EBC week 1 and EBC weeks 1-8, respectively (shown in
Table 3.1). However, ghrelin does show di↵erences between individuals for both of
these sets of data, with significance values of 1.9x10 22 for London to EBC week
1 and 0.0015 for EBC weeks 1-8. Adiponectin does not show a di↵erence between
individuals between EBC week 1-8, with a significance value of 0.076. All other
metabolites show di↵erences between individuals and altitudes for both London
to EBC week 1 and EBC weeks 1-8, indicating both hypoxia-dependent changes
(London - EBC week 1) and hypoxia independent changes (EBC weeks 1-8) are
occurring in these metabolites, and that there are di↵erences between individuals.
Figures 3.6a and 3.6b show the results for adipsin and adiponectin, respec-
tively. Both of these metabolites show low outlying values that skew the box and
whisker plot, even when log-transformed, and make it di cult to see the general pat-
tern during the expedition. The low outlier seen for Kathmandu for both adipsin
and adiponectin is for the same individual, denoted X18, indicating that this indi-
vidual is showing a particularly low response for these metabolites at that altitude.
The low outlier for adipsin at Namche is for a di↵erent individual, denoted X14.
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Figure 3.7 shows the responses for C-peptide, GIP, glucagon, GLP-1, IL-6,
insulin and visfatin. Only C-peptide (Figure 3.7a), glucagon (Figure 3.7c), GLP-
1 (Figure 3.7d) and insulin (Figure 3.7f) show changes between altitudes between
London and EBC week 1. This was indicated by a rejection of the ANOVA null
hypothesis at the 5% level, with significance levels of 0.0024, 0.00000037, 0.00045
and 0.00001, respectively (shown in Table 3.1). However, all of the metabolites show
altitude-independent changes between EBC weeks 1-8, shown by a rejection of the
ANOVA null at 5%, shown in Table 3.1. The increase seen between EBC weeks
1-8 is seen for both lab sta↵ and climber groups in all cases, even though the two
groups were exposed to di↵erent conditions during these time points, as shown in
Figure 1.1. It is also worth considering that the time between EBC 1-6 is in terms
of weeks and not days, as the earlier measurements were.
Figure 3.8 shows the change in glucose levels during the expedition. Glucose
levels show a change between London and EBC week 1, indicated by a significance
value of 0.0015, shown in Table 3.1. Interestingly, glucose does not show a change
between EBC weeks 1-8, as shown by significance value of 0.8. Many of the metabo-
lites reported in Figure 3.7 that show an increase between EBC weeks 1-6 play a
role in glucose metabolism, including C-Peptide (Figure 3.7a), GIP (Figure 3.7b),
glucagon (Figure 3.7c), GLP-1 (Figure 3.7d) and insulin (Figure 3.7f).
Glucose metabolism is strictly controlled, which would explain why it only
shows a small change between London and EBC week 1, and does not show a change
in-between EBC weeks 1-8. The sharp increase seen for many of the glucose-related
metabolites between EBC weeks 1-6 suggests some form of breakdown in these path-
ways during prolonged exposure to extreme hypoxia. It may even suggest some form
of hypoxia-induced insulin-resistance, and requires further investigation to gain an
understanding of what is happening at extreme altitude. Additional plasma sam-
ples are available at intermediate time points between Everest Base Camp weeks
1-8, however, there was not su cient time to measure these additional samples dur-
ing my thesis project. The measurement of these samples would help gain a better
understanding of what happens to glucose metabolism during prolonged exposure
to extreme hypoxia.
76
M
et
ab
ol
it
e
L
on
d
on
to
E
ve
re
st
B
as
e
C
am
p
w
ee
k
1
E
ve
re
st
B
as
e
C
am
p
w
ee
ks
1
-
8
A
lt
it
u
d
e
In
d
iv
id
u
al
T
im
e-
p
oi
nt
In
d
iv
id
u
al
F
-v
al
u
e
p
-v
al
u
e
F
-v
al
u
e
p
-v
al
u
e
F
-v
al
u
e
p
-v
al
u
e
F
-v
al
u
e
p
-v
al
u
e
A
d
ip
on
ec
ti
n
(p
g/
m
L
)
6.
75
•8
.3
E
-0
5
13
.9
4
•6
.4
E
-2
1
2.
73
7.
6E
-0
2
6.
62
•5
.8
E
-0
8
A
d
ip
si
n
(p
g/
m
L
)
28
.3
1
•2
.5
E
-1
5
3.
89
•1
.7
E
-0
6
35
.6
2
•7
.5
E
-1
0
5.
44
•9
.3
E
-0
7
G
h
re
li
n
(p
g/
m
L
)
1.
65
1.
7E
-0
1
15
.4
7
•1
.9
E
-2
2
0.
62
5.
4E
-0
1
2.
85
•1
.5
E
-0
3
L
ep
ti
n
(p
g/
m
L
)
8.
82
•4
.5
E
-0
6
9.
89
•3
.4
E
-1
6
7.
86
•1
.2
E
-0
3
4.
13
•3
.0
E
-0
5
P
A
I-
1
(p
g/
m
L
)
13
.8
3
•7
.5
E
-0
9
1.
95
•1
.4
E
-0
2
11
.7
7
•8
.4
E
-0
5
1.
76
5.
5E
-0
2
R
es
is
ti
n
(p
g/
m
L
)
9.
25
•2
.5
E
-0
6
4.
39
•1
.8
E
-0
7
11
.8
5
•8
.0
E
-0
5
2.
50
•4
.7
E
-0
3
T
N
F
al
p
h
a
(p
g/
m
L
)
3.
50
•1
.1
E
-0
2
8.
38
•4
.1
E
-1
4
4.
28
•2
.0
E
-0
2
2.
29
•9
.3
E
-0
3
C
-P
ep
ti
d
e
(p
g/
m
L
)
4.
46
•2
.4
E
-0
3
2.
61
•6
.4
E
-0
4
44
.8
9
•3
.0
E
-1
1
1.
53
1.
1E
-0
1
G
IP
(p
g/
m
L
)
1.
42
2.
3E
-0
1
1.
95
•1
.4
E
-0
2
21
.7
3
•3
.0
E
-0
7
3.
27
•3
.9
E
-0
4
G
lu
ca
go
n
(p
g/
m
L
)
10
.7
0
•3
.7
E
-0
7
7.
27
•1
.9
E
-1
2
25
.2
4
•5
.6
E
-0
8
1.
64
7.
9E
-0
2
G
L
P
-1
(p
g/
m
L
)
5.
59
•4
.5
E
-0
4
8.
64
•1
.7
E
-1
4
38
.6
4
•2
.5
E
-1
0
1.
52
1.
2E
-0
1
In
su
li
n
(p
g/
m
L
)
8.
21
•1
.0
E
-0
5
8.
30
•5
.3
E
-1
4
32
.5
4
•2
.5
E
-0
9
1.
43
1.
5E
-0
1
IL
-6
(p
g/
m
L
)
0.
30
8.
7E
-0
1
6.
73
•1
.4
E
-1
1
47
.0
2
•1
.5
E
-1
1
1.
67
7.
3E
-0
2
V
is
fa
ti
n
(p
g/
m
L
)
0.
50
7.
4E
-0
1
9.
98
•2
.6
E
-1
6
24
.5
8
•7
.6
E
-0
8
2.
38
•6
.9
E
-0
3
G
lu
co
se
(m
M
)
4.
78
•1
.5
E
-0
3
3.
18
•4
.4
E
-0
5
0.
23
8.
0E
-0
1
0.
74
7.
8E
-0
1
T
ab
le
3.
1:
2-
w
ay
A
N
O
V
A
re
su
lt
s
as
se
ss
in
g
th
e
e↵
ec
t
of
al
ti
tu
d
e
an
d
in
d
iv
id
u
al
,
p
er
fo
rm
ed
b
et
w
ee
n
5
al
ti
tu
d
es
(L
on
d
on
to
E
ve
re
st
B
as
e
C
am
p
w
ee
k
1)
,
re
p
re
se
nt
in
g
al
ti
tu
d
e-
d
ep
en
d
en
t
ch
an
ge
s,
an
d
se
p
ar
at
el
y
on
th
e
th
re
e
ti
m
e-
p
oi
nt
s
at
E
ve
re
st
B
as
e
C
am
p
(E
ve
re
st
B
as
e
C
am
p
w
ee
ks
1,
6
an
d
8)
,
re
p
re
se
nt
in
g
al
ti
tu
d
e-
in
d
ep
en
d
en
t
ch
an
ge
s.
p
-v
al
u
es
m
ar
ke
d
w
it
h
a
d
ot
(•)
in
d
ic
at
e
a
re
je
ct
io
n
of
th
e
nu
ll
hy
p
ot
h
es
is
at
th
e
5%
le
ve
l,
in
d
ic
at
in
g
a
d
i↵
er
en
ce
b
et
w
ee
n
m
ea
n
s,
as
d
es
cr
ib
ed
in
S
ec
ti
on
2.
5.
6.
77
Chapter 4
Diary Data
The diary data is an additional dataset of simple physiological measurements col-
lected for the 24 core team members. It consists of daily measurements taken during
the expedition, and shows the day-to-day variation of each physiological measure-
ment within the dataset. The analysis presented in this chapter aims to assess the
precision and reproducibility of these measurements during the ascent, to inform the
analysis of the main core dataset. Similar physiological measurements are available
in the main dataset, therefore, the analysis performed on the diary data can be used
to highlight any measures that may potentially be useful for further analysis in the
core dataset.
The diary data contains information collected on blood pressure, oxygen sat-
uration, heart rate and respiratory rate. For each of these four main physiological
measurements, there are two measured variables and two derivations available. The
blood pressure measurements are Systolic and Diastolic blood pressure, as well as
the ratio of and di↵erence between these two biological measurements. For oxygen
saturation, heart rate and respiratory rate, measurements were taken at rest and
after a 2-minute step exercise test, and the ratio of and di↵erence between these two
biological measurements were also calculated. A full description of all 16 physiolog-
ical measurements contained in the diary data, and the shorthand names that will
be used throughout the rest of the analysis, can be found in Table 4.1.
The 2-minute step test exposes an individual to a small amount of physical
stress on each day. The di↵erence between and ratio of measurements at rest and
after exercise show an individual’s response to a defined amount of stress at di↵erent
altitudes, and can be used as a measure of how well that individual is adapting to the
environmental change. It was important to ascertain which of the four derivations
for each physiological measurement was the most consistent, useful or biologically
78
relevant, as there may be redundancy within the measurements. This dataset al-
lows an assessment of the validity of the single-point measurements collected in the
main core study dataset, by analysing whether changes between altitudes seen for
a particular measurement are within the normal day-to-day variability, or larger,
indicating a true response to altitude.
This dataset can also be used to detect di↵erent patterns of adaptation be-
tween individuals. For example, individuals may show no significant change in
response to a change in altitude, a steady change in response to a change in al-
titude, or an erratic or extreme response to a change in altitude. Comparing the
responses seen at di↵erent altitudes allows the analysis of how individuals respond to
changes in altitude, considering both short-term responses (to changes in altitude)
and long-term adaptation.
Data is available for a maximum of 78 days for each individual, however, all
individuals have at least one day where measurements were not collected. This may
be due to an individual being ill or otherwise unavailable for testing on a particular
day. Data is available for an average of 73 days for lab sta↵ members and 63 days
for climber individuals, as defined in Section 1.3. This di↵erence is mainly due to
the climber team attempting to summit between days 60-70 (shown in Figure 1.1),
and measurements not being taken at extreme high altitudes.
4.1 Aims
The diary data has been used to assess the following questions:
1. Do the physiological measurements change with altitude?
2. Which of the physiological measurements are the most reliable?
3. Is there redundancy among these physiological measurements?
4. Is there evidence of di↵erent levels or types of adaptation?
5. Which of the physiological measurements are potentially the most suitable for
further analysis?
4.1.1 Lab sta↵ vs. climber group
In conducting the analyses of the diary data, the dataset was initially split into two
groups, one containing the records for the 10 lab sta↵ and the other containing the
records for the 14 climbers, as detailed in Section 1.3. The climber group was a
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self-selected group with more experience and exposure to high altitude than the lab
sta↵ group. The two groups had very di↵erent ascent profiles between days 37-71,
as shown in Figure 1.1, and were therefore expected to respond di↵erently during
these times.
ANOVA was performed to assess for di↵erences between the means of the lab
sta↵ and climber groups during the entire expedition, as described in Section 2.5.6.
The results for these tests did not show a significant di↵erence between the two
groups for any of the physiological measurements at the 5% level, up to 5300m.
However, due to such small sample sizes at extreme altitude (down to one or two
individuals, and on some days no individuals, at altitudes above 5300m), it was
not possible to obtain meaningful results between the two groups at altitudes above
5300m. Therefore, the main analyses were conducted on all 24 core team members
to improve the power of subsequent tests, due to the larger sample size. Lab sta↵
and climber groups were still visually assessed separately for some variables, mainly
to split the group into smaller subgroups to allow for easier visual analysis of trends
or patterns.
4.2 Results
Several di↵erent statistical analyses have been performed on the diary dataset, in
order to address the questions posed in section 4.1. A summary of the results is
described in the following sections.
4.2.1 Do the measurements change with altitude?
The aim of this analysis was to determine whether each of the physiological mea-
surements changed significantly during the expedition. Measurements that did not
change significantly would not be useful for predictive modelling purposes, as some
change is required in both the dependent and independent variable to enable the
prediction of one with the other.
Box and whisker plots were produced, as described in Section 2.5.1, to visu-
ally assess how each of the physiological measurements changed during the expedi-
tion. Figures 4.1 and 4.2 show how oxygen saturation at rest and diastolic blood
pressure changed in both lab sta↵ and climber groups during CXE 2007. The as-
cent profile is marked on both of these figures, to enable the comparison of altitude
increases to changes in the physiological measurements. Figure 4.1 shows a clear
negative correlation between oxygen saturation and altitude for both the lab sta↵
(Figure 4.1a) and climber (Figure 4.1b) groups. The change in oxygen saturation
81
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(a) Oxygen saturation at rest for 10 lab sta↵ individuals.
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(b) Oxygen saturation at rest for 14 climber individuals
Figure 4.1: Box and whisker plots showing oxygen saturation at rest overlaid with
the ascent profiles for the lab sta↵ and climber groups during CXE 2007. There
is a clear increase in variation within both groups as altitude increases, shown by
an increase in the interquartile range (length of the box). Both (a) and (b) show a
clear negative correlation with the shape of the box and whisker plot response.
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(a) Diastolic blood pressure at rest for 10 lab sta↵ individuals.
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(b) Diastolic blood pressure at rest for 14 climber individuals
Figure 4.2: Box and whisker plots showing diastolic blood pressure (DBP) at rest
overlaid with the ascent profiles for the lab sta↵ and climber groups during CXE
2007. There is an increase in DBP until day 20, for both groups, and some variability
in the DBP after day 20, which is clearest for the lab sta↵ in (a), where the altitude
remained constant.
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(a) Regression of heart rate after exercise over altitude for 24 individuals.
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(b) Regression of respiratory rate at rest over altitude for 24 individuals.
Figure 4.3: Linear regression analysis of (a) heart rate after exercise against alti-
tude and (b) respiratory rate at rest against altitude, for 24 individuals. Climber
individuals are marked in green and red, lab sta↵ individuals are marked in blue
and magenta. Individuals X01 and X07 were climber individuals who became ill,
and are labelled in red. Individual X23 is a lab sta↵ member who became ill, and is
labelled in magenta. These measurements are shown because they demonstrate the
di↵erences seen between fitted individual responses. Individual regression plots are
shown in Figures 4.4 and 4.5.
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Figure 4.4: Linear regression analysis of heart rate after exercise (HREx) against
altitude for 4 individuals. The statistic values are shown in Table 4.3 for each fit.
(a) shows the regression for individual X05, who shows a significant GOF statistic
of 10.19, but a non-significant p-value of 0.611. This indicates that the line is not
significantly di↵erent from zero, but that the response is linear, also shown by a
low LOF statistic of 0.40, which shows that the means (shown as black squares) fit
closely to the line. (b) shows the results for individual X10, who shows a slope sig-
nificantly di↵erent from zero (shown by a significant p-value of 0.002 and significant
GOF statistic value of 21.08), with means that deviate slightly from the regression
line (shown by a LOF statistic value of 1.16). (c) shows the results for individual
X11, who shows a significant p-value of 0.03, but a non-significant GOF statistic
of 0.97. These results indicate that there are di↵erences between means, but that
the response seen is not linear, which is also shown by a high LOF statistic of 2.32,
indicating that there is scatter around each of the means. (d) shows the results
for individual X20, who shows a fitted regression line with a slope not significantly
di↵erent from zero (shown by a non-significant p-value of 0.794 and a non-signficiant
GOF statistic of 0.03), and a large amount of scatter of points around each mean
(shown by a low LOF statistic of 0.67).
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Figure 4.5: Linear regression analysis of respiratory rate at rest (RRrest) against
altitude for 4 individuals. The statistic values are shown in Table 4.4 for each fit.
(a) shows the results for individual X03, who shows a fitted regression line that
is not significant from zero (shown by a non-significant GOF statistic of 0.06 and
a non-significant p-value of 0.176), with means (black squares) that deviate from
the fitted line (shown by a high LOF statistic of 1.70). (b) shows the response
for individual X17, who shows a line that appears to be not significantly di↵erent
from zero (shown by a non-significant GOF statistic of 0.08), however the p-value
of the F -value is significant at 0.01. This indicates that there does appear to be a
di↵erence between the means, but that the response is non-linear, which is evident
by a very high LOF statistic of 3.04, indicating that the means deviate from the
fitted line. (c) shows the response for individual X18, showing a significant GOF
statistic of 11.10, but a non-significant p-value. This indicates that the line is not
significantly di↵erent from zero, but that the response is linear, also shown by a low
LOF statistic of 0.63, which shows that the means fit closely to the line. (d) shows
the response for individual X21, who shows a fitted line significantly di↵erent from
zero (shown by significant GOF statistic of 30.11 and a significant p-value of 0.002),
with some scatter around each mean (black square, shown by a low LOF statistic
of 0.73). 87
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was identified to be statistically significant during the expedition by an analysis of
variance, at the 5% significance level, as described in Section 2.5.6. This confirms
that the level of hypoxia that the individuals were exposed to during the expedition
increased as altitude increased, which was as expected. Figure 4.2 shows a positive
correlation between altitude increase and increases in diastolic blood pressure, which
was also confirmed to be a statistically significant change by analysis of variance at
the 5% significance level.
Table 4.2 shows the results for the two-way ANOVA performed to assess the
main e↵ects of altitude and individual on each of the physiological measurements.
The table shows that the null hypothesis for the ANOVA was rejected for all phys-
iological measurements at the 5% level for both altitude and individual, indicating
that the average (mean) response by the group changed significantly at some point
during the expedition for all of the measurements, with respect to both altitude and
individual.
A simple linear regression analysis was also performed for each physiological
measurement against altitude. This was done for both the group as a whole, to as-
sess how the group was responding during the expedition, and for individuals within
each group, to assess how each individual was responding during the expedition. The
regression was performed to assess whether the change seen in each physiological
measurement could be described by a linear fit, and to assess how well this line de-
scribed the data. The results could also be used to assess whether each physiological
measurement changed significantly with altitude, shown by a regression line with
a slope significantly di↵erent from zero. Table 4.2 shows the results for the group
regression analysis performed between each physiological measurement and altitude.
The heart rate di↵erence measurement was the only physiological measurement that
did not show a regression line slope that was significantly di↵erent from zero, with
a non-significant GOF statistic of 2.46, as described in Section 2.5.10.1.
Figure 4.3a and Table 4.3 show the individual regression results for all indi-
viduals for heart rate after exercise, with the results for the group regression at the
bottom of Table 4.3. The group response shows a slope significantly di↵erent from
zero, however, Table 4.3 shows that only four individuals have a regression slope
significantly di↵erent from zero shown by significant GOF statistics, labelled in the
table with an asterisk (*). Figure 4.4 shows the linear regression of heart rate after
exercise against altitude for four individuals, and demonstrates the di↵erences in
response seen between individuals.
Figure 4.3b and Table 4.4 show the individual regression results for respira-
tory rate at rest, with the results for the group regression at the bottom of Table 4.4.
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The overall group regression shows a slope significantly di↵erent from zero, with a
significant value for the GOF statistic (labelled with an asterisk (*)). The individ-
ual responses for this measurement show some variability, with both positive and
negative slopes. Figure 4.5 shows the linear regression of respiratory rate at rest
against altitude for four individuals. This figure shows the di↵erence in response
seen between individuals. These results indicate that there is a lot of variability in
how individuals are responding, and in some circumstances, this may mean that a
group summary is not capturing the inter-individual di↵erences seen within a group.
In some cases, the group as a whole may be showing a response, however, this may
be due to only a small number of individuals within that group, and may not be
representative of the group as a whole.
4.2.1.1 Summary
• ANOVA showed a rejection of the null hypothesis for both altitude and in-
dividual at the 5% level for all physiological measurements, indicating that
all of the measurements show a significant change at some point during the
expedition;
• Simple linear regression analysis against altitude showed that the heart rate
di↵erence measurement was the only physiological measurement that did not
show a slope significantly di↵erent from zero;
• Analysis of individual regression results show that even though the group as
a whole may show a regression slope significantly di↵erent from zero, all indi-
viduals within that group may not. Therefore, analysis of both the individual
regressions and group regression is required to fully understand what is hap-
pening in the group overall;
• Individual regression and ANOVA analyses show that for each of the physio-
logical measurements, at least one individual shows a significant change during
the expedition, highlighting that there are di↵erences in how individuals are
responding to altitude.
4.2.2 Which measurements are the most reliable?
The aim of this analysis was to assess the precision and reproducibility of each of the
measurements within the diary dataset. Box and whisker plots were used to visually
assess the variability during the expedition. Figure 4.1 shows that the variability
for resting oxygen saturation increases as altitude increases for both lab sta↵ and
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Parameter Name Coe cient of Variation
from Linear Regression and
ANOVA
O2SatRatio 0.052
O2SatRest 0.053
O2SatEx 0.061
BPRatio 0.084
DBP 0.106
SBP 0.110
HREx 0.135
HRRest 0.168
HRRatio 0.200
RREx 0.216
RRRatio 0.223
PP 0.235
RRRest 0.245
 HR 0.424
 RR 0.656
 O2Sat 0.772
Table 4.5: A summary of all diary data measurements, ranked in increasing order of
the CV value, obtained from the regression, as described in Section 2.5.10.3. Low CV
values indicated low day-to-day variability, i.e. measurements taken on subsequent
days will be very similar to one another.
climber groups, indicated by a larger interquartile range (IQR, shown by the length
of the box) at higher altitudes. For example, day 1 in Figure 4.1b has an IQR of
2%, whereas day 40 has an IQR of 9%.
Figure 4.2 shows the variability for diastolic blood pressure stays roughly
the same for both lab sta↵ and climber groups at around 15-20 mmHg. Figure 4.2a
shows variability in the group response for the lab sta↵ after day 20, even though
altitude remained constant. Long-term adaptation to hypoxia would expect to show
a consistency over time, whereas the variability shown in Figure 4.2a is more di cult
to explain.
The coe cient of variation (CV ) was calculated from the regression analysis
for each physiological measurement in Table 4.1, as described in Section 2.5.10.3.
The CV can be used as a measure of the overall day-to-day variability within each
measurement, and is used here as a measure of how reproducible a particular mea-
sure is, with a low CV value indicating that two measurements taken at the same
altitude will be very similar to one another. This analysis is also important for
the assessment of the core dataset, which only contains single-point measures for
all physiological and biochemical measurements. Therefore, the results from this
analysis can be used as an indicator of how reliable a single measure is for each
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altitude.
Table 4.5 shows a ranked summary of the CV values for each measurement.
Standard deviations must always be assessed in the context of the dataset, however,
the CV is independent of the unit in which the measurement has been taken, and is
therefore dimensionless. This allows the formal comparison of the CV value across
di↵erent datasets, and is very useful for the comparison of di↵erent physiological
measurements within the diary data. Table 4.5 shows that oxygen saturation mea-
surements for rest, exercise and ratio have the lowest day-to-day variability for any
of the physiological measurements, indicated by the lowest CV values of 0.052, 0.053
and 0.061, respectively. Respiratory rate measurements show the highest day-to-day
variability, with the highest CV values of 0.216, 0.223 and 0.245 for exercise, ratio
and resting values, respectively. This is likely to be due to the di culty in taking
respiratory rate measurements, as it is very di cult to see the movement of the
chest when the subject is wearing several layers, especially in poor light conditions.
Di↵erence measurements showed the highest CV values within each measurement.
This is to be expected, as it is combining the error associated with two di↵erent
measurements.
4.2.2.1 Summary
• The measurements showing the lowest relative day-to-day variability were con-
sidered the most reliable measurements. These were oxygen saturation ratio,
oxygen saturation at rest and oxygen saturation after exercise, with CV val-
ues of 0.052, 0.053 and 0.061, respectively. This indicates that single-point
measurements should be suitable for oxygen saturation in the core dataset, as
the measurements show low day-to-day variability for measurements taken on
di↵erent days at the same altitude;
• The measurements with the highest day-to-day variability were respiratory
rate at rest, after exercise and their ratio, with CV values of 0.216, 0.223
and 0.245, respectively. This indicates that these values varied a lot between
measurements at the same altitude, and may not be suitable for use in further
analysis and modelling. However, this variability may be due to di culties in
taking those particular measurements;
• This analysis highlights the issue of the reliability of single-point measures for
the core dataset.
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4.2.3 Is there any redundancy within these measurements?
As there are multiple derivations of each physiological measurement available, this
analysis looks at any redundancy within these measurements, i.e are any of the
measurements showing the same response? If measurements are showing the same
information, then only the measurements that are the most statistically and biolog-
ically informative would be used for further analysis to help save the time taken to
carry out any further analysis.
Ideally, we want measurements that show a change with altitude and have
low day-to-day variability. Correlations were calculated and scatter plots produced
between all pairs of physiological measurements, to assess how similar the responses
were for each measurement, as described in Section 2.5.7. If two physiological mea-
surements show a strong correlation, as determined by a high correlation coe cient
and significant p-value, then potentially only one would be needed for further anal-
ysis.
The di↵erence and ratio measurements showed high levels of correlation with
one another, with correlation coe cients of 0.868 for blood pressure, -0.893 for res-
piratory rate, -0.942 for heart rate and -0.989 for oxygen saturation, shown in Ta-
ble 4.6. These high correlation values were expected, as the di↵erence and ratio
measurements are both slightly di↵erent ways of showing how the rest and exer-
cise measurements are related to one another. The ratio measurements consistently
showed a lower CV than the di↵erence measurements, as shown in Table 4.2, in-
dicating a lower day-to-day variability for the ratio measurement compared to the
di↵erence measurement.
Although the ratio measurement is the most statistically reliable, the di↵er-
ence measurement is more commonly used in the biological and medical environ-
ment. For example, blood pressure is always expressed as pulse pressure (systolic
blood pressure - diastolic blood pressure). A di↵erence measure is easy to interpret,
and removes the scale of the measurement. For example, if an individual has a very
low blood pressure, the di↵erence would not take this into account, and only provide
the absolute di↵erence between the values. A ratio may be misleading here, because
if the blood pressure is low, then the resulting ratio may also be low. For example,
a ratio value of 2 can be obtained by a 4:2 ratio, or by a 8:4 ratio, whereas the
di↵erence values for these ratios would be di↵erent. Which measure to use depends
on the information required, and which method would best display this information.
Oxygen saturations at rest and after exercise show a strong significant pos-
itive correlation with a correlation coe cient of 0.824 and a p-value that was too
small to be calculated by Excel (shown as ./), indicating that they are showing a
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very similar response to altitude. Resting oxygen saturation levels show a lower
CV of 0.053 than oxygen saturations after exercise, which shows a CV of 0.061.
However, oxygen saturations after exercise show a larger change in response to al-
titude, shown by a steeper slope of -0.0041 compared to -0.0032 for resting oxygen
saturation. Oxygen saturation after exercise also shows a slight di↵erence between
individual responses, whereas oxygen saturation at rest does not, suggesting this
may be the most informative oxygen saturation to use for further analysis.
Respiratory rate at rest and respiratory rate after exercise show a weak pos-
itive correlation with a correlation coe cient of 0.505 and a p-value of 9.4x10 93.
Systolic and diastolic blood pressure show a strong significant positive correlation,
with a correlation coe cient of 0.709 and p-value of 1.9x10 218, shown in Figure 4.6.
Both of these measurements show di↵erent information, and are most often used in
a clinical environment together (as pulse pressure), therefore, both values would
be potentially informative in further analysis, rather than using one measurement
alone.
Correlations between unrelated measurements are weaker than those seen
between related measurements, as shown in Table 4.6, and was to be expected, as
they are measuring di↵erent physiological responses. Figure 4.7a shows a significant
weak negative correlation between oxygen saturation at rest and respiratory rate
after exercise for the whole core group, with a correlation coe cient of -0.346 and a
p-value of 3.1x10 41. However, individuals within the group show di↵erent relation-
ships, for example individual X18 shows a strong significant negative correlation in
Figure 4.7b, with a correlation coe cient of -0.710 and a p-value of 0.034, whilst
individual X08 shows no correlation in Figure 4.7c with a correlation coe cient of
-0.210 and a p-value of 0.140. However, this low r -value and high p-value may be
due to 4 high values for respiratory rate at high oxygen saturation levels. This corre-
lation shows one of the adaptive responses that occurs during exposure to hypoxia;
as the oxygen saturation level of the blood drops, the respiratory rate increases to
try and increase the blood oxygen saturation. These individual correlations provide
information on di↵erences between individuals, and can be used to assess whether
individuals are showing similar relationships between variables. Correlations be-
tween unrelated measurements that have a correlation coe cient above 0.392 are
summarised in Table 4.6.
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(a) Scatter plot showing the correlation between systolic blood pressure
and diastolic blood pressure for 24 individuals over 78 days. r=0.709,
p=1.9x10 218.
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(b) Individual X19, r = 0.824, p = 3.7x10 13.
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(c) Individual X04, r=0.335, p=0.010.
Figure 4.6: Correlation between systolic blood pressure and diastolic blood pressure.
The p-value is the probability of getting a correlation as large as the observed value
by random chance, when the true correlation is zero, as described in Section 2.5.7.
p-values below 0.05 indicate that the correlation between x and y was significant.
(a) shows a strong significant correlation for all 24 individuals, with an r -value of
0.709 and a p-value of 1.9x10 218. (b) shows a strong significant correlation for
individual X19, with an r -value of 0.824 and a p-value of 3.7x10 13. (c) shows a
very weak but significant correlation in individual X04, with an r -value of 0.335 and
a p-value of 0.010.
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(a) Correlation between oxygen saturation at rest and respiratory rate after
exercise, for all individuals over 78 days. r= -0.346, p=3.1x10 41.
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(b) Individual X18, r= -0.710, p=3.4x10 12.
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(c) Individual X08, r= -0.210, p=0.140.
Figure 4.7: Correlations between resting oxygen saturations and respiratory rate
after a 2 minute step-exercise test. The p-value is the probability of getting a corre-
lation as large as the observed value by random chance, when the true correlation is
zero, as described in Section 2.5.7. p-values below 0.05 indicate that the correlation
between x and y was significant. (a) shows a weak but significant correlation in
all 24 individuals, with an r -value of -0.346 and a p-value of 3.1x10 41. (b) shows
a strong significant correlation for individual X18, with an r -value of -0.710 and a
p-value of 3.4x10 12. (c) shows a very weak correlation for individual X08, with an
r -value of -0.210 and a p-value of 0.140. However, this low r -value and high p-value
may be due to 4 extreme values in the top right of the graph.
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A - Related
Parameter x Parameter y r -value p-value
 O2Sat O2SatRatio -0.989*** • ./
 HR HRRatio -0.942*** • ./
 RR RRRatio -0.893*** • ./
PP BPRatio 0.868*** • ./
O2SatRest O2SatEx 0.824*** • ./
SBP PP 0.725** •8.9E-234
RREx  RR 0.713** •2.2E-221
SBP DBP 0.709** •1.9E-218
HREx  HR 0.703** •8.2E-209
HRRest HRRatio 0.682** •2.6E-109
O2SatEx O2SatRatio -0.580* •1.9E-128
RRRest RREx 0.505* •9.4E-93
RREx RRRatio -0.503* •7.3E-92
O2SatEx  O2Sat 0.486* •4.0E-85
HREx HRRatio -0.483* •2.5E-82
HRRest  HR -0.465* •5.1E-76
DBP BPRatio -0.442* •1.9E-69
B - Unrelated
Individual Group
Parameter x Parameter y Number r >0.39 r -value p-value
O2SatRest RREx 19 -0.346 •3.1E-41
O2SatEx RREx 19 -0.361 •4.0E-45
O2SatEx DBP 14 -0.249 •5.9E-21
O2SatEx  RR 13 -0.318 •8.4E-35
O2SatRest  RR 11 -0.296 •4.7E-11
O2SatRest RRRatio 10 0.319 •6.7E-35
O2SatEx SBP 9 -0.174 •7.0E-11
O2SatRest HRRest 7 -0.288 •6.3E-30
HR Rest RREx 7 0.142 •6.8E-8
O2SatEx HRRest 5 -0.235 •2.4E-19
Table 4.6: A summary of the correlations between measurements of the diary data,
as defined in Table 4.1. The p-value is the probability of getting a correlation as
large as the observed value by random chance, when the true correlation is zero.
Measurements marked with a dot (•) show a p-value less than 0.05, indicating that
the correlation between x and y was significant. p-values marked as ./ were too
small to be calculated by Excel, but greater than zero. Weak correlations have an
r -value between either -0.4 to -0.59 or 0.4 to 0.59 and are marked with an asterisk
(*). Medium strength correlations have an r -value between either -0.6 and -0.79 or
0.69 and 0.79, and are marked with a double asterisk (**). Strong correlations have
an r -value between either -0.8 to -1.0 or 0.8 to 1.0, and are marked with a triple
asterisk (***). Correlations between unrelated measurements show the number of
individuals who show a weak correlation or stronger (>0.39). The r -value and
p-value are for the correlation for the entire group.
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4.2.3.1 Summary
• All of the di↵erence measurements show strong correlations with the corre-
sponding ratio measurement;
• The CV values for the ratio measurement show lower day-to-day variability
compared to the di↵erence measurement, indicating it may be the more reliable
of the two measurements. However, the di↵erence measurement may be more
biologically useful, as it may be easier to interpret;
• Other related measurements tend to correlate strongly with one another, how-
ever, not strongly enough to justify the removal of one for the other, as they
may both provide useful information on their own or in combination. There
seems to be some amount of redundancy, but not enough to remove any of the
measurements from further analysis;
• Some weak correlations are present between unrelated measurements. These
can be used to confirm that known adaptive responses to hypoxia are oc-
curring, to assess relationships between variables, and to look for di↵erences
between individuals (by assessing individual correlations of variables).
4.2.4 Is there evidence of di↵erent levels of adaptation?
The most important characteristic of measurements used in predictive modelling is
the ability to distinguish between di↵erent types of behaviour. A smoothing algo-
rithm was implemented, as described in Section 2.5.8, to allow the visual analysis of
di↵erent individual responses during the expedition. These figures were used to visu-
ally identify individuals who were showing di↵erent responses compared to the other
individuals within the group. Figures 4.8 and 4.9 show the raw and smoothed values
for heart rate at rest and diastolic blood pressure, respectively. After smoothing,
individual responses are much easier to identify. For example, individual X14 shows
a very high response in Figure 4.8b, which is di cult to identify in Figure 4.8a.
Figure 4.9b shows diastolic blood pressure after rest, where it is easy to identify
individual X17 who shows a very low response, and individual X10 who shows a
very high response, compared to Figure 4.9a.
For each individual, a simple linear regression analysis was carried out for
each physiological measurement against altitude. This was done to assess whether
the response seen for each of the physiological measurements against altitude could
be described with a linear fit, and to assess any di↵erences in the fit between indi-
viduals. Figures 4.3a and 4.3b show the fitted regression lines for all individuals for
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(a) Heart rate at rest for 10 lab sta↵ individuals (raw data)
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(b) Heart rate at rest for 10 lab sta↵ individuals (smoothed)
Figure 4.8: Heart rate at rest for 10 lab sta↵ individuals. The figures show the raw
data plotted for each individual, and smoothed data plotted, respectively. Here, (b)
shows much clearer responses, allowing the identification of individuals such as X14,
who shows a very high response compared to other individuals.
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(a) Diastolic blood pressure at rest for 14 climber individuals (raw data)
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(b) Diastolic blood pressure at rest for 14 climber individuals (smoothed)
Figure 4.9: Diastolic blood pressure for 14 climber individuals. The figures show
the raw data plotted for each individual, and smoothed data plotted, respectively.
Here, (b) shows much clearer responses, allowing the identification of individuals
such as X17, who shows a very low response compared to other individuals.
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(a) Individual regressions of respiratory rate after exercise against altitude, in 10 lab sta↵ individ-
uals.
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(b) Individual regressions of blood pressure ratio (SBP:DBP) against altitude, in 10 lab sta↵ indi-
viduals.
Figure 4.10: Simple linear regression analyses for (a) respiratory rate after exer-
cise against altitude and (b) blood pressure ratio against altitude, for 10 lab sta↵
individuals. Individuals X09 and X23 became ill during the expedition, and are
both marked in magenta. Both figures show individual X23 as having a linear re-
sponse that is di↵erent compared to other individuals within the group for these
measurements, whereas only (b) shows a response that is di↵erent for individual
X09.
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(a) Individual regressions of respiratory rate at rest against altitude, in 14 climber individuals.
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(b) Individual regressions of respiratory rate ratio against altitude, in 14 climber individuals.
Figure 4.11: Simple linear regression analyses for (a) respiratory rate at rest against
altitude and (b) respiratory rate ratio against altitude, for 14 climber individuals.
Individuals X01 and X07 became ill during the expedition, and are both marked in
red. Both figures show individuals X01 and X07 having a linear response that is
di↵erent compared to others within the group for these measurements.
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heart rate after exercise and respiratory rate at rest, respectively. These responses
are also summarised in Tables 4.3 and 4.4. Both of these measurements show dif-
ferences in how individuals are responding to altitude, indicated by positive and
negative slopes for individual regression lines. However, only 4 and 10 individuals
show slopes that are significantly di↵erent from zero for heart rate after exercise and
respiratory rate at rest, respectively, shown in Tables 4.3 and 4.4 as having a sig-
nificant GOF statistic (marked with an asterisk (*)) and significance value (marked
with a dot (•)).
Figures 4.4 and 4.5 show four individual responses for heart rate after exercise
and respiratory rate at rest, respectively. These figures show di↵erences in response
between individuals, as well as di↵erences in the strength of the linear fit. The
summary statistics in Tables 4.3 and 4.4 can be used to assess the linear fit for each
individual, by comparing the slope, CV , goodness of fit statistic, lack of fit statistic
and F -value.
Individual’s fitted regression figures can also be used to assess whether any
individuals were showing responses very di↵erent from others within their group.
To assess this, individuals who became ill during the expedition were highlighted in
each figure (magenta for lab sta↵ individuals, or red for climber individuals). This
aided in visually identifying these specific individuals. Figures 4.10 and 4.11 show
instances where ill individuals do seem to be responding di↵erently to others within
their group. This information can be used to inform future modelling analysis, and
identifies measurements that may be potentially useful for discriminating between
individuals who struggled during CXE 2007, and those who did not.
4.2.4.1 Ill individuals
Individuals X01, X07, X09 and X23 all became ill at di↵erent points during the
expedition. It was hoped that these particular individuals would show a response
that was di↵erent to other individuals within the group, to help account for why
they became ill and others did not. There were several measurements that showed
di↵erences in how these particular individuals were responding.
Figure 4.3a and Table 4.3 show the simple linear regression results for heart
rate after exercise against altitude. This particular measurement shows di↵erences
for how individuals X01, X09 and X23 are responding, compared to others within
the total core group. Figure 4.3a shows that these three individuals have negative
slopes, compared to most of the other individuals, who show positive slopes. The
slope for individual X09 is the only slope that is significantly di↵erent from zero,
shown in Table 4.3 as having a significant GOF statistic of 13.62 (marked with an
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asterisk (*)) and a significance value of 0.009 (marked with a dot (•)). The GOF
statistic and significance value for individual X01 and X23 are 0.25 and 0.059, and
4.84 and 0.121, respectively.
Figure 4.3b and Table 4.7 show the simple linear regression results for respira-
tory rate at rest against altitude. This particular measurement shows steep positive
slopes for individuals X01, X07 and X23, shown as 0.00165, 0.00066 and 0.00123 in
Table 4.4, respectively. All of these individuals show slopes that are significantly
di↵erent from zero, with individual X01 showing GOF and significance values of
11.90 and 0.000003, individual X07 showing GOF and significance values of 5.46
and 0.004, and individual X23 showing GOF and significance values of 16.58 and
0.012. Individual X10 also shows a steep slope that is comparable to the individuals
who became ill. The steep slope for individual X01 is also shown in Figure 4.11a.
Other respiratory rate measurements also show ill individuals as having a
response that is di↵erent from others within the group. Figures 4.10a and 4.12b and
Table 4.7 show the fitted regression lines for respiratory rate after exercise against
altitude. Individuals X01 and X23 both show slopes that are steeper than other
individuals, with slope values of 0.003 and 0.004, respectively. All ill individuals
slow slopes that are significantly di↵erent from zero, with significant GOF values
(marked with an asterisk (*)), and significance values (marked with a dot (•)) in
Table 4.7. Figures 4.11b and 4.12c, and Table 4.7 show the fitted regression lines for
respiratory rate ratio against altitude. Individuals X01 and X07 both show slopes
that are not significantly di↵erent from zero, whereas other individuals show steep
negative slopes.
Figures 4.10b and 4.12a and Table 4.7 show the fitted regression lines for
blood pressure ratio against altitude. Individual X09 shows a high intercept value
of 1.76, with a slope that does not change significantly with altitude. Individual X23
shows a positive response here, whereas all other individuals show negative responses
over altitude. The fitted regression line for individual X23 shows a significance value
of 0.04, however, the GOF statistic is non-significant at 3.33. This may indicate
that there are di↵erences between the means at each altitude for individual X23,
but the response may not be linear, as indicated by a significant LOF statistic of
2.24. All of these measurements could be useful in modelling attempts, to allow the
discrimination between individuals who became ill, and those who did not.
4.2.4.2 Summary
• There are di↵erences seen between individuals for all measurements, however,
the di↵erences seen between individuals are clearer for some measurements
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than others;
• Smoothed responses and individual regression analyses against altitude can
both be used to assess how individuals responded during the entire expedition,
and identify individuals who are responding in a di↵erent way to others within
the group;
• Several of the physiological measurements showed di↵erences in how ill individ-
uals were responding compared to other individuals within the group. These
measurements were BPRatio, HREx, RREx, RRRatio, RRRest and  RR. These
measurements may be useful in the next stages of modelling for discriminating
between individuals who became ill and those who did not.
4.3 Which parameters are most suitable for use in mod-
elling?
The analyses carried out on the diary data have been used to determine which
of the measurements available are the most informative for further analysis, by
looking at whether individual’s responses change with increasing altitude, how stable
each measurement is day-to-day and whether and they can be used to di↵erentiate
between di↵erent individuals, especially individuals who became ill.
Table 4.8 shows a final ranked summary of the diary data measurements,
indicating which would be most useful for further analysis and modelling. The top
section of this table contains BPRatio, HREx, RREx, RRRatio, RRRest and  RR.
These measurements are ranked in order of increasing CV value, as a measure of the
relative day-to-day reliability of each measurement. Whilst these measurements do
not show the best reliability out of all of the measurements assessed, these measure-
ments all show di↵erences in how individuals are responding (indicated by di↵erences
in slopes and intercepts for fitted regression lines), and di↵erences in how ill individ-
uals are responding, compared to other individuals within the group, as described
in Section 4.2.4.1.
The second group of 6 measurements are HRRest, SBP, DBP, PP, O2SatRatio
and  O2Sat. These measurements are also ranked in order of increasing CV value,
as a measure of their reliability. Each of these measurements show di↵erences in
how individuals are responding, but do not show di↵erences in how ill individuals
are responding. These measurements were deemed the next most useful group of
measurements to use in further analysis/modelling.
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(a) Individual regressions of blood pressure ratio at rest against altitude,
in 24 core individuals.
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(b) Individual regressions of respiratory rate after exercise against
altitude, in 24 core individuals.
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(c) Individual regressions of respiratory rate ratio against altitude, in
24 core individuals.
Figure 4.12: Simple linear regression analyses for (a) blood pressure ratio against
altitude, (b) respiratory rate after exercise against altitude and (c) respiratory rate
ratio against altitude, for 24 core team individuals. Climber individuals X01, and
X07 became ill during the expedition, and are both marked in red. Lab sta↵ in-
dividuals X09 and X23 also became ill during the expedition, and are marked in
magenta.
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The final four measurements are O2SatRest, O2SatEx, HRRatio and  HR.
Whilst these measurements show some of the lowest CV values for any of the di-
ary data measurements, they either do not show di↵erences in how individuals are
responding (O2SatRest, O2SatEx and HRRatio), or they do not show a slope sig-
nificantly di↵erent from zero ( HR). However, measurements that do not show a
change with altitude could still be useful as explanatory variables, as long as they
show di↵erences between individual responses.
The next stage in this analysis will be to repeat these and other statistical
analyses on the main core dataset, and to identify other physiological measurements
that may be useful indicators of how well an individual is adapting to altitude, as
well as identifying which of the biochemical metabolites may be good predictors of
acclimatisation. Any variables identified in this way will then be used in further
modelling processes.
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Parameter Name Slope CV GOF Di↵erences? Ill individuals?
BPRatio -0.00002 0.084 * 50.66 §Yes • Yes
HREx 0.00112 0.135 * 7.79 §Yes • Yes
RREx 0.00184 0.216 * 48.23 §Yes • Yes
RRRatio -0.00005 0.223 * 246.77 §Yes • Yes
RRRest 0.00042 0.245 * 8.51 §Yes • Yes
 RR 0.00148 0.656 * 64.10 §Yes • Yes
HRRest 0.00234 0.168 * 23.42 §Yes No
SBP 0.00203 0.110 * 26.49 §Yes No
DBP 0.00269 0.106 * 73.61 §Yes No
PP -0.00065 0.235 * 7.67 §Yes No
O2SatRatio 0.00001 0.052 * 26.34 §Yes No
 O2Sat -0.00088 0.772 * 17.39 §Yes No
O2SatRest -0.00323 0.053 * 261.75 No No
O2SatEx -0.00408 0.061 * 1064.99 No No
HRRatio 0.00002 0.200 * 7.82 No No
 HR -0.00126 0.424 2.46 §Yes No
Table 4.8: A summary of all diary data measurements, ranked in decreasing order of
potential usefulness in further analysis/modelling. Slope is the slope for the fitted
regression line for all 24 individuals. CV is the coe cient of variation calculated
from the regression, as described in Section 2.5.10.3. GOF is the goodness of fit
statistic, as described in Section 2.5.10.1. Values marked with an asterisk (*) show
slopes that are significantly di↵erent from zero. Di↵erences? indicates whether there
are di↵erences in how individuals are responding, such as di↵erences in slope and
intercept values for the fitted regression lines. Ill individuals? indicates whether the
particular measurement is showing di↵erences in how ill individuals are responding,
as detailed in Section 4.2.4.1.
The first 6 measurements show a slope significantly di↵erent from zero, di↵erences in
how individuals are responding and di↵erences in how ill individuals are responding.
These are ranked in increasing order of CV value, as a measure of reliability. These
measurements are deemed the most likely to be of use in further analysis/modelling.
The second 6 measurements show di↵erences in how individuals are responding, but
not specifically for ill individuals. These measurements are also ranked in order
of increasing CV value, and are deemed the next group of measurements to be of
most use in the next stage of analysis/modelling. The final four measurements are
deemed the least useful for modelling, as they show no di↵erences in how individuals
are responding, or do not show a slope that is significantly di↵erent from zero.
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Chapter 5
Exploratory Data Analysis
Exploratory data analysis (EDA) is a hypothesis-generating approach to analysing
data, which avoids any unnecessary bias that may be present when undergoing
confirmatory data analysis. The aims of EDA are to maximise the users insight
into the dataset, to undercover any underlying structure to the data, to clarify
important variables, to detect outliers and anomalies and to test the validity of
initial assumptions. EDA utilises various graphical techniques to allow the user to
explore the data with an open-mind. Graphical representations allow fast and easy
identifications of any patterns or outliers in the data, whilst allowing the user the
ability to gain new and unexpected insight into the dataset.
5.1 Which data are available?
Data is available for two groups of individuals, comprising a group of 24 core team
members and a larger group of 190 trekker individuals, as detailed in Table 1.2.
The full lists of biochemical metabolites and physiological measurements available
for the core team are detailed in Tables 2.3 and 2.4. A majority of the trekker
samples have yet to be analysed up to this date. Data is available at London (75m),
Kathmandu (1300m), Namche (3500m), Pheriche (4250m) and Everest Base Camp
Weeks 1, 6 and 8 (5300m), as shown in Figure 1.1.
One important point to take into consideration is that these analyses are
almost exclusively based on the results of a small self-selected group of 24 core team
members, consisting of doctors and scientists who each had a certain level of fitness
and mountaineering experience. As these 24 are a highly selected group, they may
not be truly representative of the population as a whole. EDA was used here to
generate hypotheses from the biochemical data for the 24 core team members, which
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may be validated at a later date once the 190 trekker plasma samples have been
measured.
It is also important to note that the 24 core team members did not simply rest
at Everest Base Camp for the period over which samples were taken. 14 individuals
attempted to summit after EBC week 1, and their ascent profile is shown in red in
Figure 1.1. Individuals who ascended to altitudes higher than Base Camp would
have been subjected to much higher levels of oxidative stress than the individuals
who stayed at Base Camp. However, the main focus of this study was to assess
the di↵erences in individual responses to an identical ascent profile (i.e. the same
amount of hypoxic exposure). Therefore, most analyses were performed for data
collected on 5 occasions from London to Everest Base Camp week 1 only.
5.2 Aims
The aims of this preliminary analysis were to:
• Visually summarise all of the available data and identify the main patterns
of hypoxic response seen in the physiological measurements and biochemical
metabolites;
• Identify physiological measurements and biochemical metabolites that are
changing in a similar way across individuals as altitude increases;
• Identify any outliers and quality check the data before further analysis and
modelling;
• Assess and rank the physiological measurements in order of suitability as
a proxy for hypoxia adaptation, based on their statistical suitability, and
whether they are of biological interest;
• Assess and rank the biochemical metabolites in order of suitability as poten-
tial predictors of the physiological measurements, based on their statistical
suitability and whether they are of biological interest.
5.3 Data analysis techniques
Several di↵erent operations have been performed on the dataset, comprising:
1. Plotting box and whisker plots for all physiological measurements and bio-
chemical metabolites to assess how each measurement changes in response to
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increasing altitude, and the variability of each measurement across altitudes
and between individuals;
2. Plotting all individual responses for a particular measurement on one figure
or subplot, to show the di↵erent responses seen and assess inter-individual
variability in response;
3. Performing simple linear regression analyses against altitude to assess how
each biochemical metabolite and physiological measurement changes with in-
creasing altitude, and to see whether a linear fit is appropriate to describe the
relationship between the two;
4. A two-way Analysis of Variance (ANOVA) without interactions for each phys-
iological measurement and biochemical metabolite to assess the e↵ect of alti-
tude and individual on the response.
This section will look at the di↵erent data analysis techniques used, and summarise
interesting results from each technique.
5.3.1 Box and whisker plots
The boxplot function was implemented in matlab, as described in Section 2.5.1, to
produce box and whisker plot graphs of all 124 physiological measurements and
biochemical metabolites for the core group, and 63 physiological measurements for
the trekker group. Each plot shows a summary of all individuals over five increasing
altitudes.
5.3.1.1 Results
The box and whisker plots produced for the core data show several di↵erent pat-
terns of response during CXE 2007. Figures 5.1 and 5.2 show examples of di↵erent
patterns of response seen for the biochemical metabolites and physiological mea-
surements, respectively. Table 9.2 (located in the appendix) shows the full results
for the interquartile ranges (IQR) for each variable for each altitude, as a measure
of the variability. Table 5.1 shows a summary of the results for a 2-way ANOVA
performed for these particular variables. A full list of the ANOVA results for all
biochemical metabolites and physiological measurements is shown in Table 9.1, in
the appendix.
Figures 5.1a and Figure 5.1b show an overall increase for both nitrite and
cGMP levels during the expedition. This was expected, as they are known to play
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a key role in hypoxia adaptation (as described in Section 1.4.1.1). The increase of
nitrite levels between Kathmandu and Pheriche may be due to the large increase
in altitude between these two time-points, as shown in Figure 1.1. cGMP only
shows an increase between London and Namche, which may be due to only initial
adaptive responses involving the increase of cGMP. Figure 5.1c shows an initial
decrease of RSNO levels between London and Kathmandu, and then an increase
between Kathmandu and Everest Base Camp week 1. The reasons for this particular
pattern are less clear, but may be due to lower NO availability to form RSNOs
at Kathmandu [Rassaf et al., 2002]. Figure 5.1d shows that osmolality shows no
change during the expedition, and is described in more detail in Section 3.2. All
of these changes were tested for their significance by a two-way ANOVA without
interactions, to assess the e↵ect of altitude and individual, and the ANOVA results
for these particular metabolites are shown in Table 5.1.
Figures 5.2a and 5.2b show a general decrease for both oxygen saturation
at rest and work rate at VO2max, which is to be expected. Oxygen saturation is
known to decrease during hypoxia, and is used later in the analysis as a proxy for
hypoxia exposure. Work rate is a measure of the body’s ability to utilise oxygen,
and is also known to decrease in response to decreasing oxygen availability [McArdle
et al., 2007].
Figure 5.2c shows a general increase for haematocrit levels, which is to be
expected. Haematocrit is the volume percentage of red blood cells in whole blood.
One of the main adaptations to hypoxia is an increase in the blood’s oxygen carrying
capacity [McArdle et al., 2007]. This is achieved by increased urine output, shifting
of body fluid and increased red blood cell production, as described in Sections 1.2.3
and 3.2, which leads to an increase in haematocrit. Figure 5.2d shows that resting
heart rate only shows an increase between Pheriche and Everest Base Camp week 1.
A much earlier increase was expected, as increasing heart rate is an early response
to hypoxia, as described in Section 1.2.3. However, the late increase may be due to
the high fitness level of the 24 core individuals, and only increases when they are
exposed to very high levels of hypoxic stress.
Some of the figures show an increase in variability during the expedition,
shown by an increase in the interquartile range (IQR, length of the box). For
example, Figures 5.1d and 5.2a and Table 9.2 show an increase in the IQR for both
osmolality (from 0.036 to 0.064), and oxygen saturation at rest (from 0.020 to 0.100)
between London and Everest Base Camp week 1. This is to be expected, due to
various adaptive responses taking e↵ect. The more stress an individual is exposed
to, the stronger the expected response to that stress, which accentuates any inter-
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ANOVA (altitude) ANOVA (individual)
Variable F -value p-value F -value p-value
Nitrite (mM) 22.07 • 8.6E-13 2.25 • 3.5E-03
RSNO (nM) 18.01 • 5.9E-11 2.04 • 9.1E-03
cGMP (pmol/mL) 9.21 • 2.7E-06 2.65 • 5.4E-04
Osmolality (mOsmo/kg) 1.57 1.9E-01 1.48 9.8E-02
Oxygen saturation at rest 146.30 • 5.2E-38 3.97 • 1.5E-06
Work rate at VO2max 239.68 • 9.3E-47 56.48 • 2.5E-43
Haematocrit 57.79 • 2.7E-24 5.60 • 1.1E-09
Resting heart rate 24.58 • 1.0E-13 13.88 • 1.8E-20
Table 5.1: 2-way ANOVA results for a selection of biochemical metabolites and
physiological measurements, looking at the e↵ects of altitude and individual, with-
out interaction. Significance levels marked with a dot (•) indicate that the null
hypothesis has been rejected at the 5% level.
individual variability seen in those response readouts. The change in variability may
have an impact on the power of the ANOVA carried out.
Some variables show similar variability during the expedition, shown by sim-
ilar IQR values for each altitude. Figures 5.1a, 5.1b, 5.2b, 5.2c and 5.2d show box
and whisker plots for nitrite, cGMP, work rate at VO2max, haematocrit and resting
heart rate, respectively. These figures and Table 9.2 show that the IQR is similar
across altitudes for these particular variables. A small number of variables show
a decrease in variability during the expedition, shown by a decrease in the IQR.
For example, Figure 5.1c and Table 9.2 shows that the IQR for RSNO decreases
from 1.026 for London to 0.488 for Everest Base Camp week 1. The reason for this
decrease is less clear.
5.3.1.2 Treatment of potential outliers
Here, outliers are defined as data points that are more than 1.5 times the interquar-
tile range either above the 75th percentile, or below the 25th percentile [McGill et al.,
1978], and are labelled as a red ‘+’ on the box and whisker plots. Outliers may
be due to instrument or calculation error, or they may show an individual-specific
response, resulting in an unusually high or low observation. They may also indicate
illness of an individual at the time the sample was taken. If a datapoint is labelled
as a potential outlier, it needs to be checked as it can have a great impact on the
overall outcome of any analysis performed on the data. Any potentially outlying
values were double-checked in the original dataset, to confirm the value was correct.
Potential outliers for the physiological data in the smaller core group can
be compared to data from the larger trekker group to identify the position of the
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Figure 5.1: Examples of di↵erent patterns of response seen in several biochemi-
cal metabolites in 24 individuals during CXE 2007. (a) shows nitrite, (b) shows
cGMP, (c) shows RSNO and (d) shows osmolality. (a) shows an increase between
Kathmandu and Namche, (b) shows a general increase until Namche and then a
levelling-o↵, (c) shows an initial decrease between London and Kathmandu, fol-
lowed by an increase, and (d) shows no change during the expedition. All of these
changes were confirmed with a 2-way ANOVA without interactions, as shown in
Table 5.1.
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(a) Log-transformed oxygen saturation at rest
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(b) Log-transformed work rate at VO2max
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Figure 5.2: Examples of di↵erent patterns of response seen in several physiological
measurements in 24 individuals during CXE 2007. (a) shows oxygen saturation at
rest, (b) shows work rate at VO2max, (c) shows haemoatocrit and (d) shows resting
heart rate. (a) and (b) show a general decrease during the expedition, (c) shows
a general increase and (d) shows an increase between Pheriche and Everest Base
Camp week 1. All of these changes were confirmed with a 2-way ANOVA without
interactions, as shown in Table 5.1.
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outlier in a larger sample size. Figure 5.3 shows an observation at London that
appears to be a potential outlier within the 24 individuals, but is not for the 190
individuals. This emphasises that whilst a sample size of 24 is suitable to show
the general population response, a larger sample size gives more information about
individual responses, especially when highlighting individuals who are responding
di↵erently to everyone else.
5.3.2 Subplots
Subplots allow a swift visual representation of several individual’s responses to be
compared and analysed for trends, and clearly show individuals who show a response
vastly di↵erent from others. Subplots also highlight potential outliers and indicate
the individual to whom the outlier belongs, to aid in further analysis. The subplot
function was implemented in matlab, as described in Section 2.5.2, to produce figures
showing all individual responses for all biochemical metabolites and physiological
measurements. Males were labelled in cyan (lab sta↵) and blue (climbers) and
females in magenta (lab sta↵) and red (climbers), to look for any obvious gender
di↵erences, or di↵erences between lab sta↵ and climber groups. Individuals who have
data points labelled as asterisks (*) became ill during the expedition (individuals
X01, X07, X09 and X23).
5.3.2.1 Results
The subplot figures indicate that most of the physiological measurements show low
inter-individual variability (i.e. individuals show a similar response over altitude),
whereas the biochemical metabolites tend to show a higher level of inter-individual
variability in their response. Figure 5.5 shows subplots for haemoglobin and work
rate at VO2max, which both show low variability between individuals. In compari-
son, Figure 5.4 shows subplots for nitrate and IL-8, which both show much higher
variability between individuals compared to Figure 5.5. This is to be expected, as
the biochemical metabolites are showing the response of multiple stress-response
pathways, which cross-over and communicate with one another, or may just contain
more noisy data. This creates a very complex pattern of responses, which can vary
greatly between individuals. Analysis of the biochemical metabolites in the remain-
ing 190 trekker individual’s plasma samples will be vital for further assessing the
inter-individual variability seen for the biochemical metabolites.
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(a) CO2 production at VO2max for 24 core team individuals.
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(b) CO2 production at VO2max for 190 individuals.
Figure 5.3: box and whisker plots showing carbon dioxide production at VO2max
for (a) 24 core team individuals and (b) 190 trekker individuals. (a) shows generally
a higher CO2 production compared to (b), and both figures show a general decrease
over altitude. (a) shows an outlier for London, which becomes part of the whisker
for (b). The whiskers for (b) are also much larger compared to (a). This figure
shows the importance of the size of a sample when looking at potential outlying
points.
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(a) Subplot of log-transformed nitrate levels in 24 individuals during CXE 2007
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(b) Subplot of log-transformed IL-8 in 24 individuals during CXE 2007
Figure 5.4: Subplots showing how log-transformed nitrate levels (a) and IL-8 (b)
change during CXE 2007 in 24 individuals. The horizontal axis shows the increase in
altitude, with 1-5 representing London, Kathmandu, Namche, Pheriche and Everest
Base Camp. Females are labelled in magenta (lab sta↵) and red (climbers) and males
are labelled in cyan (lab sta↵) and blue (climbers). The labels above each graph
represent that individual’s denotative. Missing data points are due to observations
not being available in the dataset. Both figures show relatively high inter-individual
variability compared to physiological measurements (shown in Figure 5.5).
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(a) Subplot of log-transformed haemoglobin levels in 24 individuals during CXE 2007
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(b) Subplot of log-transformed work rate at VO2max in 24 individuals during CXE 2007
Figure 5.5: Subplots showing how log-transformed haemoglobin levels (a) and work
rate at VO2max (b) change during CXE 2007 in 24 individuals. The horizontal axis
shows the increase in altitude, with 1-5 representing London, Kathmandu, Namche,
Pheriche and Everest Base Camp. Females are labelled in magenta (lab sta↵) and
red (climbers) and males are labelled in cyan (lab sta↵) and blue (climbers). The
labels above each graph represent that individual’s denotative. Missing data points
are due to observations not being available in the dataset. Both measurements
show relatively low inter-individual variability compared to biochemical metabolites
(shown in Figure 5.4).
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5.4 Variable selection
Frequently, experiments generate a large amount of data, which can be used to
create hypothesis-generating models, capable of predicting the output of further ex-
periments. In the absence of any prior biological knowledge, many, if not all of the
possible variables may be used in initial models to reduce possible model bias (ap-
proximation error). However, a complex model that encompasses many insignificant
variables may have less predictive power, and the results may be di cult to inter-
pret. In this case, a simpler model with fewer variables may be more appropriate.
Variable selection is key to solving this problem, and looks at selecting the variables
with the most predictive power over the dependent variable. Automatic methods
such as step-wise selection or elimination allow the swift analysis of large numbers
of potential variables. However, they can be computationally expensive and may
not take into consideration any prior biological knowledge. The main question here
is which variables to choose, and the main challenge is how to choose them. The
methods in this section look at selection methods for both the physiological mea-
surements (dependent variable) and biochemical metabolites (explanatory variables)
of interest for modelling methods.
5.4.1 Variable selection criteria
Suitable dependent and explanatory variables for modelling were selected based on
the following criteria, which were assessed with a statistical approach:
1. A significant change during the expedition. This was assessed via an ANOVA
and by assessing fitted regression lines against altitude;
2. Variability in response between individuals, to allow the distinction between
how individuals are responding. This was assessed by analysing fitted regres-
sion lines against altitude;
3. Ideally, low day-to-day variability, shown by a low CV value (as described
in Section 2.5.10.3). Diary data was used here for some measurements, as
described in Chapter 4;
4. Ideally, a di↵erence between lab sta↵ and climbers, and ill individuals and
individuals who did not become ill. Diary data was also used here for some
measurements.
Physiological measurements and biochemical metabolites were assessed for
their suitability for use in modelling by calculating several summary statistics, and
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combining this with prior biological knowledge. Variables that measured very similar
components were compared via correlations to see if both were needed for modelling
purposes. Binary information such as gender was removed from the analysis, as well
as any variables missing a large amount of data, so that any models constructed
would be as accurate and complete as possible.
5.4.2 Physiological measurement selection
For each individual, a simple linear regression (SLR) model was fitted for each phys-
iological measurement against altitude, as described in Section 2.5.9. Fitting a SLR
model against altitude allowed the assessment of whether the measurement showed
a linear response with increasing altitude, and whether there were di↵erences be-
tween individuals for the response. The fitted lines were then summarised across all
individuals for each measurement, by calculating the mean and standard deviation
of the slopes, intercepts and R2 values. The mean and standard deviation for the R2
values were used as indicators of how well a SLR described the relationship between
the physiological measurement and altitude, across all individuals. The intercept
was used as an indicator of the calculated physiological measurement value when
hypoxia exposure was zero, and the slope mean and standard deviation were used
as indicators of how much variability there was between individuals for the response
seen. If any measurements overlapped with the diary data, then the information
gained during Chapter 4 was used to inform the analysis of the corresponding mea-
surement in the core data.
Several physiological measurements were highlighted by members of the CXE
team as being of high biological interest. Indicators of hypoxaemia (low partial pres-
sure/content of oxygen within the blood) show how well an individual is loading
haemoglobin with oxygen and transporting it in the blood. Hypoxaemia indica-
tors include haemoglobin, oxygen saturation at rest and oxygen content. Oxygen
consumption is an analogue of how well the body utilises oxygen, and can be an
indicator of how well an individual is adapting to low oxygen levels. Parameters
of interest that show oxygen consumption are work rate at LaT and VO2max and
oxygen consumption at rest, LaT and VO2max. Oxygen e ciency is a measure of
how well oxygen is being used by the body, and is measured by looking at oxygen
economy.
For the SLR analysis, a high standard deviation of the slope coupled with a
low standard deviation for the intercept and high R2 was preferred. This indicated
that there was a good linear relationship between the physiological measurement
and altitude (shown by a high R2 value), and that there was a di↵erence in how
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individuals were responding to the exposure to hypoxia (shown by di↵erences be-
tween individual’s fitted slopes). If any measurements did not change significantly
over altitude, as determined by an ANOVA, or did not show di↵erences between
individual responses, then they were not used in further modelling e↵orts. The
resulting ranked physiological measurement list is shown in Table 5.2. This was
constructed by looking at the summary statistics, and highlighting metabolites of
specific biological interest with an asterisk (*).
Figures 5.6a and 5.6b show examples of the fitted regression models for the
physiological measurements against altitude, for all individuals. Figure 5.6a shows
the results for work rate at LaT and Figure 5.6b shows the results for heart rate
at VO2max. Both of these measurements are ranked highly as potential dependent
variables for modelling in Table 5.2, due to high mean R2 values for the fitted lines,
and a high standard deviation for the slopes.
Work rate at LaT is also a measurement of particular biological interest, as
it is a measure of oxygen consumption. Heart rate after exercise was identified in
the diary data as showing responses for ill individuals that were di↵erent to other
individuals within the group. Figure 4.3a shows the simple linear regression results
for heart rate after exercise against altitude for the diary data. Heart rate after
exercise and heart rate at VO2max are not identical measurements, but both show
the heart rate after exercise. Interestingly, the diary data measurement shows a
general increase in heart rate for most individuals, with ill individuals showing a
decrease. However, the core data shows a general decrease for most individuals.
This may be due to di↵erences in what the measurements are actually showing, and
may limit how useful the diary data information is for analysing the core dataset.
The top group of measurements in Table 5.2 are all measurements of biolog-
ical interest, and are ranked by decreasing standard deviation of the slope (to show
di↵erence in how individuals are responding). The second group includes measure-
ments identified from the diary data as showing di↵erences in how ill individuals
were responding, as described in Section 4.2.4.1. The measurements are also ranked
by decreasing standard deviation of the slope. The final group of measurements
have been identified purely by their statistical summaries, and are also ranked by
decreasing standard deviation of the slope.
5.4.3 Biochemical metabolite selection
Explanatory variables are variables that are expected to have some influence over a
dependent variable of interest. The biochemical metabolites were used as potential
explanatory variables, with the aim of finding a combination of biochemical metabo-
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(a) Work rate at VO2 max regressed against altitude
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(b) Heart rate at VO2max regressed against altitude
Figure 5.6: Examples of simple linear regression analyses carried out for the physio-
logical measurements against altitude. (a) shows work rate at LaT against altitude,
and (b) shows heart rate at VO2max against altitude. Both figures show separate
fitted regression lines for 24 individuals. These measurements are both ranked highly
as potential dependent variables for modelling in Table 5.2, due to a high mean R2
value for the fitted lines (indicating that the model is a good fit to the data) and
di↵erences between individual slopes (shown by a high slope standard deviation in
Table 5.2), indicating di↵erences between how individuals are responding. Lab sta↵
individuals are in blue, with ill individuals in magenta, and climber individuals are
in green, with ill individuals in red.
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Parameter name Slope mean Slope
SD
Intercept
mean
Intercept
SD
R2
mean
R2
SD
⇤Work rate at LaT -0.010561 0.00513 158.27 30.90 0.729 0.284
⇤Work rate at VO2max -0.017348 0.00397 317.00 47.86 0.882 0.067
⇤Oxygen saturation at rest -0.003058 0.00096 99.43 1.11 0.903 0.073
⇤Oxygen consumption at
LaT (kg)
-0.001556 0.00088 26.69 4.63 0.749 0.221
⇤Economy -0.000222 0.00023 10.88 0.90 0.488 0.329
⇤Haemoglobin 0.000584 0.00022 13.72 0.67 0.671 0.198
⇤Resting oxygen consump-
tion (kg)
0.000080 0.00014 5.24 0.82 0.309 0.296
•Heart rate at LaT -0.003113 0.00333 132.11 15.40 0.515 0.347
•Heart rate at VO2max -0.006097 0.00265 181.72 10.16 0.782 0.192
•Respiratory rate at
VO2max
0.001186 0.00178 45.98 10.27 0.435 0.293
•Resting respiratory rate 0.000492 0.00052 17.16 2.83 0.297 0.268
Maximum voluntary venti-
lation
0.006373 0.00383 168.24 27.95 0.598 0.311
Minute ventilation at LaT 0.002077 0.00230 44.65 10.41 0.518 0.340
Diastolic blood pressure at
rest
0.001240 0.00211 78.58 9.13 0.331 0.278
Resting heart rate 0.001802 0.00208 72.80 10.91 0.338 0.290
Resting minute ventilation 0.001085 0.00064 11.60 1.84 0.547 0.274
Resting oxygen pulse -0.000054 0.00021 5.60 1.05 0.376 0.307
Respiratory exchange ratio
at VO2max
-0.000014 0.00002 1.22 0.06 0.304 0.288
Respiratory exchange ratio
at LaT
-0.000008 0.00001 0.89 0.05 0.371 0.308
Table 5.2: A ranked list of physiological measurements for use as dependent variables
in the modelling analysis. The top group are all measurements of specific biologi-
cal interest (labelled with an asterisk (*)), and are ranked by decreasing standard
deviation of the slope (to show di↵erence in how individuals are responding). The
second group were highlighted during analysis of the diary data, for ill individuals
showing responses that were di↵erent to other individuals within the group (labelled
with a dot (•), as described in Section 4.2.4.1. These measurements are also ranked
by decreasing standard deviation of the slope. The final group have high mean R2
values for the fitted regression lines, indicating a good fit to the model, and are
ranked by decreasing standard deviation of the slope.
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lites that would be able to predict a value or change in a particular physiological
measurement of interest. To ensure only the most suitable biochemical metabolites
were used as potential explanatory variables in modelling, all of the biochemical
metabolites were assessed for several characteristics. They had to show a significant
change between altitudes during the expedition, show di↵erences in how individuals
were responding and only be missing a small number of data points.
Several biochemical metabolites were highlighted as being of high biological
interest. These included members of the NO and ROS pathways, as described in
Sections 1.4.1.1 and 1.4.2. These particular biochemical metabolites are known
to play a role in hypoxia adaptation, and it was thought that these may play an
important role in the modelling process.
Data was available for a total of 59 biochemical metabolites, and 13 metabo-
lites were removed from modelling for several reasons. proANP, BNP and CNP are
known to influence cGMP levels, and were originally measured to determine whether
any change seen in cGMP levels was due to changes in these three metabolites (a
non-hypoxic response) or the action of nitric oxide on soluble guanylate cyclase (a
hypoxic response). These metabolites were only measured as a control for cGMP,
and were removed from the modelling process. Protein carbonyls are an important
measure of oxidative stress within the body. Protein carbonyls were measured with
a protein ELISA plate, which showed high variability between plates measuring
samples from the same altitude (a 75-80% decrease was seen between two plates).
Therefore, the data was considered spurious and removed from further analysis.
Nine biochemical metabolites were removed due to a lack of data points.
These metabolites included all four glutathione measurements, due to a lack of data
points at London levels (the vital measurement used for modelling and compara-
tive analysis). Other metabolites removed due to a lack of data points included
IL-1↵, IL-1 , IL-4, IL-10 and interferon- . Explanatory variables must also show
di↵erences between individual responses. This was analysed by performing a linear
regression between each of the biochemical metabolites against altitude, and look-
ing for di↵erences in individuals slope values. All biochemical metabolites showed
di↵erences in slopes, intercepts and gradients for fitted regression lines, indicating
di↵erences in how individuals were responding. This may also be caused by noise
within the dataset, and is an important point to take into consideration in the next
stage of analysis.
A final list of the 46 biochemical metabolites suitable for initial modelling
e↵orts is shown in Table 5.3, with metabolites of specific biological interest marked
with an asterisk (*).
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Metabolite Slope Mean Slope SD Intercept
Mean
Intercept
SD
R2 Mean R2 SD
*Nitrite 0.00002 0.00002 0.12 0.04 0.350 0.24
*Nitrate 0.00170 0.00392 21.57 10.83 0.261 0.21
*Total NOx 0.00172 0.00393 21.68 10.83 0.261 0.21
*RSNO 0.00053 0.00111 5.51 2.41 0.284 0.27
*RNNO 0.00003 0.00129 11.16 4.32 0.229 0.23
*Total RXNO 0.00056 0.00213 16.67 5.73 0.221 0.21
*cGMP 0.01782 0.01617 93.02 83.05 0.450 0.26
*8-isoPGF 0.00787 0.00851 40.14 20.86 0.303 0.28
*HNE 0.00190 0.00691 36.70 42.56 0.451 0.28
IL-1ra -0.00047 0.00392 39.53 17.40 0.198 0.22
IL-6 0.00004 0.00067 12.08 3.31 0.259 0.27
IL-8 0.00034 0.00036 4.11 1.24 0.243 0.21
IL-12(p70) 0.00031 0.00094 7.24 7.48 0.222 0.22
IL-13 0.00017 0.00018 1.46 0.65 0.327 0.24
IL-18 -0.00546 0.00767 116.20 56.31 0.405 0.33
MIF 0.53250 0.69174 5905.25 1545.77 0.472 0.31
Eotaxin 0.00063 0.00691 76.23 42.42 0.290 0.25
TNFalpha -0.00067 0.00167 33.01 9.54 0.304 0.28
VEGF 0.00869 0.01189 81.63 55.27 0.359 0.31
CRP 0.60843 1.21997 2964.17 4907.02 0.221 0.21
Adrenaline 0.00001 0.00001 0.06 0.03 0.187 0.20
Noradrenaline 0.00001 0.00004 0.14 0.05 0.249 0.32
T3 0.21402 0.75427 3318.68 1849.76 0.418 0.25
T4 2.84280 14.31760 92453.90 50772.00 0.357 0.27
C-Peptide 0.02274 0.07773 1708.52 355.25 0.221 0.25
GIP -0.00129 0.01541 127.21 64.79 0.248 0.23
Ghrelin -0.00196 0.00519 118.59 40.48 0.257 0.25
Glucagon 0.00609 0.01080 350.53 59.04 0.211 0.21
GLP-1 0.02609 0.04214 837.20 252.68 0.348 0.25
Insulin 0.03196 0.07273 1334.43 396.88 0.246 0.18
Leptin -0.11242 0.15481 1254.98 972.25 0.450 0.31
PAI-1 -0.78621 0.69800 8644.11 3286.20 0.530 0.29
Resistin -0.07318 0.08187 1018.25 442.48 0.417 0.32
Visfatin 0.07488 0.37754 4456.18 2351.47 0.269 0.23
Adiponectin 1535.64000 2071.05000 14453600.00 11682700.00 0.228 0.20
Adipsin 27.54690 17.51600 147056.00 61527.00 0.362 0.22
EPO 0.00274 0.00417 15.16 8.57 0.418 0.32
ET-1 -0.00047 0.00167 25.77 32.33 0.212 0.24
Glucose -0.00007 0.00018 4.70 0.84 0.224 0.25
Cystatin C 0.14954 0.11037 961.04 189.07 0.549 0.31
Creatinine 0.00001 0.00002 0.82 0.12 0.344 0.30
Lactate 0.00012 0.00015 1.37 0.42 0.355 0.31
Osmolality -0.00098 0.00187 293.03 5.23 0.248 0.18
ProteinContent -0.00042 0.00126 82.94 5.28 0.176 0.19
Bicarbonate -0.00123 0.00056 24.67 2.22 0.506 0.28
HSP-70 -0.00004 0.00105 3.79 8.06 0.254 0.24
Table 5.3: A list of biochemical metabolites for use as explanatory variables in the
modelling analysis. Parameters marked with an asterisk (⇤) are of specific biological
interest.
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5.5 Summary
• These analyses are based on a relatively small self-selected group of 24 individ-
uals. The results from these analyses can be verified at a later date when the
190 trekker plasma samples are measured, and will provide more information
on a population response;
• Not all of the physiological measurements and biochemical metabolites avail-
able were suitable for modelling purposes, and several statistical analyses were
combined with biological information to create two lists of variables suitable
for modelling (one for physiological measurements (dependent variables), and
one for biochemical metabolites (explanatory variables));
• Simple linear regression analysis against altitude allowed the assessment of
how physiological measurements and biochemical metabolites were changing
with increasing hypoxic exposure. This was used as a basis for the selection
of variables for modelling;
• Several physiological measurements were selected as potential indicators of
hypoxia adaptation. These measurements showed a change during the expe-
dition (assessed via an ANOVA) and showed variability between individual
responses (shown by variability in the slope for fitted regression lines against
altitude). Measurements of particular biological interest comprise of indicators
of hypoxaemia, oxygen consumption and oxygen e ciency, and are marked in
Table 5.2 with an asterisk (*);
• A list of 46 biochemical metabolites has been finalised for use as potential
explanatory variables in further modelling analysis. These metabolites show
a change during the expedition, and contain enough data to be potentially
useful for modelling. Biochemical metabolites of particular biological interest
were from the NO and ROS pathways, and are marked in Table 5.3 with an
asterisk (*).
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Chapter 6
Model Exploration
This chapter describes the initial modelling e↵orts undertaken to produce a number
of models, capable of predicting the response seen in one dependent variable (phys-
iological measurement) using a combination of one or more explanatory variables
(biochemical metabolites). This initial stage of modelling is exploratory in nature,
and several physiological measurements were used as potential dependent variables,
as identified in Chapter 5. The overall suitability of each physiological measurement
as a dependent variable was assessed by looking at the strength of the resulting pre-
dictions from the model formed, and the biological relevance of the variable (i.e. has
it been highlighted as a measurement of particular biological interest, as described
in Section 5.4.2).
6.1 Aims
The main aims of this stage of model building were to:
• Identify possible linear relationships between physiological measurements (de-
pendent variable) and a combination of biochemical metabolites (explanatory
variables);
• Identify physiological measurements that are predictable by a combination of
one or more biochemical metabolites.
6.2 Simple linear regression
Simple linear regression (SLR) looks at the linear relationship between one depen-
dent variable and one explanatory variable, as described in Section 2.5.9. This initial
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Figure 6.1: Nitrite correlated against oxygen consumption at VO2max, for each
altitude, separately. Each plot shows the two variables correlated for that altitude.
The r -values are the correlation coe cients between the two variables. Whilst none
of these correlations are strong, these figures show a change in the relationship
between these two metabolites during the expedition [Levett et al., 2011].
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method looks for simple linear relationships between two variables, and was used
to identify individual explanatory variables that may be useful for complex model
building. Each of the physiological measurements listed in Table 5.2 were regressed
against each of the biochemical metabolites listed in Table 5.3 (for all altitudes
together).
Some initial associations were identified during the writing of a paper pub-
lished in Scientific Reports in 2011, which looked at correlating NO metabolites
against oxygen consumption measures separately for each altitude [Levett et al.,
2011]. The paper identified several associations, for which the correlation coe -
cients were only significant at London (sea-level). It also identified relationships
that changed over the course of the expedition. One example is shown in Figure 6.1,
which shows correlations between oxygen consumption at VO2max and nitrite. This
figure shows an initial weak positive correlation value between the variables, that
becomes negative by Pheriche. This highlights a problem - simple models may as-
sume that the relationship between two variables remains the same throughout the
expedition, whereas the example shown in Figure 6.1 shows that this is not always
the case.
The aim of this initial analysis was to identify relationships that were con-
sistent over all altitudes. This would be the first step towards building a predictive
model, capable of looking at a variety of scenarios. In a clinical environment, it may
not be clear how hypoxic a patient is when they first arrive into the ICU (i.e. which
altitude they are equivalent to). Therefore, we want a general model that is able
to incorporate the hypoxic status of a patient and the change in the relationships
seen between variables during hypoxic exposure (such as those shown in Figure 6.1).
The fitted regression lines were assessed for their fit by assessing the scatter plot
between the dependent and independent variables, as well as the R2 value, goodness
of fit statistic, lack of fit statistic and F -statistic calculated for the fit, as described
in Section 2.5.9.
6.2.1 Results
The simple linear regression models produced showed poor R2 values, with a max-
imum R2 value of 0.35, indicating that none of the dependent variables could be
explained by one explanatory variable. Most of the regression models produced
showed very poor R2 values of less than 0.1. However, these results were expected,
due to the complex nature of the system studied. These results were used to iden-
tify potential explanatory variables that may be of use in a more complex modelling
method, to see if a combination of multiple biochemical metabolites could explain
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more of the variability associated with the physiological measurements of interest.
Figure 6.2 shows some of the typical results from the simple linear regres-
sion analysis performed for each physiological measurement. Figure 6.2a shows an
example of one of the strongest relationships seen, for the regression of oxygen con-
sumption at VO2max (normalised for body weight) against bicarbonate. This figure
shows an R2 value of 0.328, indicating that bicarbonate is explaining 32.8% of the
variability associated with oxygen consumption.
Figures 6.2b, 6.2c and 6.2d show the regression results for work rate at
VO2max against creatinine, work rate at LaT against adipsin and oxygen consump-
tion at LaT against IL-6. All of these figures show no clear relationship between the
dependent and independent variables, and were typical of the vast majority of the
results gained from the simple linear regression analyses.
6.3 Multiple linear regression
Multiple linear regression (MLR) was chosen as the next model building method
due to the number of potential explanatory variables available, shown in Table 5.3.
MLR looks at the inclusion of a combination of terms, as described in Section 2.5.11.
In some cases, additional explanatory variables were calculated as the product of
original explanatory variables. The inclusion of these combination terms allows the
assessment of interaction e↵ects within the statistical model, and may highlight
potentially interesting biological combinations to be assessed further. However,
including all possible combination terms is computationally expensive, and was only
possible when considering a relatively small subset of the biochemical metabolites as
explanatory variables, and not when using the full range of biochemical metabolites
available, shown in Table 5.3.
As there were a large number of potential explanatory variables available, an
automated selection algorithm was chosen to assess potential relationships between
each dependent variable and the multiple explanatory variables. Stepwise regression
was chosen to swiftly select the best model for the observed data, whilst minimising
the amount of time required to fit each model. In this case, the best model is the
one that best describes the observed data available, measured by the calculation
of an adjusted R2 value, as described in Section 2.5.12. The stepwisefit algorithm
was implemented in matlab to produce the best model for each of the physiological
measurements listed in Table 5.2, as described in Section 2.5.11. All of the models
fitted were formed using MLR, and as such no biological information was used to
determine the inclusion or exclusion of specific explanatory variables at this stage.
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Figure 6.2: Simple linear regression figures, regressing a physiological measurement
against a biochemical metabolite. (a) shows a very weak linear relationship between
oxygen consumption at VO2max (normalised for body weight) against bicarbonate.
The R2 value for this model is 0.32787, indicating that bicarbonate is explaining
32.8% of the variability associated with the dependent variable.
(b), (c) and (d) were more typical of the regression results, showing the results for
(b) work rate at VO2max against creatinine, (c) work rate at LaT against adipsin
and (d) oxygen consumption at LaT against IL-6. These figures show that the bio-
chemical metabolites have no relationship with their respective dependent variable.
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6.3.1 Assessment of model stability and fitting
All models produced were assessed to determine how well each model fitted the
observed data, and examine the relationships between the dependent variable and
each of the explanatory variables.
6.3.2 Uncertainty, variability and residuals
For a given model, all predicted values will exhibit some degree of uncertainty. This
uncertainty (or error) should be random, so that predicting higher or lower than the
actual response should carry the same probability (i.e. the error is symmetric). The
magnitude of error should also be independent of the time when the observation
occurred. The uncertainty represents any incomplete knowledge about a system,
and the level of uncertainty may be reduced with more or better data and a greater
understanding of the system. Error is distinct from variability, which is the range
in values of naturally occurring parameters. This variability is inherent to the data,
and cannot be reduced by increasing the amount of data, gaining better data or a
greater understanding of the system.
Residuals are defined as being the di↵erence between values fitted from a
model and the observed values. Residuals can be used as an estimate of the er-
ror associated with a model, and can be used to assess the appropriateness of each
parameter included in a model. Examination of the residual values allows the assess-
ment of whether the assumptions made during the modelling process are reasonable,
and whether the choice of each of the explanatory variables, or even the entire model
choice, is appropriate for the intended use. The overall pattern of residuals should
follow a normal distribution and be homoscedastic (i.e. show a homogeneity of vari-
ance). Any departure from these assumptions generally indicates that there is some
structure to the residuals, which is not accounted for within the model.
For each model, the residual values were plotted against each explanatory
variable, and against values fitted by the model, and assessed for heteroscedasticity.
95% confidence intervals (CI) for the residuals were added to each figure to aid in
the assessment of the residual values. They were calculated from the residual mean
square (ResMS, shown in equation 2.21) as follows:
95%CI =
p
ResMS(t  value), (6.1)
where the 5% t-value is the critical value of the t-distribution for the number of
degrees of freedom for that model, calculated as n - (the number of explanatory
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variables used in the model - 1).
6.3.3 Hypothesis testing
In order to determine the appropriateness of each fitted model, univariate correla-
tions were performed between (a) the residual values and the fitted values for the
model and (b) the residual values and each of the explanatory variables used in
the model, as described in Section 2.5.7. If a significant correlation exists between
the residuals and the fitted values, then this suggests that there is a structure to
the residuals, and that the model is not describing the variability associated with
the dependent variable. If a significant correlation exists between the residuals and
the explanatory variable, then this suggests that the particular explanatory variable
may not be suitable for use in the model, as it is not taking any of the variability
out of the model.
6.3.4 Model refinement
Initial MLR models were formed for each physiological measurement, for the com-
bined data over all altitudes. These initial models were then refined through the
following steps:
1. Apply multiple linear regression for the dependent variable for the combined
data against all altitudes, using a selection of biochemical metabolites as ex-
planatory variables;
2. Produce a summary for each dependent variable, including figures showing
observed vs. fitted values and the related adjusted R2 value, residual values
vs. fitted values and residual values vs. each explanatory variable used;
3. Use summary figures to assess the suitability of each of the explanatory vari-
ables in the model (assess for heteroscedasticity and outliers);
4. Remove any observations with high leverage, or the metabolite containing the
observation with high leverage from the analysis and refit the MLR to assess
the e↵ect of removing the values on the model formed;
5. Compare initial and refined models formed, and determine the best model for
each of the dependent variables. This may not always be the best fitting model,
but may be the most reliable model, or the model that predicts a dependent
variable of biological interest.
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6.4 Di↵erent sets of explanatory variables
Two di↵erent subsets of the explanatory variables listed in Table 5.3 were used in
multiple linear regression:
• NO metabolites only, including pairwise combination terms;
• All biochemical metabolites listed in Table 5.3, with no interactions/combinations.
The NO metabolites are labelled in Table 5.3 with an asterisk (*), and are
described in detail in Sections 1.4.1 and 1.4.2. These metabolites were considered
in a separate set of models because nitric oxide is known to play a role in hypoxia
adaptation, and it was thought that the NO and ROS-related metabolites may
interact and be good predictors of hypoxia adaptation and performance at altitude.
The second set of models were created using the complete range of biochemical
metabolites listed in Table 5.3.
6.4.1 Exploratory modelling - NO metabolites
All of the MLR analyses carried out using the NO metabolites alone resulted in poor
models with low adjusted R2 values ranging from 0.034 to 0.222, indicating that the
models produced were not explaining the variability associated with each of the ob-
served dependent variables. Figure 6.3 shows some of the best initial models formed
for oxygen consumption at LaT (normalised for body weight, Figure 6.3a), work rate
at VO2max (Figure 6.3b), economy (Figure 6.3c) and haemoglobin (Figure 6.3d).
Table 6.1 shows the best models produced for each of the dependent variables listed
in Table 5.2, using NO metabolites and their combinations as explanatory variables,
ranked in order of decreasing adjusted R2 value. The table shows that the best
model produced was for oxygen consumption at LaT (normalised for body weight),
with an adjusted R2 value of 0.222, indicating that it was explaining 22.2% of the
variability associated with oxygen consumption. The worst model produced was
for minute ventilation at LaT, which showed an adjusted R2 value of 0.034, and
only included one explanatory variable. The final models produced were similar
to the best models produced using simple linear regression, shown in Figure 6.2.
Ten of the models formed only use one explanatory variable (mostly for the lowest
ranked dependent variables in Table 6.1), making the results no more informative
than those gained from simple linear regression. Figure 6.3 shows some of the final
models produced, with fitted values plotted against observed values. All of these
figures show very poor predictability of the response.
137
D
ep
en
d
en
t
V
ar
ia
b
le
A
d
ju
st
ed
R
2
R
es
M
S
In
te
rc
ep
t
E
xp
la
n
at
or
y
V
ar
ia
b
le
C
oe
 
ci
en
t
p
-v
al
u
e
O
xy
ge
n
co
n
su
m
p
ti
on
at
L
aT
(n
or
m
al
is
ed
)
0.
22
2
14
.7
91
26
.4
8
N
it
ri
te
-1
1.
70
34
0
0.
01
43
6
8-
is
oP
G
F
2
↵
-0
.0
70
99
0.
00
00
3
R
S
N
O
x
cG
M
P
-0
.0
01
14
0.
01
45
8
R
N
N
O
x
8-
is
oP
G
F
2
↵
0.
00
46
0
0.
00
06
0
W
or
k
ra
te
at
L
aT
0.
21
9
75
3.
00
2
13
5.
74
R
N
N
O
1.
14
51
7
0.
04
96
4
N
it
ri
te
x
R
S
N
O
-1
0.
30
58
0
0.
00
03
2
cG
M
P
x
8-
is
oP
G
F
2
↵
-0
.0
00
92
0.
00
03
4
W
or
k
ra
te
at
V
O
2
m
ax
0.
20
5
22
62
.4
40
29
2.
87
R
S
N
O
x
8-
is
oP
G
F
2
↵
-0
.0
33
46
0.
00
09
1
T
ot
al
R
X
N
O
x
cG
M
P
-0
.0
05
76
0.
02
67
5
H
ae
m
og
lo
b
in
0.
20
0
2.
25
1
15
.2
0
R
N
N
O
-0
.1
00
87
0.
00
39
9
N
it
ri
te
x
R
S
N
O
0.
65
41
9
0.
00
00
3
R
N
N
O
x
H
N
E
0.
00
03
1
0.
03
54
8
O
xy
ge
n
sa
tu
ra
ti
on
s
at
re
st
(d
ia
ry
)
0.
16
0
40
.7
29
93
.9
3
R
S
N
O
x
H
N
E
-0
.0
02
03
0.
00
01
8
R
N
N
O
x
8-
is
oP
G
F
2
↵
0.
00
30
6
0.
04
13
8
cG
M
P
x
8-
is
oP
G
F
2
↵
-0
.0
00
30
0.
00
21
3
H
ea
rt
ra
te
at
V
O
2
m
ax
0.
14
0
29
9.
73
7
17
0.
78
N
it
ri
te
x
R
S
N
O
-6
.0
63
34
0.
00
00
4
R
es
ti
n
g
re
sp
ir
at
or
y
ra
te
0.
13
5
10
.2
54
15
.5
8
N
it
ri
te
7.
80
74
8
0.
04
93
8
H
N
E
0.
01
70
7
0.
00
01
9
cG
M
P
x
H
N
E
-0
.0
00
05
0.
00
28
3
E
co
n
om
y
0.
11
6
0.
83
1
10
.6
9
N
it
ri
te
x
R
S
N
O
-0
.1
80
29
0.
02
19
4
N
it
ri
te
x
cG
M
P
-0
.0
07
65
0.
01
44
5
R
es
ti
n
g
m
in
u
te
ve
nt
il
at
io
n
0.
11
0
14
.9
87
12
.8
3
N
it
ri
te
x
8-
is
oP
G
F
2
↵
0.
05
44
2
0.
03
41
9
N
it
ri
te
x
H
N
E
0.
04
01
1
0.
02
36
6
M
ax
im
u
m
vo
lu
nt
ar
y
ve
nt
il
at
io
n
0.
09
8
89
4.
28
2
16
9.
78
N
it
ri
te
x
H
N
E
0.
44
81
7
0.
00
06
2
R
es
ti
n
g
ox
yg
en
p
u
ls
e
0.
06
8
1.
52
9
5.
74
R
S
N
O
x
8-
is
oP
G
F
2
↵
-0
.0
00
68
0.
00
38
0
H
ea
rt
ra
te
at
L
aT
0.
06
6
21
1.
70
1
13
1.
08
N
it
ri
te
-4
9.
21
91
0
0.
00
43
7
R
es
p
ir
at
or
y
ra
te
at
V
O
2
m
ax
0.
05
0
98
.6
89
48
.1
3
R
S
N
O
x
8-
is
oP
G
F
2
↵
0.
00
46
8
0.
01
20
4
R
es
ti
n
g
ox
yg
en
co
n
su
m
p
ti
on
(n
or
m
al
is
ed
)
0.
04
4
0.
58
5
5.
20
N
it
ri
te
x
H
N
E
0.
00
78
6
0.
01
70
7
R
es
ti
n
g
h
ea
rt
ra
te
0.
04
3
17
4.
34
6
75
.1
8
R
S
N
O
x
8-
is
oP
G
F
2
↵
0.
00
58
3
0.
01
85
3
R
es
p
ir
at
or
y
ex
ch
an
ge
ra
ti
o
at
V
O
2
m
ax
0.
03
9
0.
00
7
1.
21
R
N
N
O
x
H
N
E
-0
.0
00
01
0.
02
35
9
R
es
p
ir
at
or
y
ex
ch
an
ge
ra
ti
o
at
L
aT
0.
03
7
0.
00
3
0.
88
H
N
E
-0
.0
00
13
0.
02
67
1
M
in
u
te
ve
nt
il
at
io
n
at
L
aT
0.
03
4
13
5.
22
6
45
.6
7
H
N
E
0.
02
94
2
0.
03
15
4
T
ab
le
6.
1:
A
n
or
d
er
ed
su
m
m
ar
y
of
M
L
R
re
su
lt
s
u
si
n
g
N
O
m
et
ab
ol
it
es
an
d
p
ai
rw
is
e
co
m
b
in
at
io
n
te
rm
s
as
ex
p
la
n
at
or
y
va
ri
ab
le
s.
A
dj
u
st
ed
R
2
is
th
e
ad
ju
st
ed
R
2
va
lu
e,
as
d
es
cr
ib
ed
in
S
ec
ti
on
2.
5.
12
.
R
es
M
S
is
th
e
re
si
d
u
al
m
ea
n
s
sq
u
ar
e
as
so
ci
at
ed
w
it
h
th
e
re
gr
es
si
on
,
as
d
es
cr
ib
ed
in
S
ec
ti
on
2.
5.
6.
C
oe
 
ci
en
t
is
th
e
co
e 
ci
en
t
sl
op
e
fo
r
th
e
ex
p
la
n
at
or
y
va
ri
ab
le
in
th
e
M
L
R
,
an
d
th
e
p-
va
lu
e
is
th
e
si
gn
ifi
ca
n
ce
le
ve
l
as
so
ci
at
ed
w
it
h
th
at
ex
p
la
n
at
or
y
va
ri
ab
le
fo
r
in
cl
u
si
on
in
th
e
m
od
el
.
D
ep
en
d
en
t
va
ri
ab
le
s
ar
e
ra
n
ke
d
in
or
d
er
of
d
ec
re
as
in
g
ad
ju
st
ed
R
2
va
lu
e.
138
As these models had low predictive power, higher orders of combined vari-
ables were not considered. This was because it was not considered meaningful to
introduce further combinations of variables purely to reduce residual values for the
fitted model without an understanding of the variable relationship or impact on the
physiological measurement being assessed. From a statistical perspective, it may
seem a good idea to incorporate higher order combinations of explanatory variables,
however, from a biological perspective it is very di cult to interpret what these
combinations of explanatory variables would actually mean.
6.4.1.1 Work rate at LaT
Table 6.1 shows that one of the most powerful models produced was for work rate at
LaT. This model is shown in detail as an example of why the NO metabolites were
not able to explain the variability associated with the dependent variables. Fig-
ures 6.4 and 6.5 show the summary figures produced for a MLR analysis for work
rate at LaT, using NO metabolites as potential explanatory variables. Figure 6.4a
shows the fitted values plotted against the observed values. The adjusted R2 value
generated is a measure of how much of the variability in the observed data is ex-
plained by the model. For this model, the adjusted R2 value is only 0.219, indicating
that the model is only describing 21.9% of the variability seen in the observed data.
The model also shows systematic error, underestimating high responses and overes-
timating low responses. This indicates that the subset of explanatory variables used
is not capturing the variability seen in the dependent variable, and that the overall
model is not describing the dependent variable.
Figure 6.4b shows the residual values plotted against the fitted values for
the model. This figure shows a clear heteroscedastic relationship, with variability
within the residual values increasing as the fitted values increase. This indicates that
there is variability in the model that is not being accounted for by the explanatory
variables being used. Figures 6.5a, 6.5b and 6.5c show the residual values plotted
against each of the explanatory variables used within the model. Each of these
figures also suggest heteroscedasticity within the residuals. These figures indicate
that the model is failing to describe the variability in the dependent variable, and
therefore may not be suitable for the observed data.
There is some evidence of redundancy within the NO metabolites, shown
by high r -values and significant p-values for correlations calculated between the
metabolites, shown in Table 6.2. This table shows very high correlations between
related metabolites, such as Nitrate and NOx (r -value = 1, p-value = 1.9x10 250) and
RNNO and RXNO (r -value=0.925, p-value=2.2x10 51), which is to be expected,
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as NOx is calculated as the sum of nitrate and nitrite levels, and RXNO is the
sum of RNNO and RSNO. As the NO metabolites are strongly linked with the
response to hypoxia, they may be showing too narrow a response, and may not
be able to explain the variability associated with non-hypoxic factors such as UV
exposure or the physical e↵ort associated with the expedition. Therefore, there may
not be enough variability in the NO metabolite values to explain the physiological
responses.
Alternatively, as NO is known to play a crucial role in several bodily func-
tions across several organs and tissues (as described in Section 1.4.1.1), then these
metabolites may be highly regulated independently of oxygen availability, to ensure
the proper performance across the whole physiological oxygen gradient. There is
also evidence that some of the NO metabolites do not show a significant change
over altitude during the expedition. For example, nitrate shows a very low slope
value for the fitted simple linear regression line against altitude, shown in Table 5.3,
and an acceptance of the null hypothesis for a two-way ANOVA performed for al-
titudes and individuals. Therefore, the NO metabolites may not be good enough
as explanatory variables on their own to explain the variability associated with the
dependent variables of interest.
6.4.2 Exploratory modelling - All biochemical metabolites
In order to try and explain as much of the variability in the dependent variables
as possible, the next stage of modelling looked at utilising all of the available bio-
chemical metabolites described in Table 5.3 as potential explanatory variables. Only
linear relationships were looked at here, due to the large initial number of explana-
tory variables available. The initial results from this analysis were more promising,
with higher adjusted R2 values between the fitted and observed values than those
seen using the NO metabolites alone. The results for the initial models produced
are shown in Table 6.3, and are ranked in order of decreasing adjusted R2 value.
A series of statistical tests was then performed on the eight models with
an adjusted R2 value above 0.4, shown in Table 6.3 as dependent variables above
the line. Only initial models that had an adjusted R2 above 0.4 were refined. 0.4
was chosen as an arbitrary cut-o↵ value for model refinement, as there was not
su cient time to refine all of the models. Any refinement may include the removal
of observations or explanatory variables from the model, leading to a decrease in
the adjusted R2 value. Therefore, only the strongest models were refined, to ensure
the final models were meaningful and explained as much of the observed variability
as possible.
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Figure 6.3: Examples of the best MLR models produced for various physiological
measurements, using the NO metabolites as explanatory variables.
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Figure 6.4: Summary figures produced for a MLR between work rate at LaT and
NO metabolites (metabolites playing a role in NO and ROS pathways). (a) shows
observed vs. fitted values and (b) shows the residual values for work rate at LaT
(observed y - fitted yˆ) plotted against the fitted values for work rate at LaT. (b)
shows a large amount of variability within the residual values when plotted against
fitted values, indicating that it is not explaining the variability associated with the
dependent variable. Therefore, this model is not appropriate for this dependent
variable. 142
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Figure 6.5: Residual figures plotted against explanatory variables used in a MLR for
work rate at LaT. All residuals show heteroscedasticity (higher variability associated
with lower values for the explanatory variable values), indicating they may not be
suitable explanatory variables for this model.
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Metabolite x Metabolite y r -value p-value
Nitrate Total NOx ***1.000 • 1.9E-250
RNNO Total RXNO ***0.925 • 2.2E-51
RSNO Total RXNO ***0.899 • 4.2E-44
RSNO RNNO **0.682 • 9.4E-18
Nitrite cGMP 0.349 • 9.2E-05
cGMP HNE 0.343 • 2.6E-04
Nitrite Total NOx 0.248 • 6.2E-03
Nitrite Nitrate 0.242 • 7.7E-03
Nitrite HNE 0.239 • 1.2E-02
cGMP 8-isoPGF2↵ 0.198 • 3.0E-02
Total NOx Total RXNO 0.191 • 3.7E-02
Nitrate Total RXNO 0.190 • 3.7E-02
Total NOx RSNO 0.170 6.3E-02
Nitrate RSNO 0.169 6.4E-02
Total NOx RNNO 0.161 8.0E-02
Nitrate RNNO 0.160 8.1E-02
Nitrite RSNO 0.160 8.1E-02
Total NOx cGMP 0.144 1.2E-01
Nitrate cGMP 0.142 1.2E-01
Nitrite Total RXNO 0.121 1.9E-01
RNNO HNE -0.109 2.6E-01
Nitrite 8-isoPGF2↵ 0.098 2.9E-01
Total RXNO HNE -0.090 3.5E-01
Total NOx HNE 0.088 3.6E-01
Nitrate HNE 0.087 3.7E-01
RNNO cGMP -0.085 3.6E-01
Nitrite RNNO 0.081 3.8E-01
8-isoPGF2↵ HNE -0.073 4.5E-01
RNNO 8-isoPGF2↵ -0.057 5.4E-01
Total RXNO cGMP -0.053 5.6E-01
Total RXNO 8-isoPGF2↵ -0.047 6.1E-01
RSNO 8-isoPGF2↵ -0.031 7.4E-01
RSNO HNE -0.029 7.6E-01
RSNO cGMP 0.015 8.7E-01
Total NOx 8-isoPGF2↵ 0.009 9.2E-01
Nitrate 8-isoPGF2↵ 0.007 9.4E-01
Table 6.2: Correlations calculated between the NO and ROS metabolites, ranked
in decreasing strength of the absolute value for the correlation coe cient (r -value).
The p-value is the probability of getting a correlation as large as the observed value
by random chance, when the true correlation is zero. Metabolites marked with a
dot (•) show a p-value less than 0.05, indicating that the correlation between x and
y was significant.
Medium strength correlations have a correlation coe cient between either -0.6 and -
0.79 or 0.69 and 0.79, and are marked with a double asterisk (**). Strong correlations
have a correlation coe cient between either -0.8 to -1.0 or 0.8 to 1.0, and are marked
with a triple asterisk (***).
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Several figures of the residuals were produced to check the quality of the fitted
models. These figures showed the residual values for the fitted response plotted
against each of the explanatory variables used within the model, and the residual
values plotted against the fitted values for the model. Ideally, we want to see an
even scatter of residual values around zero as either the explanatory variable or the
fitted values increase. Correlation values were computed for each of the plots, as
described in Section 2.5.7, and the null hypothesis (H0 = there is no correlation
between the observations of variables x and y) was accepted for all correlations
between residual and explanatory variables, and residual and fitted values. The
figures were also visually assessed for heteroscedasticity, to determine whether there
was any underlying structure to the residuals.
95% confidence intervals were added to the figures to assess how well the
model was predicting the dependent variable. If the model is estimating the depen-
dent variable well overall, then 95% of the total points should lie within the green
intervals. Observations that lay outside of the confidence intervals were poorly fit-
ted. Observations with high leverage that gave a residual value close to zero may
skew the model by influencing the resulting regression between that explanatory
variable and the dependent variable, as shown in Figure 6.6. Any observations that
were thought to have high leverage were highlighted for further assessment. These
observations were removed one-by-one to assess the impact of the observation on
the model. It is important to note that removal of any one observation would also
remove this specific observation from all other explanatory variables for that model.
Therefore, if that observation was also important for the strength of the regression
seen between the dependent variable and another explanatory variable, then it may
have an e↵ect here also.
For each of the dependent variables assessed, the initial model best described
the observed data available, indicated by the largest adjusted R2 value, which was
to be expected, as the initial models were all based on the full dataset available.
Once the model was refined and any observations with high leverage or explanatory
variables were removed, then the adjusted R2 value decreased, indicating that the
removal of the values led to less of the variability within the observed data being
described by the resulting model. However, the full model may be strongly influ-
enced by the observations with high leverage included. It is also important to note
that these models were fitted without any prior biological information being used
to determine whether or not a particular explanatory variable was included in the
model. The refinement of the model allowed the use of prior biological information,
to assess whether the outlying values made biological sense, and should be left in
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the model or omitted.
6.4.3 Results
Table 6.3 shows the initial models formed for each dependent variable by stepwise
MLR, using all biochemical metabolites as possible explanatory variables. The table
also shows that several of the biochemical metabolites used as explanatory variables
are included in multiple models. Figures 6.7, 6.8 and 6.9 show examples of the
models formed from MLR for di↵erent dependent variables, and show how well the
fitted values by the model match the observed data.
Figure 6.7 shows the results for the MLR performed for heart rate at VO2max.
Figure 6.7a shows the observed values plotted against the fitted values by the model,
colour-coded by altitude, and Figure 6.7b shows the residual values plotted against
the fitted values by the model. Figure 6.7a shows a reasonable fit of the observed
data to the fitted data, with an adjusted R2 value of 0.566, indicating that the model
is explaining 56.6% of the variability associated with the observed data. This figure
also shows an even scatter of points around the dashed line, indicating that it is
fitting values for all altitudes with similar levels of error.
The physiological measurement of heart rate after a 2-minute step-exercise
test (HREx) from the diary data (described in Chapter 4) is similar to the heart rate
at VO2max measurement in the core data. Both measurements show the heart rate
at di↵erent altitudes after exercise, although the amount of exercise at VO2max is
much higher. Therefore, the results from the analysis of HREx within the diary data
may be used to inform the use of heart rate at VO2max as a dependent variable, to
aid in understanding the model formed.
Heart rate after exercise was highlighted in the diary data as showing di↵er-
ences between ill individuals, and is marked with a dot (•) in Table 6.3. The diary
data showed that HREx was a reasonably stable measurement between days, with a
low CV value of 0.135 calculated from the simple linear regression performed for the
diary data measurement against altitude, shown in Table 4.2. HREx also showed
di↵erences in how individuals were responding, shown by di↵erences in the slopes
and intercepts for simple linear regression analyses performed against altitude for
each individual, identifying it as a potentially good dependent variable for mod-
elling. The adjusted R2 for the MLR performed for heart rate at VO2max may be
low due to the inter-individual variability being relatively high for this type of mea-
surement, shown in Figure 4.3a and Table 4.3. Some di↵erences in how individuals
are responding are required for modelling. However, the MLR is attempting to fit a
model to all individuals, therefore, the high inter-individual variability for this type
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Figure 6.6: An example of a linear regression performed, where x contains two
observations with high leverage, in red. Data points far from the mean x value are
potentially more informative than those near it. If there are only a few of these
points, then they can have a misleading e↵ect on the fitted line, as shown here.
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Figure 6.7: Observed vs. fitted values for a multiple linear regression model predict-
ing heart rate at VO2max, and residuals plotted against fitted values from the model.
(a) shows each altitude colour-coded, and shows relatively even scatter around the
line, indicating that the model is fitting high and low values with equal probability.
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Figure 6.8: Observed vs. fitted values for a multiple linear regression model pre-
dicting diastolic blood pressure at rest, and residuals plotted against fitted values
from the model.
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of measurement may make it more di cult to reliably predict a population response
using MLR.
Figure 6.8 shows the results for the MLR performed for diastolic blood pres-
sure (DBP). Figure 6.8a shows the observed values plotted against the fitted values
from the model, and Figure 6.8b shows the residual values plotted against the fitted
values from the model. Figure 6.8a shows no relationship between the fitted data
and observed data, with an adjusted R2 value of 0.097. Analysis of DBP in the diary
data (shown in Chapter 4) indicated that DBP seemed a good potential dependent
variable. DBP showed good day-to-day consistency, shown by a low CV calculated
from a simple linear regression of DBP against altitude. DBP also showed a signifi-
cant change against altitude and between individuals, tested by a two-way ANOVA
for altitude and individual. The reason for the poor prediction from the MLR is
unclear, but may be due to the lack of linear relationships being present with any
of the explanatory variables, as only two explanatory variables were included in the
MLR, but even these do not appear to be predictive.
6.4.3.1 Work rate at VO2max
Table 6.3 shows that similar biochemical metabolites were used in several of the MLR
models formed. These included biochemical metabolites that were highlighted as
containing observations with high leverage, that may be having a high impact on
the resulting relationships within the MLR. The model produced for work rate at
VO2max contained a high number of explanatory variables, including several that
were contained in other models and contained observations with high leverage (listed
in Table 6.4). Therefore, the model for work rate at VO2max is detailed here as an
example of the refinement process, and to determine whether any of the explanatory
variables highlighted may be highly influential on the MLR models formed.
Work rate at VO2max was identified as a variable of biological interest in
Section 5.4.2, as it is a measure of how well the body is using oxygen to do work
(i.e. oxygen utilisation vs. consumption). Work rate is known to decrease during
exposure to hypoxia, and how much it changes can be used as an indication of how
well an individual is adapting to the hypoxic conditions. An individual who shows a
low reduction is considered to have adapted to that change better than an individual
who has a larger reduction in work rate. This is because a low reduction in work
rate indicates that an individual is still able to perform a similar amount of work
with less oxygen available.
MLR was performed on work rate at VO2max using all of the biochemical
metabolites listed in Table 5.3 as potential explanatory variables. The initial MLR
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produced a model with an adjusted R2 value of 0.717 - the highest adjusted R2
value for any initial model formed, as shown in Table 6.3. This model was chosen
for refinement due to the high adjusted R2 value associated with the initial model
and the fact that the variable is of biological interest. This model also contained a
relatively large number of explanatory variables, and was assessed further to see if
a reduction in the number of explanatory variables used would yield similar results
to the initial modelling, or whether all of the explanatory variables were required
to produce a reasonable model with a high adjusted R2 value, indicating that it
is explaining a good proportion of the variability associated with the dependent
variable.
Figures 6.9 and 6.10a show the observed vs. fitted values for the MLR
performed between work rate at VO2max, using all biochemical metabolites listed
in Table 5.3 as potential explanatory variables. Figure 6.9 shows a colour-coded
version of Figure 6.10a, labelling each altitude in a di↵erent colour. The figures
show a high adjusted R2 value of 0.717, indicating that the model is describing
71.7% of the variability seen within the observed values for work rate at VO2max.
Figure 6.9 shows relatively even scatter around the dashed line (which shows where a
perfect 1:1 relationship would lie between the fitted and observed values), indicating
that the model is fitting high and low values equally well. The model also seems
to be fitting values for each altitude equally well, shown by even scatter for each
colour above and below the dashed line. Figure 6.10b shows the residual values
plotted against the fitted values from the model, and shows reasonable homogeneity
of variance (i.e. no underlying structure or pattern to the residual values from the
model). This indicates that the assumptions for the model are being met. The top
row of Table 6.5 shows the explanatory metabolites included in this model, as well
as their associated coe cients and significance levels for use in the model.
Figures 6.11 and 6.12 show the residual values for work rate at VO2max
plotted against each of the explanatory variables included in the model. The figures
shown in Figure 6.11 show explanatory variables that were deemed to be suitable
for use within the model without further assessment. They showed no discernible
patterns or heteroscedasticity. This indicates that these explanatory variables show
true relationships with the dependent variable, and are suitable for use within the
model.
There were some explanatory variables within Figure 6.11 that showed po-
tential outlying observations, however, they were not deemed to need further as-
sessment, as they were not considered to be observations with high leverage. The
outlying value seen for MIF (shown in Figure 6.11h) is also associated with a large
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Figure 6.9: Observed vs. fitted values for a multiple linear regression model pre-
dicting work rate at VO2max, and residuals plotted against fitted values from the
model. The figure is colour-coded by altitude, with London values in yellow, Kath-
mandu values in green, Namche values in cyan, Pheriche values in blue and Everest
Base Camp values in red. The figure shows relatively even scatter around the line,
indicating the model is fitting high and low responses equally well.
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Figure 6.10: Observed vs. fitted values for a multiple linear regression model pre-
dicting work rate at VO2max, and residuals plotted against fitted values from the
model.
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Figure 6.11: Figure 1 of 2 showing residuals for work rate at VO2max plotted
against each explanatory variable used in a multiple linear regression. None of these
residuals show any discernible pattern, or require further assessment.
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Figure 6.12: Figure 2 of 2 showing residuals for work rate at VO2max plotted against
each explanatory variable used in a multiple linear regression. None of these resid-
uals show any heteroscedasticity, however, some potentially outlying values were
cause for concern due to their correlation with low value residuals. This indicates
that these values may be having a biasing e↵ect on the regression between the de-
pendent variable and the explanatory variable in question. Therefore, all of these
values were assessed further to ascertain their impact on the model formed.
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Explanatory variable Individual Altitude
Adiponectin X24 Kathmandu
X24 Pheriche
X21 EBC week 1
X24 EBC week 1
IL-1ra X02 London
Resistin X02 London
VEGF X16 EBC week 1
8-isoPGF2↵ X21 Namche
X08 EBC week 1
Table 6.4: A summary of observations considered to have high leverage in MLR.
residual value, indicating that this point is not having a large e↵ect on the model,
and is badly predicted by the model overall. Low residual may also be balanced out
by other values. For example, Figure 6.11i shows low residual values for nitrite that
are both above and below the zero residual line in red, balancing each other out.
Figure 6.12 shows plots of explanatory variables that require further inves-
tigation. Although these figures all show a good homoscedastic spread of points,
there are individual points that require further assessment, as they have the poten-
tial to be observations with high leverage. These explanatory variables were also
used in several of the other models shown in Table 6.3, therefore, it is important to
determine whether these points are suitable for use in further modelling e↵orts.
All of the explanatory variables shown in Figure 6.12 have observations with
high leverage values associated with low residual values from the model, indicating
that they may be having a strong influence on the resulting regression between the
dependent variable and that particular explanatory variable. Each of these points is
listed in Table 6.4. Three of the high leverage adiponectin values are associated with
individual X24, indicating that this individual may have unusually high values for
this particular metabolite. The other observations with high leverage are distributed
well between individuals and over di↵erent altitudes, indicating that it is not one
individual or altitude that is associated with these potentially highly influential
observations.
6.4.3.2 Assessment of potential outliers
It is di cult to ascertain whether the outlying values measured are truly erroneous,
or a real response to the extreme conditions experienced during CXE 2007. The
current literature on these biochemical metabolites in human samples is very poor,
and mostly consists of clinical situations at sea level. The literature does not contain
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information about these metabolites measured at di↵erent altitudes, and many of the
metabolites are measured via a variety of di↵erent techniques, making comparisons
to our values very di cult.
To assess the impact of the potential outliers shown in Figure 6.12, the
observations with high leverage were removed one at a time, and the MLR was refit.
Four values were removed for adiponectin, two values were removed for 8-isoPGF2↵
and one value was removed for each of IL-1ra, resistin and VEGF, as detailed in
Table 6.4. MLR was run separately on each of the five new datasets formed (with
observations with high leverage omitted). The new models formed could not be
formally compared to one another or to the initial model, as they were all based on
sightly di↵erent data sets. However, the changes seen in adjusted R2 and residual
mean square values could still be assessed to see which model explained most of the
variability seen in the dependent variable. Di↵erences in the explanatory variables
included and their coe cient values could also be assessed to determine the e↵ects
of removing the potentially erroneous data points.
Table 6.5 shows information for the initial and refined models formed using
MLR on work rate for VO2max. This table shows the adjusted R2 and residual mean
square values for each of the models, as well as the intercept, explanatory variables
included in each model and their coe cients and significance levels for inclusion
in the model, as described in Section 2.5.11. The coe cient values provided for
explanatory variables not included in a particular model are the values they would
have had if they had been included. If these variables had been included, then it is
likely that the coe cient values for the other explanatory variables would change.
The initial model gave the highest adjusted R2 value for all of the models
shown in Table 6.5. This is to be expected, as it resulted from a MLR using all
of the data available for analysis. Therefore, the initial model explains more of
the variability seen within the observed data than any of the refined models, where
observations with high leverage have been removed. The initial model also has the
lowest value for the residual mean square compared to any of the refined models,
which is a measure of the di↵erence between the observed data and the model, with
a small residual mean square value indicating a good fit of the model to the data.
This indicates that the initial model is statistically the best model for the observed
data available. Observations with high leverage were removed to assess how much
of an impact they had on the regression, and their e↵ects are described below.
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6.4.3.3 Adiponectin
Adiponectin is a protein that is produced and secreted by adipocytes, and regulates
the metabolism of lipids and glucose [Nedv´ıdkova´ et al., 2005]. It is known to play
roles in the body’s response to insulin and the inflammatory response. Low levels of
adiponectin are associated with obesity and increased risks of heart attack [Ukkola
and Santaniemi, 2002; Kizer et al., 2008], although this is not currently fully under-
stood. Adiponectin is very abundant in human plasma compared to other hormones,
and shows sexual dimorphism, with females showing higher levels than males.
Adiponectin levels were measured via xMAP technology, as described in Sec-
tion 2.2.4. A diabetes panel assay was used to measure adiponectin levels, as well
as several other metabolites thought to play a role in type II diabetes, listed in
Table 2.2. The assay included information about cytokine levels that had been val-
idated in real patient samples. The samples validated by the assay manufacturer
(BioPlex) were taken from 10 healthy control patients and 10 patients su↵ering
from type II diabetes. However, the validated levels were measured in serum, which
has had clotting factors such as fibrin removed, and may result in slightly di↵erent
measurements when compared to the CXE plasma samples. It is important to note
that these validated samples were measured by BioPlex and were only measured in
a very small sample size. The BioPlex validated samples and CXE samples gave
results in the range of:
• BioPlex healthy validated samples: mainly ⇠8,000,000 to ⇠40,000,000 pg/mL,
with outliers up to ⇠100,000,000 pg/mL
• BioPlex type II diabetes validated samples: mainly⇠10,000,000 to⇠60,000,000
pg/mL, with outliers up to ⇠90,000,000 pg/mL;
• CXE samples: mainly ⇠5,000,000 to ⇠50,000,000 pg/mL, with outliers down
to ⇠30,000 and up to ⇠110,000,000 pg/mL.
This indicates that the values obtained from measurement of the CXE sam-
ples seem reasonable when compared to the BioPlex validated samples. The CXE
samples have a larger range than the BioPlex validated samples, however, the CXE
samples were taken from individuals exposed to an extreme environment. No in-
formation is given on the sex of the individuals for the BioPlex validated samples,
which would impact the range of results obtained. Finally, serum was measured
for the BioPlex validated samples compared to plasma for the CXE samples, which
may give cleaner results with a lower variability compared to plasma samples.
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The MLR analysis was run with the four observations with high leverage
removed, and the results for this analysis are shown in Table 6.5. This refined
model has a lower adjusted R2 value than the initial model of 0.697 compared to
0.717, indicating that it is describing 2% less of the variability seen in the observed
data than the initial model. The intercept value for the model decreases from -
273.27 to -317.30 compared to the initial model, and the ResMS increases from
827.34 for the initial model to 880.22 for the refined model. This indicates that
there is a larger discrepancy between the model and the observed data, compared
to the initial model.
Adiponectin is still included as an explanatory variable in the refined model,
although its coe cient value increases by 57.14% compared to the initial model
value. The refined model no longer includes nitrite or resistin as explanatory vari-
ables in the model, with their p-values dropping to 0.074 and 0.065, respectively.
Figure 6.13 shows individual responses for adiponectin, nitrite and resistin. Ta-
ble 6.4 shows that the observations with high leverage removed for adiponectin were
for individual X24 (Kathmandu, Pheriche and Everest Base Camp week 1) and X21
(Everest Base Camp week 1), and are also shown in Figure 6.13a. However, the
corresponding data points for nitrite (shown in Figure 6.13b) and resistin (shown in
Figure 6.13c) are not outlying points. Therefore, it is not clear why the removal of
these points leads to the removal of nitrite and resistin as explanatory variables.
Several explanatory variable coe cient values change in the refined model,
with the largest di↵erences seen in 8-isoPGF2↵, GIP and protein content, which
change by "28.04%, #61.54% and "47.5%, respectively. These results indicate that
the removal of the four outlying points has an e↵ect on the explanatory variables
included in the model, as well as their coe cient values. The refined model explained
less of the variability seen in the observed data, and is a slightly worse fit to the
data compared to the initial model.
Adiponectin levels are relatively straightforward and quick to measure in a
high-throughput manner along with other cytokines due to the multiplexing abilities
of the xMAP technology. Combined with the biological information suggesting that
similar values have been measured in human samples before, the four outlying values
should not be removed, as they are likely to be reliable values for adiponectin levels
in human plasma.
6.4.3.4 IL-1ra
Interleukin-1 (IL-1) is a pro-inflammatory cytokine, which binds to the IL-1 receptor
to promote inflammation and aid in the defence against infection [Arend et al., 1998].
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Figure 6.13: Subplots of all 24 individual responses during CXE 2007 for: (a)
adiponectin, (b) nitrite and (c) resistin.
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Interleukin 1 receptor antagonist (IL-1ra) binds to the interleukin-1 receptor in a
competitive manner with IL-1, acting as an anti-inflammatory cytokine. The levels
of IL-1ra were measured via xMAP technology, as described in Section 2.2.4
MLR was run with the highest outlying value for IL-1ra removed, and the
results are shown in Table 6.5. This refined model showed a lower adjusted R2
value and higher ResMS value compared to the initial model, of 0.683 and 933.97,
respectively. There are also several di↵erences in the explanatory variables included
in the model, as well as their coe cients. 8-isoPGF2↵, VEGF, GIP and resistin
are no longer included in the model, and IL-13 and C-Peptide are new explanatory
variables included in the refined model, but not in the initial model.
Table 6.4 shows that the observation with high leverage removed for IL-1ra
was for individual X02 at London, and is shown to be a potential outlier in Fig-
ure 6.14a. This datapoint is also shown to be a potentially outlying value for GIP
(shown in Figure 6.14b), resistin (shown in Figure 6.13c) and VEGF (shown in
Figure 6.16a). This indicates that this datapoint may also be an observation with
high leverage for the regressions between those explanatory variables and the de-
pendent variable, and the removal of the point results in those explanatory variables
being removed from the MLR, as the relationship with the dependent variable is
no longer strong enough. The datapoint is not an outlying value for 8-isoPGF2↵
(shown in Figure 6.15a), and it is unclear why the removal of this point would result
in 8-isoPGF2↵ no longer being included in the model.
6.4.3.5 Resistin
Resistin is secreted by immune and epithelial cells in humans. Resistin is thought
to be the link between obesity and type II diabetes [Steppan et al., 2001], however,
how resistin may link these two processes is currently unknown. Resistin levels were
measured via a BioPlex system as part of the diabetes panel, and as such provided
information on validated patient samples in a similar way to adiponectin. The
validated and CXE samples gave results in the range of:
• Healthy validated samples: ⇠2000 to ⇠7500 pg/mL;
• Type II diabetes validated samples: ⇠2000 to ⇠7500 pg/mL, with an outlier
at ⇠14000 pg/mL;
• CXE samples: ⇠250 to ⇠1500 pg/mL, with an outlier at ⇠3000 pg/mL.
The samples measured from CXE gave values that were much lower than
the validated samples. Therefore, the outlying value measured in the CXE samples
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Figure 6.14: Subplots of all 24 individual responses during CXE 2007 for: (a) IL-1ra
and (b) GIP.
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may be an extreme value for this dataset, but a reasonable measured value when
compared to the validated samples. Resistin levels are known to be higher in obese
individuals [Steppan et al., 2001]. High levels of fitness were required to take part
in CXE 2007, and this may account for the relatively low resistin values in CXE
participants compared to the validated samples.
MLR was run without the highest outlying value for resistin, which was
the same datapoint removed for IL-1ra, (individual X02 at London) as shown in
Table 6.4. As removing one value removes the corresponding point from all other
metabolites, the same refined model was produced for IL-1ra and resistin.
6.4.3.6 8-isoPGF2↵
Isoprostanes are a class of prostanoids that are formed by the attack of arachidonic
acid by free radicals during oxidative stress, and can be used as a marker of oxidative
stress, as described in Section 3.1. MLR was run with the two highest outlying
values for 8-isoPGF2↵ removed, and the results are shown in Table 6.5. This refined
model had the lowest adjusted R2 and the highest ResMS value for all of the models
formed, of 0.629 and 1087.69, respectively. This indicates that this refined model is
the worst fitting of any formed for this dependent variable, and that the two points
removed are important in the relationship between 8-isoPGF2↵ and work rate at
VO2max, as well as in other relationships within the MLR.
The explanatory variables included in the model were di↵erent to those in-
cluded in the initial model. IL-1ra, MIF, VEGF, resistin, osmolality and protein
content were no longer included in the model, and IL-13 was included as a new
explanatory variable. Table 6.4 and Figure 6.15a show the observations with high
leverage for 8-isoPGF2↵ were for individual X21 at Namche, and individual X08
at Everest Base Camp week 1. The first data point (for individual X21) shows a
low value for MIF (shown in Figure 6.16b), and a relatively high value for resistin
(shown in Figure 6.13c). The second data point (for individual X08) shows a high
value for C-peptide at Everest Base Camp week 1, shown in Figure 6.16c. These
points may also be observations with high leverage for these explanatory variables,
indicating why they are removed from the MLR if those two points are removed.
Neither of the observations with high leverage were outlying values for IL-1ra (shown
in Figure 6.14a), VEGF (shown in Figure 6.16a), osmolality (shown in Figure 6.15b)
or protein content (shown in Figure 6.15c), and the reason for the removal of these
explanatory variables from the MLR is less clear.
The coe cient values for explanatory variables were also di↵erent from the
initial model, with the largest di↵erences seen for nitrite ("52.96%) and 8-isoPGF2↵
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("74.77%). The intercept value changed from -273.27 for the initial model to 84.03
for the refined model, indicating that the removal of these two points is having a
large e↵ect on every aspect of the model formed, as is vital for several relationships
within the MLR.
6.4.3.7 VEGF
Vascular endothelial growth factor (VEGF) is a signalling protein that is produced
by cells to stimulate angiogenesis and vasculogenesis. This hormone is released to
increase the oxygen supply to tissues when the circulation of oxygen is not adequate,
as previously mentioned in Section 1.4.1.
MLR was run with the highest outlying value for VEGF removed, and the
results are shown in Table 6.5. The refined model has a lower adjusted R2 value
and a higher ResMS value compared to the initial model of 0.631 and 1076.70,
respectively. This model includes the same explanatory variables as the 8-isoPGF2↵
model, with similar coe cient values for the explanatory variables used. However,
the value removed was not the same as either value removed for 8-isoPGF2↵. The
intercept is also similar to that for the 8-isoPGF2↵ model, at 76.69. This indicates
that the removal of this datapoint is having a similar e↵ect on the MLR as the
removal of the 8-isoPGF2↵ points.
The observation with high leverage for VEGF is shown in Figure 6.16a and
Table 6.4 to be for individual X16 at Everest Base Camp week 1. This particular
datapoint is also shown to be an outlier for MIF (shown in Figure 6.16b), and may
explain why this explanatory variable is removed from the MLR if the datapoint
is removed. However, this datapoint does not seem to be an outlying value for
IL-1ra (shown in Figure 6.14a), C-Peptide (shown in Figure 6.16c), resistin (shown
in Figure 6.13c), osmolality (shown in Figure 6.15b) or protein content (shown
in Figure 6.15c), and the reason for the removal of these particular explanatory
variables from the MLR is less clear.
6.4.4 Summary
The models formed in this sectionshow that several of the explanatory variables
used within the models contain observations with high leverage, which may a↵ect
the relationships in the MLR. Removal of any of these points leads to a worse model
being formed, which explains less of the variability associated with the dependent
variable compared to the initial model formed. As previously stated, the literature
regarding the measurement of these biochemical metabolites in samples similar to
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Figure 6.15: Subplots of all 24 individual responses during CXE 2007 for: (a) 8-
isoPGF2↵, (b) osmolality and (c) protein content.
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Figure 6.16: Subplots of all 24 individual responses during CXE 2007 for: (a) VEGF,
(b) MIF and (c) C-Peptide.
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the CXE samples is very poor, with most measurements involving clinical patients
at sea-level. The range of techniques used to measure these di↵erent metabolites
also makes the comparison with other studies problematic. Therefore, for the pur-
poses of further modelling, it was assumed that the results obtained for each of
the explanatory variables are showing true responses to the extreme conditions the
individuals are exposed to. Measurement of the trekker samples will further verify
whether this assumption is reasonable or not.
6.5 Conclusions
• The NO metabolites alone are not enough to describe the variability seen
within any of the dependent variables. This may be due to there not being
enough variability within the NO metabolite values to explain the physiological
responses, or NO metabolite levels being kept highly regulated independently
of oxygen availability;
• Linear combinations selected from all of the biochemical metabolites can be
used to produce a model capable of predicting some of the physiological mea-
surements;
• Some of the physiological measurements of interest are poorly predictable,
even when all available biochemical metabolites are used as explanatory vari-
ables. This may be due to high inter-individual variability for some of the
physiological measurements. The reasons for the poor predictability for some
of the physiological measurements remain unclear;
• MLR on work rate at VO2max produces the model with the highest adjusted
R2 value, explaining 71.7% of the variability seen within the observed data.
This makes it a good potential dependent variable in the next stage of targeted
modelling;
• The initial models formed for each dependent variable describe the largest pro-
portion of the variability seen in the dependent variable, which is as expected;
• Any refinement of the initial models resulted in a lower adjusted R2, a higher
residual mean square value and di↵erent explanatory values and coe cients
being included in the model, which is as expected. Any removal of observations
lead to the removal of the corresponding observations in all other explanatory
variables for that model. Therefore, if that observation was also important
for the strength of the regression seen between the dependent variable and
168
M
o
d
e
l
N
it
ri
te
8
-i
so
P
G
F
IL
-1
ra
IL
-1
3
M
IF
V
E
G
F
C
-
P
e
p
ti
d
e
G
IP
R
e
si
st
in
A
d
ip
o
n
e
c
ti
n
G
lu
c
o
se
C
y
st
a
ti
n
C
C
re
a
ti
n
in
e
O
sm
o
la
li
ty
P
ro
te
in
C
o
n
te
n
t
B
ic
a
rb
o
n
a
te
In
it
ia
l
R¯
2
=
0
.7
1
7
C
o
e
f
-9
7
.8
1
-0
.1
0
7
0
.6
8
7
0
.1
2
-0
.0
0
3
0
.1
5
2
0
.0
0
7
3
0
.1
6
8
-0
.0
2
3
2
-0
.0
0
0
0
0
0
7
1
5
.6
4
-0
.0
4
2
3
1
1
7
.3
0
.9
1
8
1
.2
3
.5
0
6
In
te
rc
e
p
t=
-2
7
3
.2
7
p
-
v
a
lu
e
0
.0
1
6
9
0
.0
6
8
0
.0
0
0
7
0
.9
8
0
6
0
.0
1
0
.0
0
0
7
0
.4
5
1
0
.0
0
0
8
0
.0
1
6
0
.0
0
0
0
6
0
.0
0
0
0
0
2
0
.0
0
0
0
0
0
5
0
.0
0
0
0
2
0
.0
0
2
1
0
.0
0
8
6
0
.0
0
0
1
R
e
sM
S
=
8
2
7
.3
4
In m
o
d
e
l?
1
1
1
0
1
1
0
1
1
1
1
1
1
1
1
1
A
d
ip
o
n
e
c
ti
n
C
o
e
f
-7
3
.4
8
-0
.1
3
7
0
.5
8
4
-0
.7
7
-0
.0
0
2
9
0
.1
6
3
0
.0
0
3
0
.1
0
4
-0
.0
1
7
7
-0
.0
0
0
0
0
1
1
1
3
.3
3
-0
.0
3
9
3
1
0
1
.9
5
0
.9
4
2
1
.7
7
3
.1
4
7
R¯
2
=
0
.6
9
7
C
h
a
n
g
e
#3
3
.1
1
%
"2
8
.0
4
%
#1
7
.6
4
%
-1
1
6
%
#3
.4
5
%
"7
.2
4
%
#1
4
3
.3
3
%
#6
1
.5
4
%
#3
1
.0
7
%
"5
7
.1
4
%
#1
7
.3
3
%
#7
.6
3
%
#1
5
.0
6
%
"2
.6
1
%
"4
7
.5
0
%
#1
1
.4
1
%
In
te
rc
e
p
t=
-3
1
7
.3
0
p
-
v
a
lu
e
0
.0
7
4
4
0
.0
2
3
0
.0
0
3
2
0
.8
8
2
6
0
.0
1
6
0
.0
0
0
5
0
.7
3
6
0
.0
3
3
8
0
.0
6
5
0
.0
0
1
3
4
0
.0
0
0
0
6
5
0
.0
0
0
0
0
5
8
0
.0
0
0
2
0
.0
0
2
7
0
.0
0
0
1
0
.0
0
0
6
7
R
e
sM
S
=
8
8
0
.2
2
In m
o
d
e
l?
0
1
1
0
1
1
0
1
0
1
1
1
1
1
1
1
IL
-1
ra
C
o
e
f
-1
2
7
.4
4
-0
.1
0
6
0
.6
6
4
1
2
.2
-0
.0
0
3
5
0
.1
3
8
0
.0
2
4
5
0
.1
1
3
-0
.0
1
7
9
-0
.0
0
0
0
0
0
5
1
0
.3
4
-0
.0
4
2
1
1
0
1
.9
2
0
.6
6
5
1
.3
7
3
.8
9
9
R¯
2
=
0
.6
8
3
C
h
a
n
g
e
"3
0
.2
9
%
#0
.9
4
%
#3
.4
6
%
"1
0
0
6
7
%
"1
6
.6
7
%
#1
0
.1
4
%
"2
3
5
.6
2
%
#4
8
.6
7
%
#2
9
.6
1
%
#4
0
.0
0
%
#5
1
.2
6
%
#0
.4
8
%
#1
5
.0
9
%
#3
8
.0
5
%
"1
4
.1
7
%
"1
1
.2
1
%
In
te
rc
e
p
t=
-2
3
3
.9
1
p
-
v
a
lu
e
0
.0
0
4
8
0
.0
9
4
0
.0
0
6
5
0
.0
0
0
2
0
.0
0
4
0
.0
6
0
5
0
.0
0
2
0
.1
2
3
5
0
.1
5
0
1
0
.0
0
2
5
9
9
0
.0
0
1
7
9
9
0
.0
0
0
0
0
2
1
4
0
.0
0
0
3
1
0
.0
3
5
5
0
.0
0
4
4
0
.0
0
0
0
3
1
R
e
sM
S
=
9
3
3
.9
7
In m
o
d
e
l?
1
0
1
1
1
0
1
0
0
1
1
1
1
1
1
1
R
e
si
st
in
C
o
e
f
-1
2
7
.4
4
-0
.1
0
6
0
.6
6
4
1
2
.2
-0
.0
0
3
5
0
.1
3
8
0
.0
2
4
5
0
.1
1
3
-0
.0
1
7
9
-0
.0
0
0
0
0
0
5
1
0
.3
4
-0
.0
4
2
1
1
0
1
.9
2
0
.6
6
5
1
.3
7
3
.8
9
9
R¯
2
=
0
.6
8
3
C
h
a
n
g
e
"3
0
.2
9
%
#0
.9
4
%
#3
.4
6
%
"1
0
0
6
7
%
"1
6
.6
7
%
#1
0
.1
4
%
"2
3
5
.6
2
%
#4
8
.6
7
%
#2
9
.6
1
%
#4
0
.0
0
%
#5
1
.2
6
%
#0
.4
8
%
#1
5
.0
9
%
#3
8
.0
5
%
"1
4
.1
7
%
"1
1
.2
1
%
In
te
rc
e
p
t=
-2
3
3
.9
1
p
-
v
a
lu
e
0
.0
0
4
8
0
.0
9
4
0
.0
0
6
5
0
.0
0
0
2
0
.0
0
4
0
.0
6
0
5
0
.0
0
2
0
.1
2
3
5
0
.1
5
0
1
0
.0
0
2
5
9
9
0
.0
0
1
7
9
9
0
.0
0
0
0
0
2
1
4
0
.0
0
0
3
1
0
.0
3
5
5
0
.0
0
4
4
0
.0
0
0
0
3
1
R
e
sM
S
=
9
3
3
.9
7
In m
o
d
e
l?
1
0
1
1
1
0
1
0
0
1
1
1
1
1
1
1
V
E
G
F
C
o
e
f
-1
1
9
.5
7
-0
.1
3
2
0
.3
7
1
1
4
.1
2
-0
.0
0
1
6
0
.1
2
8
0
.0
1
0
6
0
.1
4
8
-0
.0
1
4
1
-0
.0
0
0
0
0
0
6
1
3
.2
-0
.0
4
8
6
1
1
7
.7
6
0
.6
6
5
0
.9
7
4
.1
5
2
R¯
2
=
0
.6
3
1
C
h
a
n
g
e
"2
2
.2
5
%
"2
3
.3
6
%
#8
5
.1
8
%
"1
1
6
6
7
%
#8
7
.5
0
%
#1
8
.7
5
%
"4
5
.2
1
%
#1
3
.5
1
%
#6
4
.5
4
%
#1
6
.6
7
%
#1
8
.4
8
%
"1
4
.8
9
%
"0
.3
9
%
#3
8
.0
5
%
#2
3
.7
1
%
"1
8
.4
3
%
In
te
rc
e
p
t=
7
6
.6
9
p
-
v
a
lu
e
0
.0
0
5
6
0
.0
4
5
0
.0
6
3
0
.0
0
0
1
0
.2
1
7
0
.0
9
7
7
0
.2
9
6
0
.0
0
5
3
0
.1
5
8
0
.0
0
2
5
6
0
.0
0
0
1
8
3
0
.0
0
0
0
0
0
4
0
.0
0
0
0
8
0
.0
5
0
1
0
.0
5
2
7
0
.0
0
0
0
2
R
e
sM
S
=
1
0
7
6
.7
0
In m
o
d
e
l?
1
1
0
1
0
0
0
1
0
1
1
1
1
0
0
1
8
-
is
o
P
G
F
2
↵
C
o
e
f
-1
4
9
.6
1
-0
.1
8
7
0
.3
4
7
1
2
.1
5
-0
.0
0
1
9
0
.1
0
4
0
.0
0
5
9
0
.1
5
4
-0
.0
1
3
8
-0
.0
0
0
0
0
0
6
1
2
.3
2
-0
.0
4
9
5
1
2
8
.5
3
0
.6
4
8
0
.9
3
4
.0
9
9
R¯
2
=
0
.6
2
9
C
h
a
n
g
e
"5
2
.9
6
%
"7
4
.7
7
%
#9
7
.9
8
%
"1
0
0
2
5
%
#5
7
.8
9
%
#4
6
.1
5
%
#2
3
.7
3
%
#9
.0
9
%
#6
8
.1
2
%
#1
6
.6
7
%
#2
6
.9
5
%
"1
7
.0
2
%
"9
.5
7
%
#4
1
.6
7
%
#2
9
.0
3
%
"1
6
.9
1
%
In
te
rc
e
p
t=
8
4
.0
3
p
-
v
a
lu
e
0
.0
0
0
9
0
.0
1
8
0
.0
9
0
2
0
.0
0
0
3
0
.1
5
1
0
.1
7
8
0
.5
9
2
0
.0
0
3
9
0
.1
7
7
0
.0
0
2
5
4
0
.0
0
0
5
0
3
0
.0
0
0
0
0
0
3
0
0
.0
6
2
1
0
.0
6
3
4
0
.0
0
0
0
3
R
e
sM
S
=
1
0
8
7
.6
9
In m
o
d
e
l?
1
1
0
1
0
0
0
1
0
1
1
1
1
0
0
1
T
ab
le
6.
5:
R
efi
n
em
en
t
re
su
lt
s
fo
r
a
M
L
R
m
od
el
fo
r
w
o
rk
ra
te
a
t
V
O
2
m
a
x
,
sh
ow
in
g
th
e
e↵
ec
ts
of
re
m
ov
in
g
in
d
iv
id
u
al
p
oi
nt
s
fr
om
th
e
ex
p
la
n
at
or
y
va
ri
ab
le
s
av
ai
la
b
le
.
T
h
e
R¯
2
va
lu
e
is
th
e
ad
ju
st
ed
R
2
va
lu
e
fo
r
th
at
p
ar
ti
cu
la
r
m
od
el
,
C
oe
f
is
th
e
co
e 
ci
en
t
va
lu
e
fo
r
a
p
ar
ti
cu
la
r
ex
p
la
n
at
or
y
va
ri
ab
le
(v
al
u
es
p
ro
vi
d
ed
fo
r
ex
p
la
n
at
or
y
va
ri
ab
le
s
n
ot
in
cl
u
d
ed
in
a
p
ar
ti
cu
la
r
m
od
el
ar
e
th
e
co
e 
ci
en
t
va
lu
es
th
ey
w
ou
ld
h
av
e
h
ad
if
th
ey
h
ad
b
ee
n
in
cl
u
d
ed
),
th
e
p
-v
al
u
e
is
u
se
d
to
d
et
er
m
in
e
w
h
ic
h
va
ri
ab
le
s
ar
e
in
cl
u
d
ed
in
th
e
m
od
el
,
an
d
In
m
od
el
?
sh
ow
s
th
e
ex
p
la
n
at
or
y
va
ri
ab
le
s
in
cl
u
d
ed
in
ea
ch
m
od
el
.
169
another explanatory variable, then it may have an e↵ect here also, reducing
the strength of the model further compared to the initial model;
• The removal of observations with high leverage was performed to assess the
extent of the changes that would occur with the removal of specific observations
with high leverage;
• The decision to remove a data point or explanatory variable depends on the
reliability of the values obtained for that variable. This is di cult to deter-
mine, due to a lack of information in current literature surrounding values
obtained from human plasma, especially during exposure to extreme environ-
ments. Therefore, the assumption that the dataset is reliable will be used for
the next stage of modelling.
6.6 Relevance to modelling approaches in critically ill
patients
The results from this analysis were used as a basis for the next stage of targeted
modelling, specifically aimed for application to a critical illness environment. The
next stage of modelling focusses on dependent variables highlighted in the initial
modelling stages as predictable with a combination of the biochemical metabolites
available. This stage will also look at predicting a change in a dependent variable, as
a predictor for how well an individual will adapt to hypoxic exposure. Explanatory
variables used in this stage of analysis are expected to be used as part of the MLR
in the next stage of modelling.
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Chapter 7
Model Development
This chapter describes the final stage of modelling, involving the targeted MLR of
the change seen in six specific physiological measurements. This chapter describes
the steps undertaken during the modelling process, comprising technique, refinement
and model selection.
7.1 Aims
The main aims of the final stage of modelling were to:
• Build on the exploratory modelling undertaken in the previous chapter, tar-
geting the use of MLR on the % change seen in specific dependent variables
(oxygen consumption and work rate);
• Identify which, if any, of the oxygen consumption or work rate measurements
can be predicted using absolute biochemical metabolite values at one low al-
titude;
• Identify which, if any, of the oxygen consumption or work rate measurements
can be predicted using a % change in biochemical metabolite values between
two low altitudes;
• Refine the four initial models produced for one dependent variable (one for
each altitude di↵erence) to produce a generalised model, capable of predicting
the % change seen in a dependent variable over all altitude di↵erences;
• Produce a list of biochemical metabolites present in several models formed, for
measurement in the trekker samples for model validation, and for the future
XE2 study;
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• Understand the uses and limitations of any models formed.
7.2 Targeted multiple linear regression
The final stage of modelling expanded on the approach used in the previous chap-
ter, focussing on predicting a change in a physiological measurement (dependent
variable), with a combination of biochemical metabolites (explanatory variables).
Ideally, an absolute value, or change between two low altitudes would be used for
the explanatory variables, in order to apply the models to a critical illness en-
vironment (the explanatory variables need to be easily measurable in critically ill
patients). This stage of modelling focussed on predicting a change in a physiological
measurement for two reasons; firstly, to see if a change would be more predictable
than an absolute value, and secondly, because a change would be a more biologically
relevant value to predict.
The dependent variables chosen for this stage of modelling were work rate and
oxygen consumption. These measurements were chosen as they were considered the
most biologically relevant out of all of the physiological measurements available, and
therefore the most informative to be able to predict. Work rate was also identified in
the previous chapter as a physiological measurement that was highly predictable by
the biochemical metabolites (explanatory variables) available. Exercise is severely
limited at high altitude, and this limitation has been well documented [McArdle
et al., 2007]. Oxygen consumption is a measure of an individual’s ability to transport
and utilise oxygen to do work, and reflects the aerobic fitness of that individual.
Work rate is a measure of the body’s ability to perform work, and is highly correlated
with oxygen consumption, as shown in Figure 7.1a. Both Oxygen consumption and
work rate are known to decrease with increasing altitude, although the underlying
mechanism of this is not well understood.
Individuals who adapt well to the decrease in oxygen availability will show
the smallest decrease in oxygen consumption and work rate at higher altitudes,
compared to London. Presumably, this is because they are able to adapt better to
the lower oxygen levels available, and still transport and utilise oxygen e ciently.
Therefore, the percentage loss in oxygen consumption and work rate were used in
this final stage of modelling as dependent variables, as they were considered good
indicators of acclimatisation to hypoxia. Oxygen consumption is usually normalised
for body weight, which does not correlate as highly with work rate, as shown in Fig-
ure 7.1b. Therefore, di↵erent variations of these two measurements were assessed
during modelling to determine which, if any, could be successfully predicted with
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(a) O2 consumption at VO2max vs work rate at VO2 max
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Figure 7.1: Two scatter plots, showing (a) oxygen consumption at VO2max vs.
work rate at VO2max, and (b) oxygen consumption at VO2max normalised for body
weight (/ kg) vs. work rate at VO2max. Both correlations are performed between
log-transformed values. (a) shows a higher correlation between work rate and oxygen
consumption, compared to (b) work rate and oxygen consumption normalised for
body weight over all altitudes.
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Variable type Altitude / Time-point Measurement type Hypoxic level
Physiological Kathmandu - London % Di↵erence Low
(Dependent variable) Namche - London % Di↵erence Medium
Pheriche - London % Di↵erence High
Everest Base Camp - London % Di↵erence Very high
Biochemical London Absolute values Normoxia
(Explanatory variable) Kathmandu Absolute values Low
Namche Absolute values Medium
Kathmandu - London % Di↵erence Low
Namche - London % Di↵erence Medium
Table 7.1: A list of di↵erent variations of dependent and explanatory variables used
in targeted multiple linear regression. MLR was run for each of the dependent
variable altitude di↵erences, using one of the variations of the explanatory variables
listed above. The four models produced for the dependent variable (one for each
altitude di↵erence) were then combined to create a generalised model, capable of
predicting the dependent variable over a range of di↵erent altitudes. Absolute values
at low altitude and di↵erences between low altitudes were used for the explanatory
variables to see which altitude was the most predictive, and to produce a series of
models that could be applied to di↵erent situations, depending on the information
available.
MLR. Using the percentage loss allowed a more generalised model to be formed,
which would be more applicable to the population as a whole. The di↵erent vari-
ations of work rate and oxygen consumption used in this final stage of modelling
were:
• Oxygen consumption at LaT;
• Oxygen consumption at LaT, normalised for body weight (/kg);
• Oxygen consumption at VO2max;
• Oxygen consumption at VO2max, normalised for body weight (/kg);
• Work rate at LaT;
• Work rate at VO2max.
7.2.1 Explanatory variables
The full range of biochemical metabolites shown in Table 5.3 were used as poten-
tial explanatory variables for this stage of modelling. However, several variations
of the biochemical metabolites were used, to try to establish the best relationship
between the dependent and explanatory variables. The explanatory variables used
174
in modelling needed to be measurable in critical ill patients, so that any final models
produced could be applied to predict how well a critically ill patient will adapt to hy-
poxic conditions. Therefore, only absolute measurements taken at low altitudes and
the percentage di↵erences between low altitudes were used for the explanatory vari-
ables for this stage of modelling. These included measurements taken at London
(normoxic levels), Kathmandu (moderate hypoxia), Namche (substantial but not
severe hypoxia) and percentage changes between these low hypoxia measurements.
To measure the changes in biochemical metabolites, one would apply a small hy-
poxic stress to a patient and take blood samples for measurement before and after
the stress was applied. This method would not threaten the patient’s health and
would enable the examiner to see how the individual responds to a small amount of
stress. The di↵erent variations of the explanatory variables used in modelling are
summarised in Table 7.1.
7.2.2 Producing a general model
MLR was run four times for each dependent variable listed in Section 7.2, once for
each altitude di↵erence shown in Table 7.1. These four initial MLR models were then
summarised for analysis, showing the adjusted R2 value for predicted vs. measured
values, the intercept, and the explanatory variables and coe cient values fitted in
each MLR model.
A generalised MLR model was then constructed by combining the four initial
MLR models for each dependent variable. The coe cient values for each of the
explanatory variables used in the MLR were assessed to determine whether they
were similar between the four MLR models, or whether they showed an altitude-
dependent change. All coe cients and the intercept value for each model were
regressed against di↵erent measurements of hypoxia, in order to create one model
that could predict a range of outcomes based on one set of input variables, and a
hypoxia-based measure.
This was achieved by expanding the normal MLR equation of y = ax1+bx2+c
(shown in equation 7.1), so that a, b and c are all dependent on some measure of
hypoxia exposure, shown in equations 7.2, 7.3 and 7.4, respectively. Therefore,
each explanatory variable was regressed against hypoxia exposure in turn, and the
resulting equation was substituted back into the original (shown in equation 7.5),
as follows:
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y = ax1 + bx2 + c; (7.1)
a = [a1(hypoxia) + a2]; (7.2)
b = [b1(hypoxia) + b2]; (7.3)
c = [c1(hypoxia) + c2]; (7.4)
y = [a1(hypoxia) + a2]x1 + [b1(hypoxia) + b2]x2 + [c1(hypoxia) + c2]. (7.5)
This was repeated using each of the five variations of the biochemical metabolites
shown in Table 7.1 as explanatory variables. In summary, for each dependent vari-
able:
1. Run multiple linear regression on each altitude di↵erence shown in Table 7.1
(four in total), using all biochemical metabolites in Table 5.3 as explanatory
variables;
2. Produce a summary of the four initial models produced, including explanatory
variables used, coe cient values and intercept value;
3. Run simple linear regression analysis for each explanatory variable, looking at
how the coe cient value changes over some measure of hypoxia exposure (e.g.
altitude);
4. Run simple linear regression analysis for the four intercept values, assessing
how the intercept value changes over some measure of hypoxia exposure;
5. Combine the four initial models into one generalised model, substituting the
explanatory variable coe cient value for the equation gained from the regres-
sion analysis;
6. Assess the fit for the generalised model by plotting measured values against
values predicted from the model, assessing residuals and calculating the good-
ness of fit statistic, lack of fit statistic and F -value for the fit.
7.2.3 Finding a suitable hypoxia measure
In order to construct a generalised model, each explanatory variable used in the four
initial models was assessed, to see how its coe cient value changed with increasing
altitude di↵erence. Simple linear regression analysis was performed between each
explanatory variable coe cient value and a measure of hypoxic exposure. The mea-
sure of hypoxic exposure would be used in the final generalised model, and needed
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Figure 7.2: Examples of linear regression analyses carried out between coe cients
for explanatory variables used in a MLR and three di↵erent measures of hypoxia
exposure. (a) and (b) show coe cient values regressed against a change in altitude,
(c) and (d) against cumulative oxygen debt and (e) and (f) against oxygen satura-
tion. The final three data points are most closely clustered together for altitude, and
most evenly spaced out for cumulative oxygen debt. Altitude gives the best linear
relationship, whereas cumulative oxygen debt gives the weakest linear relationship.
Oxygen saturation is the only measure easily taken in critically ill patients, and is
a good compromise between the other two measurements.
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to be measurable in critically ill patients. Altitude was initially used, and whilst this
measure showed a good linear relationship with most of the coe cients (as shown in
Figures 7.2a and 7.2b), it would not be a good surrogate for the hypoxic level of a
critically ill patient. An even spread of data points is important for linear regression
analysis, as uneven clustering of data points can have a biased impact on the regres-
sion formed, especially if the number of data points is small. The values for altitude
di↵erence showed an uneven spread of altitude points, with three values clustered
at higher altitudes. This would have had a high influence on the regression analysis
performed. This emphasises that the design of CXE was not ideal for performing
this type of modelling analysis, and was the main limitation to the analysis that
was carried out.
Oxygen debt looks at the cumulative exposure to an increasingly hypoxic
environment. A detailed expedition ascent profile was constructed, which took into
consideration how far the group ascended each day, any stop-overs they had, average
breathing rates at each altitude both at rest and during exercise, and relative oxy-
gen availability at di↵erent altitudes. This detailed ascent profile was then used to
calculate how much oxygen had been inhaled into the lungs during di↵erent stages
of the expedition. These values were then compared to the amount of oxygen an
individual would have inhaled if they had stayed in London (75m above sea level) for
the entire expedition. The di↵erence between these two values, denoted oxygen debt
could be used as a measure of hypoxic exposure. This measure had the most even
spread of data points for all hypoxic measures assessed, as shown in Figures 7.2c
and 7.2d. Whilst this is the most accurate measure of how much hypoxia an in-
dividual has been exposed to, it would be very di cult to measure in critically ill
patients, especially if they were already hypoxic before entering the ICU. If a patient
is hypoxic due to an inability to transport oxygen or use the oxygen once it reaches
the tissues, then this measure would not capture that information.
Oxygen saturation of the blood is well documented in hypoxia studies, and
is known to decrease on exposure to hypoxia, due to less oxygen being available.
Oxygen saturation is also very easy to measure in a critically ill patient in a non-
invasive manner, minimising disruption to the patient. However, if the patient is
hypoxic due to an inability to use the oxygen being delivered to the tissues, the
oxygen saturation could be high, but the individual could still be severely hypoxic
at the cellular level. This is an important limitation to this study, and has to be
taken into consideration when looking at the application of the models formed. The
resulting regressions would be a mirror image of the previous two hypoxic measures,
as oxygen saturation decreased during the expedition, whereas altitude and oxygen
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debt increased. The four data points are more evenly spread out than they were for
altitude di↵erence, however, they are not as evenly spaced as they were for oxygen
debt. Therefore, this measure is a compromise between the information we need to
perform the regression analysis, and what can be measured in a critically ill patient.
It may not be applicable in all cases, however, it is the best measure available from
this dataset.
As only four data points are available for the regression analysis, any kind
of fit is a best guess, and requires a lot of assumptions to be made (for example,
for a linear fit we assume that the response remains linear in-between the altitude
points available). We cannot say with certainty that a relationship is 100% linear or
otherwise with only four data points, even if the R2 value is very high - as we do not
know what is happening in-between these data points. If the R2 value is high, we
can only say that a linear relationship seems appropriate from the data available.
Fitting a higher order polynomial to only four points is not appropriate, as we do
not have enough information to fit such a curve. It is also not meaningful to remove
data points to improve the fit, as there are only four points to begin with, removing
any of them would reduce the certainty of the fit further still.
7.3 Results
MLR analysis was run for six di↵erent dependent variables, as listed at the end of
Section 7.2. Each MLR was run four times, once for each altitude di↵erence shown
in Table 7.1. This was also done for each variation of explanatory variables shown
in Table 7.1. Summary tables were produced, detailing statistics for the four initial
models produced for each dependent variable. Table 7.2 shows an example of the
generic summary of the MLR results for all dependent variables, in this example
using absolute values at London for the explanatory variables.
Models that had an adjusted R2 value of 0.4 or above were marked with an
asterisk (⇤). This was judged to be an appropriate threshold value for refinement,
as the models explained 40% or more of the variability of the dependent variable.
In order to produce a generalised model, each of the four initial models formed for
one dependent variable needed to have an adjusted R2 value above 0.4, in order to
give the best possibility for producing a good generalised model. These dependent
variables were marked with a plus (+) in the summary table, as shown in Table 7.2.
One model was refined for each variation of biochemical metabolites shown
in Table 7.1, to show the principle of producing a generalised model, and due to time
constraints. The models refined were chosen due to high adjusted R2 values for each
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of the four initial models, and the number of metabolites used within each model
(a low number was preferred, for easy measurement in critically ill patients). One
model was refined for each variation of biochemical metabolites in order to produce
a range of models that would be applicable to di↵erent situations, depending on the
information available. For example, a model based on absolute London values (i.e
normoxia) for the biochemical metabolites would be most appropriate for applying
to an individual who is not yet hypoxic. If the individual was already slightly
hypoxic, then a model based on absolute values at Kathmandu for the biochemical
metabolites (i.e. moderately hypoxic, equivalent to around 1300m altitude or 96%
oxygen saturation) would be more appropriate. If more than one dependent variable
produced four good initial models, then the dependent variable with the highest
overall adjusted R2 values was refined, to maximise the probability of forming a
good generalised model, however, this was not guaranteed. Further work could look
at refining the other initial models produced, to see if they produce a generalised
model with better predictability than those shown here.
7.3.1 Work rate at VO2max vs. absolute values at London
Table 7.2 shows the summary of the results for the MLR for all dependent variables,
using absolute London values of the biochemical metabolites as explanatory vari-
ables. Two dependent variables showed good adjusted R2 values for all four initial
models produced; oxygen consumption at VO2max and work rate at VO2max, and
are marked with a plus (+) in Table 7.2. Table 7.3 shows an expansion of the table
for work rate at VO2max, showing the explanatory variables included in each ini-
tial model. Both of these variables show adjusted R2 values above 0.4, and a good
number of explanatory variables used in the models. These two variables are known
to correlate highly with one another, as shown in Figure 7.1a. Therefore, only work
rate at VO2max was refined, as it showed higher overall adjusted R2 values and
lower ResMS values for the initial models formed compared to oxygen consumption
at VO2max. One potential next step in this analysis would be to construct a gen-
eralised model for the oxygen consumption model, and compare it to the work rate
model formed.
Table 7.3 shows the full summary for the four initial models formed for
work rate at VO2max, including explanatory variables used in each model and their
associated coe cient values. Each of these explanatory variables was regressed
against oxygen saturation, and the results are shown in Table 7.4. The table shows
that a majority of the explanatory variables show a reasonable linear relationship
with oxygen saturation. This is shown by mostly high R2 values between the linear
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Explanatory variable Slope Intercept R2 F -value df p-value
Intercept -1.76438 4.4388 0.647 3.67 3, 17 0.196
Nitrate -0.01310 0.2963 0.370 1.18 3, 17 0.392
RSNO -0.03084 0.3391 0.362 1.13 3, 17 0.399
cGMP 0.00261 -0.0331 ⇤0.160 ⇤0.38 3, 17 ⇤0.601
8-isoPGF -0.01584 0.0283 0.771 6.72 3, 17 0.122
IL-1ra 0.00380 -0.0248 0.494 1.96 3, 17 0.297
IL-8 -0.06459 0.7463 0.953 40.76 3, 17 •0.024
IL-18 -0.00112 0.0156 0.458 1.69 3, 17 0.324
VEGF -0.00119 0.0101 0.581 2.77 3, 17 0.238
Adrenaline -4.89147 -12.7149 0.733 5.50 3, 17 0.144
T3 0.00001 0.0003 ⇤0.143 ⇤0.33 3, 17 ⇤0.622
GLP-1 0.00030 0.0027 ⇤0.032 ⇤0.07 3, 17 ⇤0.820
Leptin 0.00007 -0.0009 0.686 4.36 3, 17 0.172
Visfatin -0.00001 -0.0001 ⇤0.013 ⇤0.03 3, 17 ⇤0.885
EPO 0.03769 -0.4822 0.789 7.48 3, 17 0.112
Creatinine 1.43553 -19.9378 0.894 16.93 3, 17 0.054
Table 7.4: Summary of the regression analysis performed between coe cients for ex-
planatory variables from a MLR and oxygen saturation. The MLR was performed
between work rate at VO2max (dependent variable) and absolute values for bio-
chemical metabolites at London (explanatory variables). The slope and intercept
are for the fitted regression lines for each separate regression analysis. The R2 value
was calculated for the regression line, as described in Section 2.5.9.4.
The F -value and p-value were calculated from the regression, as described in Sec-
tion 2.5.9. This value is calculated from a lack-of-fit sum of squares, and is not
very meaningful as it is based on only four data points. The only F -test that shows
a significant p-value is for IL-8 (marked with a dot (•)), which has an R2 value of
0.953, which is the highest for any metabolite assessed. The poorly fitting regression
lines for cGMP, T3, GLP-1 and visfatin are all marked with an asterisk (⇤). These
metabolites are associated with the highest p-values, confirming that these are the
poorest fitting regression lines to the data. A larger number of data points would
provide greater power to reject the null hypothesis for this test.
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Figure 7.3: Simple linear regression analysis performed for coe cient values against
oxygen saturation. All of these coe cients show a reasonable linear relationship
against oxygen saturation. As there are only four points available here, we are only
able to fit a linear line, which is obviously not suitable in some cases (for example
(b), (g), (h), (i), (j) and (k) look almost curved in their response). However, a linear
fit is used here as a best estimate for the data available.
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Figure 7.4: Linear regression analysis performed between coe cient values included
in MLR for work rate at VO2max and oxygen saturation. All of these coe cients
showed low R2 values for the resulting regression line and the original coe cient val-
ues. All plots show one altitude which does not follow a linear relationship, resulting
in the poor resulting R2 value. The remaining values for GLP-1 (a) and visfatin
(b) show only a small change with oxygen saturation, therefore, these coe cient
values were assessed to see if the use of a constant term was more appropriate than
a linear dependence on oxygen saturation for the MLR for these metabolites. As
cGMP (c) and T3 (d) show a change with altitude, the linear relationship against
oxygen saturation was used for these metabolites in the MLR.
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regression line and the coe cient values.
The F -statistic was calculated for each regression, as described in Section 2.5.3.
All of these linear regression analyses are based on four data points, and more data
points are needed to give the F -test the power to reject the null hypothesis. For this
dataset, only IL-8 passed the F -test with a R2 value of 0.953, a F -value of 40.76
and a p-value of 0.024 (marked with a •), showing that the model generated from
the regression analysis was a good fit to the data. However, the smallest F -values
and largest p-values were associated with the worst fitting regression lines, seen for
cGMP, T3, GLP-1 and visfatin, indicated by the lowest R2 values of 0.160, 0.143,
0.032 and 0.013, respectively. Therefore, the F -value and associated p-value give
an indication of how well each model fits the data, but there is not enough data to
definitively accept or reject the null hypothesis for the F -test.
Figures 7.3 and 7.4 show the figures produced from the simple linear re-
gression analyses of the explanatory variable coe cients for work rate at VO2max
against oxygen saturation. All figures show the actual coe cient values in magenta,
and the fitted regression line in blue. Figure 7.3 shows the regression figures where a
linear fit is a reasonable estimate for the relationship between the explanatory vari-
able coe cient and oxygen saturation. The R2 values for these regression figures
range from 0.362 to 0.953. The threshold R2 value is lower here than for previ-
ous analyses due to the smaller number of data points that the regression is based
on, and because the linear fits for nitrate (shown in Figure 7.3b with an R2 value
0.370) and RSNO (shown in Figure 7.3c with an R2 value of 0.362) both show an
increase with increasing oxygen saturation, and seem a reasonable estimate of the
relationship against oxygen saturation.
Figure 7.4 shows the weakest of the resulting regression fits. All four metabo-
lites shown in Figure 7.4 show one outlying datapoint compared to the other three.
However, it is not very meaningful to remove this one point, due to such few data
points being available. Figures 7.4a and 7.4b show an almost constant coe cient
value, apart from the one outlying datapoint. These metabolites were highlighted
for further refinement at a later stage. Figures 7.4c and 7.4d show an overall decrease
in coe cient value as oxygen saturation increases.
For the initial generalised model, the linear fits were substituted into the
MLR for all explanatory variables. The measured values were plotted against values
predicted from the model, and are shown in Figure 7.5. The adjusted R2 value for
this figure is 0.738, indicating that the generalised model is explaining 73.8% of
the variability seen in the measured data. The cyan data points show the results
for % di↵erence between Kathmandu - London, the blue for Namche - London,
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the magenta for Pheriche - London and the red for Everest Base Camp - London.
This model shows systematic error, overestimating loss at low altitude (Kathmandu,
shown in cyan) and underestimating loss at high altitude (Everest Base Camp, shown
in red).
The initial model for Kathmandu-London contained 10 explanatory variables
(as shown in Table 7.2), which have all changed slightly due to the regression against
oxygen saturation. The overestimation of the response at this altitude may be due
to the perturbation of these explanatory variables to accommodate the prediction
of other altitude di↵erences, which has led to a less accurate prediction at this par-
ticular altitude. The initial model for EBC - London only contains two explanatory
variables, and the extra explanatory variables included in the generalised model
from other initial models may not be appropriate for predicting the response at this
particular altitude. The closest predictions are for the middle altitudes of Namche
and Pheriche, shown in blue and magenta, respectively.
7.3.1.1 Further refinement
Overall, the biochemical coe cient values seemed to show a good linear relationship
with oxygen saturation. However, four explanatory variables showed very poor linear
relationships with oxygen saturation. These were GLP-1, visfatin, cGMP and T3,
shown in Figure 7.4. All of these plots show one datapoint that is very di↵erent
from the others, resulting in a poor linear fit. As the regression is only based on
four data points, the removal of one point would severely a↵ect the reliability of
the resulting regression performed. The plots for cGMP and T3 show a general
decrease with oxygen saturation, therefore, the linear relationship against oxygen
saturation was used for these metabolites in the MLR. However, GLP-1 and visfatin
could reasonably be assumed to be constant, when excluding the one outlying value.
Therefore, constant values were tested for both of these metabolites, to see if the
overall fit of the model could be improved.
Figure 7.6 shows observed values plotted against fitted values from six further
refined MLR models. These models looked at using a constant value for GLP-1 or
visfatin, or completely removing the metabolites from the MLR to assess the impact
on the final model. Figures 7.6a, 7.6b and 7.6c show refined models for GLP-1, and
Figures 7.6d, 7.6e and 7.6f show refined models for visfatin.
The adjusted R2 value was used to informally compare the di↵erent models.
The adjusted R2 value increased to 0.812 when a constant value was used for GLP-1
that was based on all four data points, shown in Figure 7.6a. This indicates that
using a constant value for GLP-1 helps to explain a further 7.4% of the variability
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Figure 7.5: Measured values vs. values fitted from a MLR model, fitting the % loss
in work rate at VO2max seen between London and 4 increasing altitudes. Cyan
shows results for Kathmandu - London (low hypoxia), blue shows Namche - London
(medium hypoxia), magenta shows Pheriche - London (high hypoxia) and red shows
Everest Base Camp - London (very high hypoxia). The adjusted R2 value for this
model is 0.738, indicating that it is explaining 73.8% of the variability associated
with work rate at VO2max. The figure shows that there is a higher % loss in work
rate at higher altitudes, which is to be expected. This model shows systematic error,
overestimating loss at low altitude (Kathmandu, shown in cyan) and underestimat-
ing loss at high altitude (Everest Base Camp, shown in red). This may be due to
the generalised model being less appropriate for fitting responses at those particular
altitude di↵erences.
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seen within the observed data. All other variants of the refined model resulted in
a decrease in the overall model’s adjusted R2 value. Therefore, the linear equation
was kept for visfatin and a constant value was used for GLP-1 in the final model.
The final refined model formed is shown in Figure 7.7, and has a adjusted R2
value of 0.812, indicating that it is explaining 81.2% of the variability seen in work
rate at VO2max. This final model still shows some systematic error, overestimating
the percentage di↵erence between Kathmandu and London, and underestimating
the percentage di↵erence between Everest Base Camp and London, as shown in
Figures 7.8a and 7.8d, respectively.
However, this appears to be less than is seen in the first refined model,
shown in Figure 7.5, indicating that the refined model describes the variability seen
at London and Everest Base Camp better than the initial model formed. Overall,
these metabolites seem to show good predictive power over work rate at VO2max.
7.4 Final models
The previous section detailed the refinement process for one model, created for work
rate at VO2max, using absolute values at London for the biochemical metabolites
(explanatory variables). This model was refined in detail, as it was considered the
most potentially useful in both a critical illness environment and for mountaineer-
ing. It would also be a good model to validate with the data for the 190 trekker
individuals, and the follow-up study XE2. The next section will present a selection
of finalised models that have already been through this refinement process, to show
some of the final results of the targeted multiple linear regression modelling process.
Multiple linear regression was used to form models for oxygen consumption
and work rate, using biochemical metabolites as explanatory variables. All of these
models were formed using the method outlined in Section 7.2.2. These models are all
based on di↵erent biochemical measurements, for example absolute values at London
or the percentage di↵erence between London and Kathmandu. Two di↵erent types
of model were formed, as summarised below:
• The London model, Kathmandu model and Namche model, produced using ab-
solute values of the biochemical metabolites at London, Kathmandu or Nam-
che as explanatory variables, to predict the percentage change in a dependent
variable for several hypoxic exposures/altitudes;
• The Kathmandu - London model and Namche - London model, produced us-
ing the percentage di↵erence of the biochemical metabolites between Kath-
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(a) Average GLP-1 (4 points)
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(b) Average GLP-1 (3 points)
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(c) GLP-1 removed
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(d) Average visfatin (4 points)
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(e) Average visfatin (3 points)
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(f) Visfatin removed
Figure 7.6: Model refinement results after MLR on percentage loss of work rate at
VO2max. Each figure shows measured values plotted against values fitted from the
model. The adjusted R2 value associated with each figure is a measure of how well
the model explains the variability seen in the observed data. The best model from
this analysis is shown in (a), where a constant coe cient term is used for GLP-1 in
the model instead of a term that changed over altitude, which is simply the average
of the four coe cient terms acquired at each of the di↵erent altitudes.
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Figure 7.7: Measured values vs. values fitted for a MLR model, fitting the % loss
in work rate at VO2max seen between London and 4 increasing altitudes. Cyan
shows results for Kathmandu - London (low hypoxia), blue shows Namche - London
(medium hypoxia), magenta shows Pheriche - London (high hypoxia) and red shows
Everest Base Camp - London (very high hypoxia). The adjusted R2 value for this
model is 0.812, indicating that it is explaining 81.2% of the variability associated
with work rate at VO2max. This model shows systematic error, overestimating loss
at low altitude (Kathmandu, shown in cyan) and underestimating loss at high alti-
tude (Everest Base Camp, shown in red). This may be due to the generalised model
being less appropriate for fitting responses at those particular altitude di↵erences.
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(a) Kathmandu - London
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(b) Namche - London
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(c) Pheriche - London
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(d) Everest Base Camp - London
Figure 7.8: Measured values vs. values fitted for a MLR model, fitting the % loss
from London for work rate at VO2max (% loss in work rate). All plots show a
general good fit, however, the fitted values show systematic error. (a) shows values
for Kathmandu - London are overestimated, and (d) shows values for Everest Base
Camp - London are generally underestimated, however, to a lesser extent than
(a). (b) and (c) show the best fits for Namche - London and Pheriche - London,
respectively. This means that the model is the most accurate at fitting the response
at a medium hypoxic exposure.
In terms of diagnosis, this model is more likely to overestimate how badly an in-
dividual will adapt to hypoxia at low hypoxic exposure (i.e. false positive, shown
in (a)), and underestimate how badly an individual will adapt at extreme hypoxic
exposures (i.e. more false negatives, shown in (d)), which could potentially be more
serious in a critical illness environment, or with a climber wanting to ascend to ex-
treme altitude. The use of a correction term could help to account for some of the
systematic error seen for (a) and (d).
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mandu and London or Namche and London as explanatory variables, to pre-
dict the percentage change in a dependent variable for several hypoxic expo-
sures/altitudes.
This provides a number of models that can be applied to di↵erent circum-
stances, depending on the information available. If the aim were to predict the
response of mountaineers during an ascent to high altitude, then the London model
would be most appropriate, as a blood sample could be taken at sea level, and used
to predict how that individual would adapt to di↵erent altitudes. For critically ill
patients, the model applied would depend on the condition of the patient. If a pa-
tient had newly arrived at the ICU and unlikely to be hypoxic, then the London
model would be the most appropriate. If the patient was slightly hypoxic, then
the Kathmandu model would be more appropriate. If the patient was in a stable
enough condition to be exposed to a small amount of stress, then the patient would
be exposed to a low amount of hypoxia via an oxygen mask, and blood samples
would be taken before and after the hypoxic exposure. These samples would then
be measured for a set of biochemical metabolites, which would be used in one of
the di↵erence models, such as the Kathmandu - London model. The final models
produced are detailed below.
7.4.1 London model
The London model was produced by performing MLR on work rate at VO2max,
using absolute values of the biochemical metabolites at London as explanatory vari-
ables. The final figure of observed vs. values fitted by the model is shown in
Figure 7.7. The final adjusted R2 value for this model was 0.812, indicating that
it is explaining 81.2% of the variability within the observed data. The model uses
a constant value for GLP-1, and a linear dependence on oxygen saturation for all
other explanatory variables. The equation for the London model is as follows:
Work rate at VO2max =
[ Nitrate * ( -0.013096 * O2Sat + 0.2963 ) ] +
[ RSNO * ( -0.030839 * O2Sat + 0.3391 ) ] +
[ cGMP * ( 0.002608 * O2Sat -0.0331 ) ] +
[ 8-isoPGF * ( -0.015838 * O2Sat + 0.0283 ) ] +
[ IL-1ra * ( 0.003798 * O2Sat -0.0248 ) ] +
[ IL-8 * ( -0.064588 * O2Sat + 0.7463 ) ] +
[ IL-18 * ( -0.001117 * O2Sat + 0.0156 ) ] +
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[ VEGF * ( -0.001185 * O2Sat + 0.0101 ) ] +
[ Adrenaline * ( -4.89147 * O2Sat -12.7149 ) ] +
[ T3 * ( 0.00001 * O2Sat + 0.0003 ) ] +
[ GLP-1 * -0.0054 ] +
[ Leptin * ( 0.000074 * O2Sat -0.0009 ) ] +
[ Visfatin * ( -0.000013 * O2Sat -0.0001 ) ] +
[ EPO * ( 0.037694 * O2Sat -0.4822 ) ] +
[ Creatinine * ( 1.43553 * O2Sat -19.9378 ) ] +
( -1.76438 * O2Sat + 4.4388 )
7.4.2 Kathmandu model
The Kathmandu model was produced by performing MLR on work rate at VO2max,
using absolute values of the biochemical metabolites at Kathmandu as explanatory
variables. The final figure of observed vs. values fitted by the model is shown in
Figure 7.9. The adjusted R2 value for this model was 0.857, indicating that it is
explaining 85.7% of the variability associated with the observed data. The model
shows a slight tendency to underestimate values, shown by a higher scatter in points
above the dashed line, which shows where a perfect 1:1 relationship between observed
and fitted data would lie. The model also shows the best predictions for Namche -
London and Pheriche - London, with lower scatter around the dashed line for these
measurements compared to Kathmandu - London and EBC - London.
This model would be a good target for further refinement, due to the high
predictability (shown by a high adjusted R2 value) and the small number of ex-
planatory variables used in the model. The model uses a constant value for GIP,
and a linear dependence on oxygen saturation for all other explanatory variables.
The equation for the Kathmandu model is as follows:
Work rate at VO2max =
[ cGMP * ( -0.000871621 * O2Sat + 0.0692098 ) ] +
[ TNFalpha * ( -0.00307143 * O2Sat + 0.373616 ) ] +
[ VEGF * ( 0.00119403 * O2Sat -0.113077 ) ] +
[ GIP * ( -0.0030042 ) ] +
[ Adipsin * ( -1.03E-06 * O2Sat + 0.000119648 ) ] +
[ Creatinine * ( -0.168058 * O2Sat + 7.24898 ) ] +
( 2.41639 * O2Sat -230.265 )
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7.4.3 Namche models
The attempts to produce a generalised model using absolute values of biochemical
metabolites at Namche as explanatory variables did not yield positive results. MLR
on individual altitudes produced some very strong modelling results, however, the
attempts to generalise these results over all altitudes did not produce a model with
strong predictive power, indicated by low and negative adjusted R2 values for fi-
nalised models. This suggests that the models produced were not suitable for the
dependent variable being predicted, over all altitudes. Therefore, two of the MLR
on individual altitudes are presented, as they provide the most predictive power
from the explanatory variables available. These include oxygen consumption at
VO2max normalised for body weight, predicting the percentage loss between Lon-
don and Everest Base Camp, and work rate at VO2max, predicting the percentage
loss between London and Namche.
These models would have fewer uses than the generalised models formed, as
they require individuals to be exposed to a high level of hypoxia to obtain values
for the explanatory variables, and are only capable of predicting the response at one
hypoxic level. However, they may still be useful for severely hypoxic patients who
were to undergo surgery or receive a treatment that would increase their hypoxic
state, to see if they will have any di culties coping with the higher level of hypoxia.
Figure 7.10a shows the observed vs. fitted values for a MLR performed on
oxygen consumption at VO2max, normalised for body weight. The adjusted R2
value for this model is very high at 0.998, indicating that the model is predicting
99.8% of the variability seen within the observed data. Figure 7.10b shows the
results for work rate at VO2max. The adjusted R2 value for this model is lower
at 0.691, indicating that it is explaining 69.1% of the variability of the observed
data. There seems to be an even scatter of points around the dashed line for both
models, indicating they are overestimating and underestimating values with the
same probability.
7.4.4 Kathmandu - London model
The Kathmandu - London model was produced by performing MLR on work rate at
VO2max, using the percentage di↵erences between London and Kathmandu (Kath-
mandu levels - London levels) for the biochemical metabolites as explanatory vari-
ables. The final figure of observed vs. fitted values for this model is shown in
Figure 7.11. The adjusted R2 value for this model was 0.902, indicating that it is
explaining 90.2% of the variability associated with the observed data. The model
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shows an even scatter of points above and below the dashed line, indicating that
the model is overestimating and underestimating values with the same probability,
and seems relatively equal for all altitude di↵erences. This model has the highest
adjusted R2 value of all models produced, indicating that it is the strongest out of
all the models produced and best fit for the observed data available.
This model would also be a good target for further refinement, due to the
high predictability and the relatively small number of explanatory variables used
in the model. The model uses a linear dependence on oxygen saturation for all ex-
planatory variables. The equation for the Kathmandu - London model is as follows:
Work rate at VO2max =
[ Nitrite * ( -0.00181257 * O2Sat + 0.154603 ) ] +
[ HNE * ( 0.000500961 * O2Sat -0.0860054 ) ] +
[ T3 * ( -0.00164845 * O2Sat + 0.142948 ) ] +
[ GIP * ( 0.00155984 * O2Sat -0.143077 ) ] +
[ Insulin * ( 0.00267985 * O2Sat -0.210178 ) ] +
[ Resistin * ( 0.00443372 * O2Sat -0.444642 ) ] +
[ EPO * ( -0.00259166 * O2Sat + 0.302993 ) ] +
[ Creatinine * ( -0.00549015 * O2Sat + 0.565245 ) ] +
( 2.01976 * O2Sat -195.07 )
7.4.5 Namche - London model
The Namche - London model was produced by performing MLR on work rate at
VO2max, using the percentage di↵erence between London and Namche for the bio-
chemical metabolites as explanatory variables. The final figure of observed vs. fitted
values for this model is shown in Figure 7.12. The model shows an adjusted R2 value
of 0.87472, indicating that it is explaining 87.472% of the variability associated with
the observed data. The data shows a relatively even spread of points above and
below the dashed line, indicating that the model is underestimating and overesti-
mating values with the same probability. The model shows the least scatter around
the line for the EBC - London predictions, shown in red. This indicates that the
model produced the strongest predictions for the response to high levels of hypoxia.
The model uses a constant term for resistin, and a linear dependence on oxygen sat-
uration for all other explanatory variables. The equation for the Namche - London
model is as follows:
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Work rate at VO2max =
[ 8-isoPGF * ( 0.00212489 * O2Sat -0.208226 ) ] +
[ IL-1ra * ( 0.00679786 * O2Sat -0.610947 ) ] +
[ IL-12(p70) * ( -0.00188627 * O2Sat + 0.199826 ) ] +
[ IL-13 * ( 0.000280559 * O2Sat + 0.0438252 ) ] +
[ VEGF * ( -0.00479035 * O2Sat + 0.411325 ) ] +
[ T3 * ( 2.93E-05 * O2Sat -0.0087744 ) ] +
[ GIP * ( 0.000328302 * O2Sat -0.0373064 ) ] +
[ Resistin * ( -0.024176051 ) ] +
[ Creatinine * ( 0.0105785 * O2Sat -0.942044 ) ] +
[ Protein Content * ( 0.00664081 * O2Sat -0.53097 ) ] +
( 1.64614 * O2Sat -161.588 )
7.5 Biochemical metabolites of interest
There were several biochemical metabolites that were used as explanatory variables
in more than one MLR analysis. Table 7.6 shows the biochemical metabolites used
as explanatory variables in all of the generalised models reported in this chapter.
The table ranks biochemical metabolites in order of how many times they were used
as an explanatory variable in MLR. This list indicates metabolites that need to be
measured in the 190 trekker plasma samples in order to validate the generalised
models reported in this project.
All of the generalised models formed are for work rate at VO2max, as this
was the strongest model formed for each of the di↵erent biochemical metabolite
variations used as explanatory variables shown in Table 7.1. This indicates that the
biochemical metabolites measured have the strongest relationship with the exercise
measurement work rate at VO2max, which is the amount of work the body can do at
VO2max, i.e. a measure of the body’s maximal work output. The use of this partic-
ular physiological measurement as a diagnostic tool for hypoxic adaptation is based
on the assumption that performance at altitude can be used as a proxy for hypoxia
adaptation. This assumption formed the basis for this model building, and would
need to be tested, for example during the XE2 follow-up study, to determine if this
assumption is reasonable, and how accurate and useful this particular measurement
is.
The biochemical metabolites included in the MLR include metabolites from a
range of di↵erent biochemical pathways, including oxidative stress, metabolism and
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Figure 7.9: Measured vs. fitted % loss of work rate at VO2max from London levels,
calculated using a MLR with biochemical metabolites at Kathmandu as explanatory
variables. The model shows a good adjusted R2value of 0.857, indicating that it is
explaining 85.7% of the variability associated with the observed data.
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Figure 7.10: Measured vs. fitted values for two MLR analyses, using absolute values
at Namche for the biochemical metabolites as explanatory variables. (a) shows the
results for a MLR for oxygen consumption at VO2max, normalised for body weight
(Everest Base Camp - London). This figure shows a very strong adjusted R2 value
of 0.998, indicating that it is explaining 99.8% of the variability seen in the observed
data. (b) shows the results for work rate at VO2max (Namche - London). This figure
shows a lower adjusted R2 value of 0.691, indicating that the model is explaining
69.1% of the variability associated with the observed data.
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Figure 7.11: Measured vs. fitted values for a MLR for work rate at VO2max from
London levels, using the % di↵erence in biochemical metabolites between Kath-
mandu and London as explanatory variables. This model shows a strong adjusted
R2 value of 0.902, indicating that the model is describing 90.2% of the variability
associated with the observed data. There is an even scatter of points either side of
the dashed line, indicating that the model is overestimating and underestimating
values with the same probability. This is the strongest out of all of the models
formed, indicated by the highest adjusted R2 value.
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Figure 7.12: Measured vs. fitted values for a MLR for work rate at VO2max from
London levels, using the % di↵erence in biochemical metabolites between Namche
and London as explanatory variables. This model shows a good adjusted R2 value
of 0.874, indicating that it is explaining 87.4% of the variability associated with
the observed data. The scatter of points around the dashed line is relatively even,
indicating that the model is overestimating and underestimating values with the
same probability. The model also seems to predict the largest percentage losses
seen with the most accuracy, shown by the red points very close to the line at
around -40% loss of work rate at VO2max.
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inflammation. In isolation, the direct relationship between each of these biochemical
metabolites and work rate at VO2max may be unclear and poor (for example the
simple linear regression analysis performed for work rate at VO2max over creatinine
(shown in Figure 6.2b) shows a very poor relationship between the two variables,
however, creatinine is one of the most highly-featured explanatory variables in the
targeted MLR), and it is only when these metabolites are combined that they show
predictive power over work rate at VO2max. The biochemical metabolites that are
used as explanatory variables in MLR on several occasions include VEGF, cGMP
and EPO, which are all known to play a role in hypoxia adaptation. VEGF induces
new vascular growth, to improve the blood supply in response to hypoxia, cGMP
increases blood flow by acting on blood vessels to induce vascular relaxation, and
EPO stimulates the production of new erythrocytes to improve the blood’s oxygen
carrying capacity.
Table 7.6 contains a total of 25 di↵erent biochemical metabolites required
for the generalised MLR models reported. These metabolites were measured by a
variety of di↵erent experimental techniques, including multiplexing assays, di↵er-
ent ELISA kits, HPLC and a tri-iodide-based chemiluminescence assay. Some of
these metabolites are relatively straightforward to measure, whereas others require
substantial upfront costs for the equipment required. 15 of the metabolites were
measured via di↵erent types of multiplexing assays. These are based on Luminex
xMAP technology, and require a multiplexing reading machine (such as the Bio-
Rad BioPlex 200) to analyse the samples. However, the actual assays are very quick
and straightforward to perform, and it is possible to measure multiple biochemical
metabolites in a single biological sample at the same time. The multiplexing sys-
tem is a high-throughput technique, making it potentially very useful in a hospital
environment after the upfront costs have been considered.
Several of the metabolites were measured via di↵erent ELISA kits, which
are easy to purchase directly from the supplier, and straightforward to carry out.
These assays require minimal upfront costs, if equipment such as a microplate reader
is already available, and all of the non-standard solutions for the assay itself are
provided with the kit. This makes these potentially the easiest out of the metabolites
to replicate in a lab environment or measure in a hospital environment.
The most di cult metabolites to measure were nitrite, nitrate and RSNO.
Nitrite and nitrate require a specialised HPLC machine, and nitrite and nitrate
levels have only been successfully quantified in plasma samples by a handful of labs
worldwide [Lauer et al., 2001; Yang et al., 2003]. RSNO was measured via a tri-
iodide-based chemiluminescence assay. This again requires specialised equipment,
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which may not be available in another lab or hospital environment, and would
require substantial upfront costs. These samples could be sent to a specialised lab
for measurement, however, the logistics of doing so, as well as a substantial wait
time makes these measurements more di cult to perform for critically ill patients.
7.5.1 Model comparison
Table 7.5 shows a comparison of the four general models produced in this chapter.
It summarises the biochemical measurements used as explanatory variables, the
adjusted R2 calculated between the observed data and values fitted from the model,
the number of explanatory variables used in each model and whether any of these
variables would be di cult to measure in another lab or hospital environment.
We want a model that will give good diagnostics, with an adjusted R2 value
close to one, a small number of explanatory variables and no metabolites that would
be di cult to measure. Nitrite, nitrate and RSNO were identified in the previous
section as di cult to measure in either another lab or a hospital environment. This is
because they require substantial upfront costs for specialised equipment to measure
these metabolites, as well as experience measuring them at low levels in human
plasma in a high-throughput manner.
Two of the models contained metabolites that would be di cult to measure,
and two did not. The two that did not were the Kathmandu model and the Namche
- London model. These two models had adjusted R2 values of 0.857 and 0.874,
respectively. They contained 6 and 10 explanatory variables, respectively. Without
any further analysis, these two models were considered better for application to
a critical illness environment, as they would be relatively easy to measure. The
Kathmandu model was considered the better of the two, because even though the
adjusted R2 value was slightly lower compared to the Namche - London model,
it only contained 6 explanatory variables, compared to 10 for the other model,
making it cheaper to measure the metabolites for this model. The Kathmandu model
also only contains two metabolites that were not measured via the high-throughput
multiplexing technique, whereas the Namche - London model contained three.
7.5.2 Further refinement
The London and Kathmandu - London models were refined, to assess the impact
of removing nitrite, nitrate and RSNO from the MLR on the final model formed.
Nitrite was removed from the final MLR between work rate at VO2max and the
percentage di↵erence in biochemical metabolites between London and Kathmandu.
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The resulting generalised model is shown in Figure 7.14. This model shows an
adjusted R2 value of 0.898, indicating that the model is describing 89.8% of the
variability associated with the observed data. Therefore, it is only describing 0.4%
less of the variability in the observed data than the original model including nitrite,
shown in Figure 7.11. It does not seem necessary to include nitrite in this model,
as it is relatively di cult to measure compared to other metabolites, and does not
significantly improve the overall e↵ectiveness of the model formed.
Nitrate and RSNO were removed as explanatory variables from the final MLR
between work rate at VO2max and absolute values of the biochemical metabolites.
The resulting generalised model loses all predictive power, as shown in Figure 7.13.
The figure shows no relationship between the observed and fitted values, indicating
that nitrate and RSNO were key explanatory variables within the model. Therefore,
it is not possible to use this model without these metabolites.
7.6 Conclusions
• Several models predicting oxygen consumption and work rate were formed,
which showed di↵erent predictive power over the di↵erent dependent variables.
For each set of biochemical metabolites (explanatory variables), one model
was refined to form a generalised model, capable of predicting a change in a
physiological measurement at several di↵erent hypoxic exposures;
• Work rate at VO2max shows the strongest relationship with the biochemical
metabolites measured, and was the most predictable physiological measure-
ment. The usefulness of this measurement as a diagnostic still needs to be
determined;
• It was not possible to form a generalised model using absolute values at Nam-
che for the biochemical metabolites as explanatory variables;
• Six di↵erent final models were formed, four generalised models, and two mod-
els that could predict the response at one hypoxic exposure. These models
varied in the strength of their predictions and used di↵erent combinations of
biochemical metabolites as explanatory variables;
• Each of these models could be used in either a critical illness environment
(to predict how well a patient will adapt if they become hypoxic), or for
predicting the adaptation of a mountaineer before ascending to high altitude.
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Figure 7.13: Measured vs. fitted values for a MLR for work rate at VO2max from
London levels, using biochemical metabolites at London as explanatory variables,
with nitrate and RSNO removed. This model now shows no predictive power over
the dependent variable, compared to Figure 7.7, where nitrate and RSNO were
included as explanatory variables.
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Figure 7.14: Measured vs. fitted values for a MLR for work rate at VO2max from
London levels, using the % di↵erence in biochemical metabolites between Kath-
mandu and London as explanatory variables, with nitrite removed. This model still
shows a strong adjusted R2 value of 0.898, indicating that the model is describing
89.8% of the variability associated with the observed data. Therefore, it is only
describing 0.4% less of the variability in the observed data, than the original model
including nitrite, shown in Figure 7.11. There is an even scatter of points either side
of the dashed line, indicating that the model is overestimating and underestimating
values with the same probability.
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The potential applications for these models are discussed further in the next
chapter;
• A list of biochemical metabolites used as explanatory variables in this stage of
modelling is shown in Table 7.6. Measurement of these metabolites in the 190
trekker plasma samples would allow the validation and training of the models
on a larger population size. These are potentially good metabolites to measure
in the XE2 study, for further validation of the models reported here.
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Explanatory variables
used
Model adjusted R2 Number of explana-
tory variables
Are any metabo-
lites di cult to
measure?
Absolute values at
London
0.812 15 Nitrate and RSNO
Absolute values at
Kathmandu
0.857 6 No
Kathmandu - London
% di↵erence
0.902 8 Nitrite
Namche - London %
di↵erence
0.874 10 No
Table 7.5: A comparison of four models formed, predicting work rate at VO2max
levels at various altitudes. Explanatory variables used shows the variation of the
biochemical metabolites used as explanatory variables in the MLR analysis. The
adjusted R2 value was calculated between the observed data and values fitted from
each model. Any metabolites that would be di cult to measure in another lab or
within a hospital environment have been highlighted. Ideally, the model will have
an adjusted R2 value close to one, a small number of explanatory variables and no
explanatory variables that are di cult to measure.
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Biochemical metabolite Number
of MLR
used in
How to measure Easy to
measure in a
hospital?
Creatinine 4 Bioassay Yes
VEGF 3 Bio-Plex multiplex assay Yes
T3 3 Millipore multiplex assay Yes
GIP 3 Bio-Plex diabetes panel Yes
cGMP 2 Immunoassay Yes
8-isoPGF 2 Immunoassay Yes
EPO 2 Immunoassay Yes
Resistin 2 Bio-plex diabetes panel Yes
IL-1ra 2 Bio-Plex Yes
⇤Nitrite 1 HPLC No
⇤Nitrate 1 HPLC No
⇤RSNO 1 Tri-iodide-based chemilu-
minescence assay
No
HNE 1 ELISA Yes
IL-8 1 Bio-Plex Yes
IL-12(p70) 1 Bio-Plex Yes
IL-13 1 Bio-Plex Yes
IL-18 1 Bio-Plex Yes
Adrenaline 1 ELISA Yes
GLP-1 1 Bio-Plex diabetes panel Yes
Leptin 1 Bio-Plex diabetes panel Yes
Visfatin 1 Bio-Plex diabetes panel Yes
TNF-↵ 1 Bio-Plex diabetes panel Yes
Adipsin 1 Bio-Plex diabetes panel Yes
Insulin 1 Bio-Plex diabetes panel Yes
Protein Content 1 Assay Yes
Table 7.6: Biochemical metabolites used as explanatory variables in multiple linear
regression analysis for work rate at VO2max. Most metabolites were measured in a
relatively straightforward manner with various assay kits. Measurement of many of
the cytokines require a multiplexing assay machine. The metabolites marked with
an asterisk (⇤) show metabolites that would be di cult to measure in another lab
environment or hospital, without substantial upfront costs for the equipment, and
specialised training.
209
Chapter 8
Discussion
This chapter brings together the key findings from the project, discusses how the
models could have been improved, any further work that can be done on these
results, and the applications of the final models developed. It also describes the
limitations to the study, and gives proposals for the follow-up study, XE2, in 2013.
8.1 Data analysis and model building
Several stages of data analysis and modelling have been carried out during this
thesis project, to gain an appreciation of the dataset and make the most out of the
modelling performed. Chapter 4 described the assessment of the diary data, which
contained a small number of simple physiological measurements, to determine their
day-to-day reliability, and identify measurements that may be useful for modelling.
The results from this chapter could be taken further, by the inclusion of the most
reliable measurements as additional explanatory variables within modelling e↵orts.
Chapter 5 described the assessment of the main core dataset, to identify
possible patterns and relationships within the di↵erent measurements available. This
analysis was used to identify the physiological measurements that were potentially
the most appropriate as dependent variables, and the biochemical metabolites that
were potentially the most appropriate as explanatory variables.
Chapter 6 described the initial stages of modelling, looking at the prediction
of several physiological measurements identified in Chapter 5 with a combination of
one or more biochemical metabolites, across all di↵erent altitudes available. These
methods identified physiological measurements that were predictable with the ex-
planatory variables available, and biochemical metabolites that were used as ex-
planatory variables in the MLR. Metabolites from the NO and ROS pathways (as
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detailed in Sections 1.4.1 and 1.4.2) were not as dominant in the modelling as an-
ticipated, however, there were several biochemical metabolites that were present in
multiple models formed.
Chapter 7 described the final targeted stage of modelling, looking at pre-
dicting the di↵erence in an explanatory variable at a certain altitude or hypoxic
exposure, compared to sea level. Six di↵erent models were formed using di↵erent
combinations of biochemical metabolites as explanatory variables, as described in
Section 7.1. Several biochemical metabolites were present as explanatory variables
in multiple models formed. This resulted in the formation of a list of biochemical
metabolites to measure in the trekker plasma samples, detailed in Table 7.6.
8.2 Applications of the fitted models
The models formed in Chapter 7 are capable of predicting the di↵erence in work
rate at VO2max in a range of altitudes or hypoxic exposures, compared to sea level.
Work rate at VO2max was used as the main dependent variable, as it was the most
predictable from the explanatory variables available. Di↵erences in work rate at a
certain altitude (level of hypoxia) compared to sea level (normoxia) were used as a
proxy for hypoxia adaptation, with individuals showing a small di↵erence compared
to sea level considered to be adapting better to the lack of oxygen available compared
to individuals who show a larger di↵erence.
The models produced could be used in di↵erent situations, depending on the
condition of the patient, and the information available. Two other models were
also produced, looking at predicting the percentage loss of oxygen consumption at
VO2max (normalised for body weight) between Everest Base Camp and London, and
the percentage loss of work rate at VO2max between Namche and London. These
models were more specific, and only allowed the prediction of oxygen consumption
or work rate at a high level of hypoxic stress.
There were three di↵erent types of model produced, as follows;
• The London model and Kathmandu model, produced using absolute values of
the biochemical metabolites at London or Kathmandu as explanatory vari-
ables, to predict the percentage change in work rate at VO2max for several
hypoxic exposures/altitudes, as described in Sections 7.4.1 and 7.4.2;
• Two Namche models, produced using absolute values of the biochemical metabo-
lites at Namche (3500m) as explanatory variables, to predict the percentage
change in oxygen consumption at VO2max (normalised for body weight) be-
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tween Everest Base Camp and London, and work rate at VO2max between
Namche and London, as described in Section 7.4.3;
• The Kathmandu - London model and Namche - London model, produced us-
ing the percentage di↵erence of the biochemical metabolites between Kath-
mandu and London or Namche and London as explanatory variables, to pre-
dict the percentage change in work rate at VO2max for several hypoxic expo-
sures/altitudes, as described in Sections 7.4.4 and 7.4.5.
Potential applications for each of these models are described below. The
choice of which model would be appropriate to use depends on the status of the
patient and the information available. Figure 8.1 shows a flowchart that could be
used for critically ill patients to decide which model would be most appropriate.
8.2.1 London model
The London model was refined in detail, as it was considered the most versatile of
the models produced. It uses absolute values for the biochemical metabolites at
London as explanatory variables, along with an oxygen saturation value to calculate
the percentage loss of work rate at VO2max at four di↵erent hypoxic levels. The
model has a good predictive power, with an adjusted R2 value of 0.812 - indicating
that the model is describing 81.2% of the variability associated with the observed
data. Figure 7.7 shows the observed values plotted against the values fitted for the
model.
This model could be used in a critical illness environment by taking a blood
sample immediately after a patient arrives in the ICU, and the results could be
used to predict whether the patient will have any problems adapting if they become
hypoxic. This model could also be used to predict how well mountaineers will adapt
to extreme hypoxic conditions during a climb, by taking a blood sample at a sea-
level testing centre. This model would be the easiest to validate during the XE2
trek, by taking blood samples during sea level testing, measuring the 15 required
metabolites (shown in Section 7.4.1), predicting the individual’s performance, and
then comparing this to the actual performance recorded at altitude. However, this
model contains the highest number of metabolites out of all of the models formed,
and also contains two metabolites that are potentially di cult to measure in a
critical illness environment - nitrate and RSNO, which require specialised equipment
and training to measure, as described in Section 7.5.2. Removal of these metabolites
from the London model removes all of the predictive power, and are therefore vital
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Figure 8.1: A flowchart providing guidance as to which of the predictive models
would be most suitable for a critically ill patient.
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for the model. This limits how useful this model will be, and would only be useful in
situations where it would be possible to measure plasma nitrate and RSNO levels.
8.2.2 Kathmandu model
This model uses absolute values for the biochemical metabolites at a moderate level
of hypoxic exposure (similar to an exposure to Kathmandu at 1300m, around 96%
blood oxygen saturation) as explanatory variables. This is combined with an oxygen
saturation value to predict the percentage loss of work rate at VO2max at four
di↵erent hypoxic levels. The model has a high predictive power, with an adjusted
R2 value of 0.857, indicating that it is explaining 85.7% of the variability associated
with the observed data. Figure 7.9 shows the observed values plotted against the
values fitted for the model.
This model would be suitable for critically ill patients who enter the ICU
already slightly hypoxic, and would allow the doctor to ascertain how well the
patient will adapt to further hypoxic exposure. This particular model would be
suited to use in a hospital environment, as all of the explanatory variables are easy
to measure in simple lab assays, as described in Section 7.5. This model contains six
explanatory variables, which is the smallest number for any of the models formed.
This model could also be used for mountaineers, where a blood sample could
be taken at an altitude similar to Kathmandu at 1300m, and be used to predict how
well the individual will cope with the ascent. This particular model would be a good
target for further refinement, to assess the importance of each of the explanatory
variables within the model.
8.2.3 Namche models
Two separate Namche models were produced, one capable of predicting the percent-
age loss for oxygen consumption at VO2max (normalised for body weight) between
Everest Base Camp and London, the other capable of predicting the percentage loss
of work rate at VO2max between Namche and London. Oxygen consumption was
identified alongside work rate as a good potential proxy for hypoxia adaptation, as
described in Section 7.2. Both of these models used absolute values of the biochem-
ical metabolites at Namche (3500m) as explanatory variables. A generalised model
was not produced for this particular explanatory variable combination, as it was
not possible to produce a model with enough predictive power from the explanatory
variables available, as described in Section 7.4.3. Therefore, these models do not
include the e↵ect of oxygen saturation (which is included in all of the other models
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produced), and are solely based on the absolute biochemical values at Namche as
explanatory variables.
The oxygen consumption model shows a very strong predictive power, with
an adjusted R2 value of 0.996, indicating that it is explaining 99.6% of the variability
associated with the dependent variable. Figure 7.10a shows the observed values
plotted against the values fitted for the model. The work rate model shows a lower
predictive power, with an adjusted R2 value of 0.691, indicating that it is explaining
69.1% of the variability associated with the dependent variable. Figure 7.10b shows
the observed values plotted against the values fitted for the model. These models
have a very limited use, as it is only possible to predict how well an individual will
adapt to a certain hypoxic exposure, which is quite high in both cases. However, the
high predictive power of the oxygen consumption model means that the model could
potentially be applied in the case of an individual who is already very hypoxic, to
see how they will respond if exposed to extreme hypoxia. For example, this model
could perhaps be applied before a hypoxic patient was to undergo surgery or receive
a treatment that would increase their hypoxic state, to see if they will have any
di culties coping with the higher level of hypoxia.
8.2.4 Kathmandu-London model
This model uses the percentage di↵erence in biochemical metabolites between Kath-
mandu and London to predict the percentage loss of work rate at VO2max over a
range of hypoxic exposure/altitudes. This model has very good predictive power,
with an adjusted R2 value of 0.902, indicting that the model is explaining 90.2% of
the variability associated with the observed data. Figure 7.11 shows the observed
values plotted against the values fitted for the model. This model includes 8 explana-
tory variables, including nitrite, which requires specialist equipment and training to
measure. The removal of nitrite from the model reduces the adjusted R2 value to
0.898, and may allow the wider use of this model, as described in Section 7.5.2.
This model has the highest adjusted R2 value out of any of the generalised models
produced.
This model would be suitable for critically ill patents who are stable enough
to be exposed to a small amount of hypoxic stress. When the patient first arrives at
the ICU a blood sample would be taken, and the individual would then be exposed to
a reduced amount of oxygen via an oxygen mask, equivalent to an altitude of 1300m.
After exposure, a new blood sample would be taken, and the percentage change in
7 biochemical metabolites would be used to predict how well that individual will
adapt to further hypoxic exposure. This particular model could also be used for
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mountaineering, with individuals having blood samples taken at sea level before
they travel, and then after they have arrived at a higher altitude of around 1300m.
The individual could also be exposed to an altitude of 1300m in a hypoxic chamber
(the same exposure they have during the flight to Kathmandu). The percentage
di↵erence between these two measures could then be used to predict how well that
individual would cope with ascent to high and extreme altitude. This model is
only useful if an individual is able to be exposed to a small amount of hypoxia,
which should not cause too much stress to the individual. There is also an ethical
consideration here, as it is not always possible or justifiable to expose all patients
to hypoxic stress, when they are already seriously ill.
8.2.5 Namche-London model
This model uses the percentage di↵erence in biochemical metabolites between Nam-
che and London as explanatory variables, in combination with an oxygen saturation
measure, to predict the percentage loss of work rate at VO2max over a range of hy-
poxic exposures. This model has good predictive power, with an adjusted R2 value
of 0.875, which indicates that it is explaining 87.5% of the variability associated
with the observed data. Figure 7.12 shows the observed values plotted against the
values fitted for the model. This model uses 10 explanatory variables, which are all
relatively easy to measure in a clinical environment. However, this model requires
the individual to be exposed to quite a high level of hypoxia, and requires a sea-level
measurement. This model may be most suitable for critically ill patients who had a
blood sample taken when they first arrived at the hospital, and are becoming quite
severely hypoxic (i.e. in a peri-operative setting). An additional blood sample could
then be taken, and the biochemical measurements compared to sea level to predict
how well that individual will respond to increased hypoxic exposure. This model
may also be of use as a hypoxic-stress test for climbers who may be more susceptible
to developing AMS symptoms in the field.
8.2.6 Combined test
If one or more of these models proves to be useful in a clinical environment, then it
may be possible to produce a combined assay, which would test all of the required
biochemical metabolites in a single blood sample (similar to the multiplexing ca-
pabilities of the Bio-Plex). A blood sample would be taken by a member of sta↵,
measured in the hospital lab, and the results transferred to a hand-held device, which
would take the information and calculate the predicted adaptability for the patient
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via one or more models. This information would be displayed in an easy-to-use
format on the device, to allow the swift transition from blood sample to prediction
for patients in a critical illness environment, where time is always a limiting factor.
8.2.7 Explanatory variables in multiple models
There were several biochemical metabolites that were used in multiple models. It
was expected that metabolites from the NO and ROS pathways would feature in the
models formed, due to the known links with hypoxia, as described in Section 1.4.1.1
and 1.4.2. However, metabolites that were used in multiple models included very
traditional measurements such as protein content, osmolality and creatinine. Mea-
sures such as protein content and osmolality were originally used in this project
as controls. Creatinine was used as a measure of kidney function, however, many
groups now favour Cystatin C over creatinine as it is more specific, but also more ex-
pensive to measure than creatinine. It is interesting that reasonably simple measures
would play such an important part in the analysis, however, the underlying reasons
are currently unknown. It may be that less specific metabolites show the integrated
response of multiple body functions compared to more specific metabolites.
8.2.8 Other applications
The models formed could also be used in the area of sports medicine, to predict
how well an individual will perform (during higher physiological stress or hypoxic
training) at a higher altitude. This would improve the safety of the train high,
sleep low method of training, where athletes train at high altitude to improve their
performance at sea level, whilst sleeping at a lower altitude to maintain their blood
oxygen saturation. These models could allow the assessment of how well individuals
will perform at di↵erent altitudes, to advise which altitude would be best for a
particular individual to train at, to get the most out of the training without becoming
too severely hypoxic.
8.3 Extension and modifications of the modelling ap-
proach
There are several ways in which the modelling undertaken during this project could
be expanded to improve on the initial models formed. These include:
1. Looking at producing a model using the di↵erence between Namche - Kath-
mandu for the explanatory variables, for patients who are already moderately
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hypoxic, and are stable enough to be exposed to a higher level of hypoxia;
2. Looking at further refinement of all of the models produced, to assess the
impact of removing each variable, with the aim of stream-lining each model;
3. Only the strongest models were refined for each set of explanatory variables,
due to time limitations and to increase the likelihood of meaningful results. It
is possible that the refinement of one of the other models produced for each
set of explanatory variables may have more predictive power than the models
reported here;
4. The possibility of log-transforming specific explanatory variables, to reduce
the impact of observations with high leverage, as described in Section 6.4.2;
5. The inclusion of simple physiological measurements as additional explanatory
variables may help to explain more of the variability associated with the de-
pendent variable of interest. These would include measurements that are easily
acquired and in most cases already available for critically ill patients, and are
known to be reliable due to the diary data analysis;
6. Targeted MLR on other physiological measurements of interest identified dur-
ing model exploration, such as physiological measurements identified in the
diary data analysis as showing di↵erences for ill individuals. These models
may be less powerful, but more biologically useful;
7. Assessment of non-linear responses, which would require additional altitude-
points;
These are all relatively straight-forward extensions to the analysis performed,
however, these were not possible to include as a part of this thesis due to time
constraints.
8.3.1 Validation and testing
The validity of any model formed is based on the reliability of the data it is con-
structed from. If the data is unreliable, then any model formed from this data will
also be unreliable. Assessing the impact of outlying values requires an understand-
ing of the biological metabolites being assessed. Ideally, the values obtained for the
CXE samples would be compared to other studies, to determine whether or not the
values were within the normal biological range, or were truly erroneous. However,
observed values for biochemical metabolites vary widely between studies, and can
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depend on the technique used to measure the samples. Additionally, the nature of
the CXE study is that the individuals were exposed to high levels of hypoxic and
environmental stresses. Therefore, what may seem an erroneous datapoint for nor-
mal sea level samples, may be within an expected response to exposure to extreme
hypoxia. Many of these measurements have never been acquired from individuals
exposed to such conditions before, making them unique, and therefore very di cult
to formally compare to values obtained from other studies.
Ideally, the model would be cross-validated using an independent data set,
however, a second data set was not available for this analysis. The original dataset
could have been split, with the model being based on one half of the data and verified
with the second half. However, due to the small sample size, it was decided to use
all of the data available in model building, in order to produce the most accurate
model possible. The next stage to this analysis will be to measure the biochemical
metabolites identified in Table 7.6 in the trekker plasma samples. This will allow
the validation of the models in a much larger sample size of 190 compared to the 24
that the models were originally based on. The model can also be validated in the
follow-up XE2 study.
8.4 Limitations
8.4.1 The design of CXE 2007
CXE 2007 was planned and conducted by the CXE team, without any plan to
measure the range of biochemical metabolites that have been assessed within this
project. The CXE team did not set up the collaboration with the Feelisch lab until
a year after the expedition had taken place, and so it was not possible for us to
have any input into the design of the study, including the timing and number of
samples taken, which is the main limitation to the modelling performed. Whilst
this is not ideal, it does not mean that the data acquired from the biochemical
analysis of plasma samples is not valid. Xtreme Alps 2010 was a follow-up expedition
designed and conducted in direct collaboration with the Feelisch lab. This expedition
incorporated intervention studies with control groups (such as supplementary nitrate
consumption), and allowed the acquisition of more directly applicable data. Similar
additions are being considered for the large direct follow-up study to CXE 2007,
denoted XE2, due to take place in 2013.
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8.4.2 Performance at altitude
This project is based on the assumption that performance at altitude in healthy in-
dividuals can be used as a proxy for hypoxia adaptation, and been used to generate
models capable of assessing the potential response to hypoxia in critically ill patients.
There may be other measures that are more suitable as a measure of hypoxia adap-
tation, however, this assumption forms the basis of the modelling for this project.
If this assumption does not hold, then the models will still be applicable to moun-
taineers, to predict how well they will perform physically at altitude. However, the
application to critically ill patients would be more limited. The models formed need
to be calibrated on data from critically ill patients, to test the assumptions made,
and assess whether the models can be adapted for a critical illness environment.
8.4.3 Self-selection
The core team members were a group of highly selected individuals. This means
that their fitness is well above the average for the general population, and they had
previous experience at altitude, which can aid in faster acclimatisation [McArdle
et al., 2007]. The trekker data contains information for 190 individuals, who have
had much less experience at altitude and may not be as physically fit as those
from the core group. However, this group is still self-selecting, as it only contains
individuals who had an interest in the expedition and who considered themselves fit
enough to participate. It is expected that the trekker group of individuals will show
responses that will be closer to critically ill individuals, however, there may still be
large di↵erences between the groups. It is important to understand this limitation
when assessing the results, and making comparisons to the normal population.
8.4.4 Translation of results
As the core individuals were a self-selected group, the training and validation of
the models for the trekker data will be vital in producing a model that is more
applicable to the population as a whole. These refined models should also be more
applicable to a critical illness environment than the original models formed, as they
are based on a less selected group of individuals. The models will then need to
be re-trained and re-validated once again to see how applicable they are to critical
illness environment. It may be the case that the models produced here are very good
at predicting the responses for healthy climbers, but are not applicable to critically
ill patients. However, if hypoxia is an overriding theme in critical illness, as it is
assumed to be by the CXE team, then the models produced should hold to a certain
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degree when applied to critically ill patients, but further work is needed to calibrate
the results of this study to a critical illness environment.
8.4.5 The role of other environmental factors
During the expedition, the team would have been exposed to multiple environmen-
tal stresses. The main stress of interest to this study is hypoxia, however, other
factors such as high UV exposure, low environmental temperatures and the physical
exertion required to ascend would all have a pronounced e↵ect on the biochemistry
and physiology of the participants as they ascended Mount Everest. Critically ill
patients are similarly exposed to multiple stresses such as hypoxia, inflammation
and infection, but the nature of these stresses is di↵erent. The aim of CXE 2007
was to study healthy volunteers exposed to extreme environments, to increase our
understanding of the complex response pathways that occur within critically ill pa-
tients. However, the overlapping of these response pathways also adds an extra layer
of complication to our understanding of the adaptation process.
The stresses that critically ill patients are exposed to are similar to those
experienced by the CXE participants, however, they would not be directly compa-
rable. In addition, critically ill patients vary in their stress exposure. We do not
know whether some of the changes seen in the participants are due to low oxygen
levels, high UV levels, strenuous exercise, or some other factor. It is important to
understand that this is both an asset and a limitation of this study. Additional stud-
ies involving the assessment of such factors in isolation would allow the modelling
to account for the factors that cannot be changed during the expedition. When
analysing any results it is important to be aware of this problem, and of the e↵ects
it may have on any inferences made from the data.
8.5 Suggestions for XE2
1. The main limitation to this modelling analysis has been the number of alti-
tude/hypoxic stress points. The models produced assessed the change between
London and Everest Base Camp week one, which meant that only four data
points were available for model building. More levels of hypoxic exposure
would allow more accurate modelling of changes that occurred during the ex-
pedition, improve the accuracy of the model and improve the application to
environments such as critical illness. It would also allow the analysis of non-
linear relationships within the dataset, which is not realistic to do using only
four levels of hypoxic exposure;
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2. The acquisition of whole blood samples would allow the analysis of additional
metabolites in white or red blood cells, which are not present in the plasma;
3. The inclusion of intervention studies, similar to those conducted during Xtreme
Alps, which looked at the role of supplementary nitrate during the expedition,
and allow the analysis of this particular metabolite in the adaptation to hy-
poxia during the expedition;
4. Oxygen intervention studies, would allow the assessment of the role supple-
mentary oxygen can play during an expedition such as CXE (i.e. does sup-
plementary oxygen during the ascent help, hinder or have no e↵ect on the
individuals?)
8.5.1 Controls
Scientific controls allow for the comparison of di↵erent hypotheses, and aid in vali-
dating any conclusions that are drawn from the results of an experiment. It is more
di cult to incorporate suitable controls into some experiments than others, due to
the logistics or cost of some experiments. It is important within scientific experi-
ments to control as many variables as possible, to allow the assessment of whether
one attribute is responsible for the changes seen during an experiment.
The inclusion of additional controls into a future expedition such as XE2
would increase the amount of information that could be gained from the experiments.
Additional controls might include:
1. Hypoxic chambers: Simulating an ascent to high altitude using an identical
ascent profile in a hypoxic chamber would allow the assessment of the hypoxic
response to a change in oxygen availability in the air, whilst minimising other
potential confounding factors such as UV, temperature and physical exertion
during a climb. The same individual could be assessed during the ascent and
then at a later date in the chamber (once the individual had su cient time to
lose acclimatisation), to allow the direct comparison of results obtained;
2. Additional oxygen: A subset of individuals ascending could ascend using
oxygen masks for the entire expedition, so that they are solely exposed to all
other stresses encountered during the ascent. A subset of these tank-carrying
individuals would also need to breathe ambient air without their knowledge,
to test for the e↵ects of utilising a mask system whilst ascending. However, it
would not be possible to send the same individual on the ascent twice, both
with and without an oxygen mask. Therefore, participants could be paired
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(one individual with a mask, and one without) based on their fitness and
previous experience, to allow the most direct comparison as possible.
Such additional controls would allow a more refined assessment of the bio-
chemical and physiological changes associated with the hypoxic response, and the
other stresses induced by the expedition itself. Such controls would only be possi-
ble with a small number of individuals, due to the high costs of running a hypoxic
chamber, and the logistical issues associated with using oxygen tanks during the as-
cent. Additional sherpas would also be required to carry the oxygen bottles during
the ascent, so that the individuals are not exercising much more than non-oxygen
wearing participants by carrying their own oxygen tanks during the ascent.
The extra information that would be gained from these additional controls
would have to be weighed against the additional costs and logistics that would be
required to incorporate them. These controls would undoubtedly give extremely
valuable data, however, whether they would be possible to do in large enough num-
bers to make comparisons statistically significant is also unclear.
8.6 Conclusions and outlook
Current tests in medicine use very specific measures, which can be expensive, and
may not necessarily be better in a model than a seemingly similar metabolite. My
modelling results support that the use of ‘simple’ metabolites, which integrate sev-
eral systems including skeletal, cardiac and pulmonary performance, may be prefer-
able for modelling compared to selective measures of specific organs. The cost and
ease in which a particular metabolite can be measured also play a role in determining
which metabolites are the most useful in modelling.
My results show that sometimes it is best to apply a simple method to a
dataset, to see what the data can tell us before using complex methodology which
requires a large number of assumptions. The results can sometimes be surprising! It
was initially thought that due to the complex nature of the responses seen by these
individuals during the expedition, it was unlikely that linear relationships would
be present, which seemed the case when looking at simple linear regression in Sec-
tion 6.2. However, the model fits from the MLR are surprisingly good, and show
some potentially valuable applications. The metabolites used within the models as
explanatory variables would not have been predicted by knowledge of the biochem-
ical pathways alone, and shows the power of correctly-applied statistical analysis of
biological data. These results can now be used to inform the analysis of the trekker
plasma samples, to allow the validation and re-training of the models formed on a
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larger sample size. Figure 8.2 shows the cyclic nature of the complete analysis of
this data, highlighting the strength of a systems biology approach to looking at this
type of dataset. This type of approach is perhaps reminiscent of the words of one
of the greatest British mountaineers of all time:
In 1923, George Mallory climbed Mount Everest. When asked ”Why climb Mount
Everest?” he replied ”Because it’s there.”
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Figure 8.2: The Systems Biology approach used during this thesis project - data
collection from CXE 2007, exploratory data analysis, model building, model analysis
and refinement, measurement of trekker samples based on information from the
modelling and refinement of the model based on the trekker data. This model would
then be used to inform XE2 and be calibrated for use for critically ill patients. It
was only possible to get to the stage of model refinement in this thesis project,
and the next steps would be to measure the trekker plasma samples, and use the
information to validate the models reported .
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Chapter 9
Appendices
9.1 2-way ANOVA results
ANOVA (Altitude) ANOVA (Individual)
Variable F -value p-value F -value p-value
Nitrite (mM) 22.07 • 8.6E-13 2.25 • 3.5E-03
Nitrate (mM) 1.18 3.2E-01 1.14 3.2E-01
Total NOx (mM) 1.21 3.1E-01 1.14 3.2E-01
RSNO (nM) 18.01 • 5.9E-11 2.04 • 9.1E-03
RNNO (nM) 11.85 • 8.3E-08 2.88 • 1.9E-04
Total RxNO (nM) 18.19 • 4.9E-11 2.90 • 1.7E-04
cGMP (pmol/mL) 9.21 • 2.7E-06 2.65 • 5.4E-04
8-isoPGF (ng/mL) 7.96 • 1.5E-05 1.49 9.6E-02
HNE (mg/mL) 4.76 • 1.7E-03 3.18 • 7.6E-05
GSH (micromolar) 15.40 • 9.1E-08 1.09 3.8E-01
GSSG (micromolar) 6.89 • 4.2E-04 0.94 5.5E-01
Total Glutathione (micromo-
lar)
3.01 • 3.6E-02 0.62 9.0E-01
GSH to GSSG ratio 8.83 • 5.4E-05 1.37 1.6E-01
IL-1beta (pg/mL) 1.03 4.0E-01 9.92 • 5.3E-11
IL-1ra (pg/mL) 3.70 • 7.7E-03 1.86 • 2.1E-02
IL-6 (pg/mL) 0.30 8.7E-01 6.73 • 1.4E-11
IL-8 (pg/mL) 3.12 • 1.9E-02 1.01 4.6E-01
IL-10 (pg/mL) 1.18 3.5E-01 1.01 5.0E-01
IL-12(p70) (pg/mL) 8.38 • 8.3E-06 12.85 • 9.5E-20
Continued on next page
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9.1 – continued from previous page
ANOVA (Altitude) ANOVA (Individual)
Variable F -value p-value F -value p-value
IL-13 (pg/mL) 9.47 • 1.9E-06 4.38 • 1.9E-07
IL-18 (pg/mL) 8.82 • 4.5E-06 18.34 • 4.7E-25
MIF (pg/mL) 11.05 • 2.3E-07 3.37 • 1.8E-05
Eotaxin (pg/mL) 4.39 • 2.7E-03 11.44 • 4.0E-18
TNFalpha (pg/mL) 3.50 • 1.1E-02 8.38 • 4.1E-14
VEGF (pg/mL) 9.86 • 1.1E-06 6.07 • 1.7E-10
CRP (ng/mL) 2.90 • 2.6E-02 1.23 2.4E-01
Adrenaline (ng/mL) 24.69 • 6.7E-14 0.89 6.1E-01
Noradrenaline (ng/mL) 5.57 • 4.6E-04 1.61 5.9E-02
T3 (pg/mL) 5.05 • 1.0E-03 11.66 • 2.1E-18
T4 (pg/mL) 1.68 1.6E-01 7.89 • 2.1E-13
C-Peptide (pg/mL) 4.46 • 2.4E-03 2.61 • 6.4E-04
GIP (pg/mL) 1.42 2.3E-01 1.95 • 1.4E-02
Ghrelin (pg/mL) 1.65 1.7E-01 15.47 • 1.9E-22
Glucagon (pg/mL) 10.70 • 3.7E-07 7.27 • 1.9E-12
GLP-1 (pg/mL) 5.59 • 4.5E-04 8.64 • 1.7E-14
Insulin (pg/mL) 8.21 • 1.0E-05 8.30 • 5.3E-14
Leptin (pg/mL) 8.82 • 4.5E-06 9.89 • 3.4E-16
PAI-1 (pg/mL) 13.83 • 7.5E-09 1.95 • 1.4E-02
Resistin (pg/mL) 9.25 • 2.5E-06 4.39 • 1.8E-07
Visfatin (pg/mL) 0.50 7.4E-01 9.98 • 2.6E-16
Adiponectin (pg/mL) 6.75 • 8.3E-05 13.94 • 6.4E-21
Adipsin (pg/mL) 28.31 • 2.5E-15 3.89 • 1.7E-06
EPO (mlU/mL) 6.26 • 1.7E-04 3.63 • 5.6E-06
ET-1 (pg/mL) 1.79 1.4E-01 34.19 • 2.2E-35
Glucose (mM) 4.78 • 1.5E-03 3.18 • 4.4E-05
Cystatin C (ng/mL) 28.37 • 2.6E-15 2.40 • 1.8E-03
Creatinine (mg/dl) 6.86 • 7.1E-05 6.15 • 1.3E-10
Lactate (mM) 5.97 • 2.7E-04 1.87 • 2.1E-02
Osmolality (mOsmo/kg) 1.57 1.9E-01 1.48 9.8E-02
Protein Content (mg/mL) 3.87 • 6.0E-03 1.52 8.5E-02
Bicarbonate (mmol/L) 35.86 • 4.9E-18 1.89 • 1.8E-02
HSP-70 (ng/mL) 1.02 4.0E-01 7.14 • 3.0E-12
Continued on next page
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9.1 – continued from previous page
ANOVA (Altitude) ANOVA (Individual)
Variable F -value p-value F -value p-value
Barometric Pressure 95623.60 • 9.4E-161 1.71 • 3.9E-02
Ambient temperature 40.31 • 3.1E-19 0.94 5.4E-01
Economy 9.83 • 1.2E-06 2.81 • 2.7E-04
Maximum voluntary ventila-
tion
27.34 • 7.4E-15 23.90 • 6.6E-29
Forced expiratory volume in 1
second
2.16 8.0E-02 59.65 • 1.1E-44
Haemoglobin 60.25 • 6.9E-25 3.92 • 1.5E-06
Blood oxygen content 1.86 1.2E-01 4.55 • 9.0E-08
Haematocrit 57.79 • 2.7E-24 5.60 • 1.1E-09
Resting oxygen consumption 5.18 • 8.5E-04 10.49 • 1.1E-16
Resting oxygen consumption
(/kg)
7.24 • 4.3E-05 4.99 • 1.7E-08
Resting respiratory exchange
ratio
7.13 • 5.0E-05 2.64 • 5.9E-04
Resting heart rate 24.58 • 1.0E-13 13.88 • 1.8E-20
Resting minute ventilation 46.64 • 4.5E-21 7.21 • 3.5E-12
Resting carbon dioxide produc-
tion
5.32 • 6.8E-04 9.47 • 2.2E-15
Respiratory equivalent for oxy-
gen at rest
76.03 • 6.9E-28 4.33 • 2.8E-07
Respiratory equivalent for car-
bon dioxide at rest
139.01 • 2.1E-37 7.81 • 4.5E-13
Resting oxygen pulse 1.52 2.0E-01 10.72 • 5.8E-17
Resting respiratory rate 15.29 • 1.5E-09 6.65 • 2.7E-11
Resting tidal volume 9.28 • 2.6E-06 5.08 • 1.2E-08
Partial pressure end tidal oxy-
gen
2702.62 • 5.5E-92 7.48 • 1.4E-12
End tidal partial pressure car-
bon dioxide
319.59 • 6.8E-52 12.99 • 1.5E-19
Work rate at LaT 42.53 • 6.7E-20 6.90 • 1.1E-11
Oxygen consumption at LaT 41.83 • 1.1E-19 7.11 • 5.0E-12
Continued on next page
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9.1 – continued from previous page
ANOVA (Altitude) ANOVA (Individual)
Variable F -value p-value F -value p-value
Oxygen consumption at LaT
(/kg)
40.69 • 2.4E-19 4.72 • 5.4E-08
Respiratory exchange ratio at
LaT
6.20 • 1.9E-04 3.46 • 1.3E-05
Heart rate at LaT 13.26 • 1.6E-08 6.92 • 9.8E-12
Minute ventilation at LaT 11.66 • 1.2E-07 8.23 • 1.1E-13
Carbon dioxide production at
LaT
41.83 • 1.1E-19 6.55 • 3.8E-11
Respiratory equivalent for oxy-
gen at LaT
319.79 • 6.6E-52 8.97 • 1.0E-14
Respiratory equivalent for car-
bon dioxide at LaT
370.75 • 1.4E-54 11.98 • 1.9E-18
Oxygen pulse at LaT 41.20 • 1.7E-19 25.28 • 1.3E-29
Respiratory rate at LaT 8.01 • 1.5E-05 9.22 • 4.8E-15
Tidal volume at LaT 0.74 5.7E-01 8.44 • 5.5E-14
Partial pressure end tidal oxy-
gen at LaT
2343.54 • 2.9E-89 10.12 • 3.2E-16
End tidal partial pressure car-
bon dioxide at LaT
706.13 • 1.7E-66 16.65 • 4.1E-23
Work rate at VO2max 239.68 • 9.3E-47 56.48 • 2.5E-43
Oxygen consumption at
VO2max
159.66 • 9.9E-40 28.72 • 1.1E-31
Oxygen consumption at
VO2max (/kg)
136.57 • 4.1E-37 14.79 • 2.2E-21
Respiratory exchange ratio at
VO2max
18.05 • 6.9E-11 3.24 • 3.7E-05
Heart rate at VO2max 62.27 • 5.4E-25 9.41 • 2.6E-15
Minute ventilation at VO2max 13.75 • 9.0E-09 16.59 • 4.6E-23
Carbon dioxide production at
VO2max
221.07 • 2.4E-45 32.56 • 8.8E-34
Respiratory equivalent for oxy-
gen at VO2max
171.15 • 6.5E-41 6.50 • 4.5E-11
Continued on next page
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9.1 – continued from previous page
ANOVA (Altitude) ANOVA (Individual)
Variable F -value p-value F -value p-value
Respiratory equivalent for car-
bon dioxide at VO2max
279.95 • 1.6E-49 11.56 • 5.8E-18
Oxygen pulse at VO2max 31.21 • 3.1E-16 24.45 • 4.5E-29
Respiratory rate at VO2max 5.14 • 9.0E-04 10.59 • 8.3E-17
Tidal volume at VO2max 4.67 • 1.8E-03 40.46 • 1.8E-37
Partial pressure end tidal oxy-
gen at VO2max
3110.84 • 1.1E-94 8.63 • 3.0E-14
End tidal partial pressure car-
bon dioxide at VO2max
231.22 • 4.0E-46 10.24 • 2.3E-16
Systolic blood pressure at rest 0.56 6.9E-01 4.13 • 1.2E-06
Diastolic blood pressure at rest 3.48 • 1.1E-02 3.15 • 8.2E-05
Systolic blood pressure after
exercise
0.50 7.3E-01 5.84 • 1.3E-08
Diastolic blood pressure after
exercise
1.27 2.9E-01 1.47 1.2E-01
Oxygen cost at LaT 7.26 • 4.2E-05 29.49 • 4.0E-32
Oxygen cost at VO2max 5.28 • 7.3E-04 24.31 • 5.7E-29
Oxygen saturations at rest 146.30 • 5.2E-38 3.97 • 1.5E-06
Oxygen saturations at LaT 119.36 • 1.0E-29 2.46 • 2.6E-03
Oxygen saturations at
VO2max
132.72 • 1.7E-28 3.87 • 2.3E-05
Table 9.1: Full 2-way ANOVA results (without interactions) looking at the e↵ect of
altitude and individual.
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9.2 Inter-quartile ranges
Interquartile ranges
Variable London Kathmandu Namche Pheriche EBC week 1
Nitrite (mM) 0.584 0.392 0.555 0.449 0.461
Nitrate (mM) 0.538 0.440 0.714 0.882 0.824
Total NOx (mM) 0.539 0.436 0.703 0.880 0.818
RSNO (nM) 1.026 0.859 0.782 0.817 0.488
RNNO (nM) 0.625 0.246 0.475 0.340 0.590
Total RxNO (nM) 0.662 0.388 0.429 0.452 0.654
cGMP (pmol/mL) 0.331 0.480 0.395 0.656 0.438
8-isoPGF (ng/mL) 0.476 0.799 0.905 0.427 1.336
HNE (mg/mL) 0.352 0.698 0.262 0.347 0.243
GSH (micromolar) NaN 0.195 0.330 0.331 0.280
GSSG (micromolar) NaN 0.817 0.758 0.639 0.811
Total Glutathione (mi-
cromolar)
NaN 0.400 0.562 0.453 0.368
GSH to GSSG ratio NaN 0.914 0.530 0.417 0.762
IL-1beta (pg/mL) 0.217 0.154 1.801 0.869 0.000
IL-1ra (pg/mL) 0.544 0.397 0.816 0.414 0.454
IL-6 (pg/mL) 0.356 0.489 0.279 0.417 0.392
IL-8 (pg/mL) 0.457 0.376 0.667 0.585 0.476
IL-10 (pg/mL) 1.554 0.725 2.729 1.526 1.608
IL-12(p70) (pg/mL) 0.903 0.887 0.648 1.203 0.776
IL-13 (pg/mL) 0.626 0.648 0.451 0.956 0.616
IL-18 (pg/mL) 0.664 0.779 0.627 0.548 0.836
MIF (pg/mL) 0.271 0.351 0.304 0.534 0.708
Eotaxin (pg/mL) 0.710 0.795 0.448 0.605 0.493
TNFalpha (pg/mL) 0.299 0.521 0.303 0.353 0.352
VEGF (pg/mL) 1.069 1.011 0.948 1.171 0.712
CRP (ng/mL) 1.976 2.771 1.809 1.481 2.224
Adrenaline (ng/mL) 1.389 0.724 0.472 0.611 0.531
Noradrenaline (ng/mL) 0.646 0.525 0.400 1.001 1.636
T3 (pg/mL) 0.983 0.505 0.743 0.610 0.634
T4 (pg/mL) 0.490 0.293 0.279 0.281 0.608
C-Peptide (pg/mL) 0.288 0.455 0.352 0.222 0.185
Continued on next page
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9.2 – continued from previous page
Interquartile range
Variable London Kathmandu Namche Pheriche EBC week 1
GIP (pg/mL) 1.024 1.023 0.676 0.825 0.571
Ghrelin (pg/mL) 0.430 0.422 0.304 0.420 0.517
Glucagon (pg/mL) 0.225 0.325 0.266 0.243 0.213
GLP-1 (pg/mL) 0.313 0.518 0.285 0.346 0.329
Insulin (pg/mL) 0.208 0.504 0.394 0.389 0.412
Leptin (pg/mL) 1.212 1.214 0.946 0.786 0.851
PAI-1 (pg/mL) 0.667 0.458 0.248 0.383 0.279
Resistin (pg/mL) 0.558 0.472 0.499 0.371 0.398
Visfatin (pg/mL) 0.842 0.837 0.671 0.646 0.619
Adiponectin (pg/mL) 0.722 0.782 0.858 0.724 1.027
Adipsin (pg/mL) 0.578 0.628 0.371 0.587 0.415
EPO (mlU/mL) 0.399 0.617 0.639 0.568 1.016
ET-1 (pg/mL) 0.955 0.974 0.819 0.663 0.915
Glucose (mM) 0.211 0.242 0.402 0.196 0.298
Cystatin C (ng/mL) 0.242 0.256 0.263 0.276 0.271
Creatinine (mg/dl) 0.163 0.148 0.206 0.205 0.133
Lactate (mM) 0.358 0.499 0.507 0.392 0.389
Osmolality
(mOsmo/kg)
0.036 0.036 0.040 0.068 0.064
Protein Content
(mg/mL)
0.110 0.084 0.109 0.115 0.102
Bicarbonate (mmol/L) 0.110 0.099 0.130 0.176 0.137
HSP-70 (ng/mL) 0.565 1.025 0.838 0.703 0.912
Groups 0.693 0.693 0.693 0.693 0.693
Gender 0.347 0.347 0.693 0.347 0.000
Weight (Kg) 0.207 0.201 0.192 0.190 0.194
Barometric Pressure 0.006 0.007 0.007 0.006 0.006
Inspired oxygen partial
pressure
0.000 0.000 0.000 0.000 0.000
Ambient temperature 0.057 0.077 0.173 0.138 0.975
Economy 0.178 0.099 0.136 0.108 0.170
Maximum voluntary
ventilation
0.270 0.254 0.196 0.169 0.232
Continued on next page
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9.2 – continued from previous page
Interquartile range
Variable London Kathmandu Namche Pheriche EBC week 1
Forced expiratory vol-
ume in 1 second
0.241 0.223 0.206 0.244 0.191
Exercise ramp wattage 0.405 0.405 0.405 0.405 0.405
Haemoglobin 0.108 0.092 0.078 0.080 0.109
Blood oxygen content 0.098 0.093 0.078 0.087 0.178
Haematocrit 0.080 0.066 0.075 0.073 0.066
Resting oxygen con-
sumption
0.242 0.215 0.313 0.250 0.256
Resting oxygen con-
sumption (/kg)
0.327 0.247 0.226 0.224 0.119
Resting respiratory ex-
change ratio
0.118 0.118 0.000 0.000 0.100
Resting heart rate 0.226 0.119 0.170 0.187 0.232
Resting minute ventila-
tion
0.199 0.231 0.292 0.253 0.306
Resting carbon dioxide
production
0.265 0.233 0.263 0.267 0.252
Respiratory equivalent
for oxygen at rest
0.139 0.114 0.158 0.142 0.191
Respiratory equivalent
for carbon dioxide at
rest
0.163 0.165 0.156 0.140 0.160
Resting oxygen pulse 0.288 0.231 0.352 0.316 0.255
Resting respiratory rate 0.219 0.264 0.218 0.197 0.261
Resting tidal volume 0.154 0.322 0.232 0.224 0.228
Partial pressure end
tidal oxygen
0.033 0.047 0.050 0.067 0.046
End tidal partial pres-
sure carbon dioxide
0.152 0.172 0.108 0.109 0.124
Work rate at LaT 0.273 0.236 0.212 0.222 0.206
Oxygen consumption at
LaT
0.216 0.181 0.236 0.143 0.163
Continued on next page
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9.2 – continued from previous page
Interquartile range
Variable London Kathmandu Namche Pheriche EBC week 1
Oxygen consumption at
LaT (/kg)
0.300 0.155 0.161 0.138 0.162
Respiratory exchange
ratio at LaT
0.074 0.063 0.082 0.063 0.070
Heart rate at LaT 0.136 0.142 0.166 0.117 0.149
Minute ventilation at
LaT
0.340 0.227 0.333 0.260 0.214
Carbon dioxide produc-
tion at LaT
0.311 0.175 0.246 0.214 0.148
Respiratory equivalent
for oxygen at LaT
0.121 0.159 0.117 0.114 0.149
Respiratory equivalent
for carbon dioxide at
LaT
0.125 0.113 0.150 0.134 0.175
Oxygen pulse at LaT 0.183 0.198 0.330 0.229 0.318
Respiratory rate at LaT 0.235 0.231 0.260 0.327 0.261
Tidal volume at LaT 0.296 0.265 0.290 0.293 0.259
Partial pressure end
tidal oxygen at LaT
0.049 0.075 0.061 0.067 0.070
End tidal partial pres-
sure carbon dioxide at
LaT
0.108 0.097 0.107 0.129 0.128
Work rate at VO2max 0.209 0.202 0.281 0.265 0.221
Oxygen consumption at
VO2max
0.236 0.197 0.305 0.258 0.246
Oxygen consumption at
VO2max (/kg)
0.238 0.176 0.167 0.086 0.155
Respiratory exchange
ratio at VO2max
0.099 0.084 0.083 0.049 0.075
Heart rate at VO2max 0.065 0.087 0.114 0.090 0.197
Minute ventilation at
VO2max
0.220 0.329 0.416 0.404 0.222
Continued on next page
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9.2 – continued from previous page
Interquartile range
Variable London Kathmandu Namche Pheriche EBC week 1
Carbon dioxide produc-
tion at VO2max
0.165 0.169 0.353 0.243 0.249
Respiratory equivalent
for oxygen at VO2max
0.203 0.178 0.137 0.128 0.187
Respiratory equivalent
for carbon dioxide at
VO2max
0.211 0.217 0.186 0.091 0.187
Oxygen pulse at
VO2max
0.170 0.260 0.337 0.297 0.335
Respiratory rate at
VO2max
0.355 0.224 0.215 0.302 0.301
Tidal volume at
VO2max
0.288 0.232 0.295 0.361 0.373
Partial pressure end
tidal oxygen at VO2max
0.055 0.058 0.058 0.043 0.045
End tidal partial pres-
sure carbon dioxide at
VO2max
0.204 0.222 0.168 0.090 0.196
Systolic blood pressure
at rest
0.225 0.167 0.227 0.150 0.271
Diastolic blood pressure
at rest
0.152 0.250 0.165 0.202 0.178
Systolic blood pressure
after exercise
0.181 0.263 0.186 0.198 0.257
Diastolic blood pressure
after exercise
0.270 0.202 0.151 0.147 0.161
Oxygen cost at LaT 0.210 0.237 0.243 0.251 0.216
Oxygen cost at
VO2max
0.247 0.193 0.218 0.239 0.203
Oxygen saturations at
rest
0.020 0.031 0.055 0.058 0.100
Oxygen saturations at
LaT
0.031 0.032 0.095 0.074 0.137
Continued on next page
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9.2 – continued from previous page
Interquartile range
Variable London Kathmandu Namche Pheriche EBC week 1
Oxygen saturations at
VO2max
0.021 0.039 0.075 0.101 0.159
Altitude 0.000 0.000 0.000 0.000 0.000
Day NaN 0.288 0.095 0.069 0.140
Table 9.2: Full interquartile range information for all variables for all altitudes, for
the core data.
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